WO2017198196A1 - Quinoline derivative having anti-tumor activity - Google Patents

Quinoline derivative having anti-tumor activity Download PDF

Info

Publication number
WO2017198196A1
WO2017198196A1 PCT/CN2017/084929 CN2017084929W WO2017198196A1 WO 2017198196 A1 WO2017198196 A1 WO 2017198196A1 CN 2017084929 W CN2017084929 W CN 2017084929W WO 2017198196 A1 WO2017198196 A1 WO 2017198196A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
arh
nmr
mmol
mhz
Prior art date
Application number
PCT/CN2017/084929
Other languages
French (fr)
Chinese (zh)
Inventor
王子厚
张晓东
曹日晖
荣祖元
陈西敬
王健
杨泽瀚
李忠野
徐�明
王忠奎
Original Assignee
王子厚
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 王子厚 filed Critical 王子厚
Publication of WO2017198196A1 publication Critical patent/WO2017198196A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms

Definitions

  • the present invention relates to a class of quinoline derivatives having antitumor activity, a process for the preparation of the quinoline derivatives, pharmaceutical compositions comprising the quinoline derivatives, and their use in the preparation of antitumor drugs.
  • Quinoline compounds are an important class of nitrogen-containing heterocyclic compounds whose backbone structure exists in the chemical structure of many clinical drugs, such as anti-malarial drugs (quinine, chloroquine, mefequolo, primaquine, etc.), antiviral Drugs (saquinavir), antibacterial drugs (quinolones ciprofloxacin, seroxacin, gatifloxacin, etc.).
  • camptothecin which opened the prelude to the application of quinoline derivatives in anti-tumor research, followed by camptothecin analogs topotecan, irinotecan, ezetacetin, etc.
  • the inventors have unexpectedly discovered that the compounds of the following formula I of the present invention have excellent antitumor activity, and the present invention has been completed based on this finding.
  • the invention provides a quinoline derivative which is a compound of formula I below:
  • R is one, two or three groups each independently selected from the group consisting of: optionally substituted hydrogen, halogen, hydroxy, amino, alkyl, alkoxy, alkanoyloxy, alkylthio, alkyl Amino, cyano, nitro, carboxy, sulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, acylamino, alkoxycarbonyl or alkyl acyl,
  • R 1 is an optionally substituted alkyl, alkenyl or alkynyl group
  • the optional substituents are each independently selected from the group consisting of aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl, alkane a heterocyclic group, an amino group, an alkylamino group, an amide group, an alkyl acylamino group, a hydroxy group, an alkoxy group, an alkyl acyl group, an alkyl acyloxy group, a decyl group, an alkylthio group, said optional substituent Further replaced; and
  • W is selected from NH, O or S.
  • At least one of said R is selected from the group consisting of: optionally substituted halogen, alkoxy, alkanoyloxy, alkylthio, alkylamino, cyano, nitro, carboxy, sulfonyl, alkane a sulfamoyl group, an arylsulfonyl group, a heteroarylsulfonyl group, an acylamino group, an alkoxycarbonyl group or an alkyl acyl group, preferably at least one of said R is selected from the group consisting of an optionally substituted cyano group, a nitro group, a carboxyl group, Sulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, amido, alkoxycarbonyl or alkylacyl.
  • At least one of said R is nitro, methoxy, fluoro, chloro or bromo.
  • the R 1 is optionally substituted C 2 -C 12 alkyl, C 3 -C 12 alkenyl or C 3 -C 12 alkynyl, for example ethyl, propyl, butyl, pentyl, hexyl, Heptyl, octyl, decyl, decyl, allyl, enbutyl, propargyl, or alkynyl butyl.
  • said R 1 is optionally substituted arylalkyl or heteroarylalkyl, preferably arylmethyl, arylethyl, arylpropyl, for example benzyl, Phenylethyl, phenylpropyl, phenylbutyl; the arylalkyl or heteroarylalkyl group optionally being substituted by one or more halogens such as fluorine, chlorine or bromine, alkyl, alkoxy, Substituted by haloalkyl or haloalkoxy, for example, R 1 may be fluorobenzyl, fluorophenethyl or fluorophenyl.
  • the present invention provides a method of preparing the quinoline derivative of the present invention, which comprises:
  • the base is preferably NaH, and/or the acid is preferably concentrated hydrochloric acid.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the aforementioned quinoline derivative of the present invention and a pharmaceutically acceptable carrier.
  • the invention also provides the use of the quinoline derivative for the manufacture of a medicament for the treatment of a proliferative disorder.
  • the proliferative disorder is a malignant tumor.
  • the proliferative disease may be selected from the group consisting of leukemia, colorectal cancer, liver cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, and gastric cancer.
  • the present invention also provides a method of treating a proliferative disease comprising administering an effective amount of a quinoline derivative of the present invention to a subject in need thereof.
  • the inventors have unexpectedly found that the quinoline derivative of the present invention has excellent antitumor activity and can be used for effectively treating proliferative diseases, especially malignant tumors.
  • alkyl denotes a straight or branched saturated hydrocarbon group, usually the alkyl group has 1 or more carbon atoms, for example, a C1-C12 alkyl group means an alkane having 1 to 12 carbon atoms. base.
  • the alkyl group may also be a C2-C12 alkyl group, a C2-C11 alkyl group, a C2-C10 alkyl group, a C2-C9 alkyl group, a C2-C8 alkyl group, a C2-C7 alkyl group, a C2-C6 alkane.
  • C2-C5 alkyl, C2-C4 alkyl for example C2 alkyl (ie ethyl), C3 alkyl (including n-propyl, isopropyl), C4 alkyl (including n-butyl, isobutyl) , C5 alkyl (including n-pentyl, isopentyl, neopentyl), C6 alkyl (including n-hexyl, various branched hexyl), C7 alkyl (heptyl), C8 alkyl (octyl) ), C9 alkyl (fluorenyl), C10 alkyl (fluorenyl), C11 alkyl (undecyl), C12 alkyl (dodecyl).
  • C2 alkyl ie ethyl
  • C3 alkyl including n-propyl, isopropyl
  • C4 alkyl including n-butyl, isobut
  • alkyl group when mentioned in another group, for example, an alkoxy group, an alkanoyl group, an alkoxycarbonyl group, wherein the alkyl group has the definition of the alkyl group herein, but some groups (such as The alkanoyl group also includes a carbon atom on the structure other than the alkyl group when calculating the number of carbon atoms.
  • alkenyl denotes a straight or branched chain hydrocarbon radical having one or more carbon-carbon double bonds.
  • alkenyl denotes a straight or branched chain hydrocarbon radical having one or more carbon-carbon double bonds.
  • the alkenyl group may be a C3 alkenyl group (such as an allyl group), a C4 alkenyl group (such as a 1,3-butadienyl group), a C5 alkenyl group, a C6 alkenyl group, a C7 alkenyl group, a C8 alkenyl group, C9 alkenyl, C10 alkenyl, C11 alkenyl, C12 alkenyl.
  • a C3 alkenyl group such as an allyl group
  • a C4 alkenyl group such as a 1,3-butadienyl group
  • C5 alkenyl group such as an allyl group
  • a C6 alkenyl group such as a 1,3-butadienyl group
  • C7 alkenyl group such as a 1,3-butadienyl group
  • C8 alkenyl group such as a 1,3-butadienyl group
  • alkynyl denotes a straight or branched chain hydrocarbon radical having one or more carbon to carbon triple bonds.
  • alkynyl denotes a straight or branched chain hydrocarbon radical having one or more carbon to carbon triple bonds.
  • the alkynyl group may be a C3 alkynyl group (such as a propargyl group), a C4 alkynyl group (such as a 1,3-butadiynyl group), a C5 alkynyl group, a C6 alkynyl group, a C7 alkynyl group, a C8 alkynyl group, C9 alkynyl, C10 alkynyl, C11 alkynyl, C12 alkynyl.
  • a C3 alkynyl group such as a propargyl group
  • a C4 alkynyl group such as a 1,3-butadiynyl group
  • a C5 alkynyl group such as a propargyl group
  • a C6 alkynyl group such as a 1,3-butadiynyl group
  • C7 alkynyl group such as a C7 alkynyl group
  • aryl denotes a carbocyclic group having a cyclic conjugated structure.
  • the aryl group may have 6 or more carbon atoms, such as a C6-C14 aryl group, a C6-C12 aryl group, a C6-C10 aryl group.
  • the aryl group may be a phenyl group, a naphthyl group, an anthracenyl group or a phenanthryl group.
  • heteroaryl denotes a cyclic group having one or more heteroatoms selected from N, O and S in a cyclic conjugated structure.
  • the number of ring atoms in the heteroaryl group may be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or more.
  • the heteroaryl group may be a pyridyl group, a thienyl group, a pyrazolyl group, a pyrimidinyl group, a fluorenyl group, a fluorenyl group, a thiazolyl group, or a morpholinyl group.
  • heterocyclyl denotes a cyclic group having one or more heteroatoms selected from N, O and S, for example piperidinyl, piperazinyl, pyrrolidinyl, pyranyl, Oxocyclopentyl, dioxane.
  • halogen denotes fluoro, chloro, bromo, iodo.
  • treatment denotes any treatment that allows the health condition of a subject to be treated to alleviate, ameliorate, restore, eliminate, and prevent the risk of disease and improve the prognosis of the disease.
  • treatments include, but are not limited to, medical treatment, radiation therapy, chemotherapy, surgery, and vaccination.
  • Table 1 below shows the correspondence between the compound 8-51 number of the present invention and the structural formula and basic parameters.
  • the quinoline derivative of the present invention is used as a pharmacological study for a medicament for treating cancer. All tested compounds were prepared as the hydrochloride salt prior to the test, using the commonly used anti-tumor drugs, cisplatin and besibutinib, as positive control drugs.
  • HCT116 Human rectal cancer cell line
  • HepG2 human hepatoma cell line
  • HepG2 human non-small cell lung cancer cell line
  • A549 and NCI-H1650 human ovarian cancer cell line
  • human cervical cancer cell line Hela
  • Human gastric cancer cell line BGC-823
  • other human tumor cell lines were tested by MTT assay.
  • the specific method is as follows: various cell lines are cultured according to standard culture methods, and cell lines in good growth state and in logarithmic growth phase are inoculated into 96-well plates at a concentration of 5 ⁇ 10 4 /ml, and 160 ⁇ l is inoculated per well, followed by The 96-well plate was incubated in an incubator containing 5% CO 2 at 37 ° C for 24 hours, the old solution was discarded, the fresh culture solution was replaced, the sterilized quinoline derivative was added, and the culture was continued for 48 hours, and then discarded.
  • the culture medium was added with 20 ul of RPMI-1640 medium containing 5 mg/ml MTT per well, and the culture was continued for 4 hours.
  • the cell survival rate was plotted against the logarithm of the drug concentration, and the IC 50 value of each sample was determined by the mapping method. The results are shown in Table 2 below.
  • reaction solution was cooled and transferred to a 500 mL beaker, and 150 mL of water was added thereto, and the mixture was extracted three times with ethyl acetate.
  • test examples all the tested compounds were prepared into the hydrochloride form before the test, and the commonly used antitumor drugs, cisplatin and besibutinib, were used as positive control drugs.
  • Human rectal cancer cell line (HCT116), human hepatoma cell line (HepG2), human non-small cell lung cancer cell line (A549), human ovarian cancer cell line (A2780), human gastric cancer cell line (BGC-823), etc. Human tumor cell lines were tested using the MTT method.
  • the specific method is as follows: various cell lines are cultured according to standard culture methods, and cell lines in good growth state and in logarithmic growth phase are inoculated into 96-well plates at a concentration of 5 ⁇ 10 4 /ml, and 160 ⁇ l is inoculated per well, followed by The 96-well plate was incubated in an incubator containing 5% CO 2 at 37 ° C for 24 hours, the old solution was discarded, the fresh culture solution was replaced, the sterilized quinoline derivative was added, and the culture was continued for 48 hours, and then discarded.
  • the culture medium was added with 20 ul of RPMI-1640 medium containing 5 mg/ml MTT per well, and the culture was continued for 4 hours.
  • the cell survival rate was plotted against the logarithm of the drug concentration, and the IC 50 value of each sample was determined by the mapping method. The results are shown in Table 3 below.

Abstract

The present invention relates to a quinoline derivative having anti-tumor activity, a preparation method for the quinoline derivative, a pharmaceutical composition comprising the quinoline derivative, and applications thereof in the preparation of anti-tumor drugs.

Description

具有抗肿瘤活性的喹啉衍生物Quinoline derivative with antitumor activity
本申请要求于2016年5月18日提交中国国家知识产权局，申请号为201610330810.2，发明名称为“具有抗肿瘤活性的喹啉衍生物”的中国专利申请的优先权，其全部内容通过引用结合在本申请中。This application claims priority to Chinese Patent Application No. 201610330810.2, entitled "Quinoline Derivatives with Antitumor Activity", filed on May 18, 2016, the entire contents of which are incorporated by reference. In this application.
技术领域Technical field
本发明涉及一类具有抗肿瘤活性的喹啉衍生物，所述喹啉衍生物的制备方法，包含所述喹啉衍生物的药物组合物，以及它们在制备抗肿瘤药物中的应用。The present invention relates to a class of quinoline derivatives having antitumor activity, a process for the preparation of the quinoline derivatives, pharmaceutical compositions comprising the quinoline derivatives, and their use in the preparation of antitumor drugs.
背景技术Background technique
喹啉类化合物是一类重要的含氮杂环化合物，其骨架结构存在于许多临床药物的化学结构中，例如抗疟疾药物(奎宁、氯喹、甲弗喹、伯氨喹等)，抗病毒药物(沙奎那韦)，抗菌药物(喹诺酮类药物环丙沙星、司氟沙星、加替沙星等)等。Quinoline compounds are an important class of nitrogen-containing heterocyclic compounds whose backbone structure exists in the chemical structure of many clinical drugs, such as anti-malarial drugs (quinine, chloroquine, mefequolo, primaquine, etc.), antiviral Drugs (saquinavir), antibacterial drugs (quinolones ciprofloxacin, seroxacin, gatifloxacin, etc.).
1966年，M.E.Wall和M.C.Wani发现喜树碱，由此拉开了喹啉衍生物应用于抗肿瘤研究的序幕，随后喜树碱类似物拓扑替康，伊立替康，依喜替康等被合成出来，并应用于癌症的治疗；2012年FDA批准了抗癌新药伯舒替尼和卡博替尼上市，这两个药物都是喹啉的衍生物，前者是一种酪氨酸激酶抑制剂，主要治疗对既往治疗耐药或不能耐受的慢性、加速型成年Ph*慢性粒细胞白血病(CML)，后者作为一种抑制MET、血管内皮生长因子受体2(VEGFR2)和RET的酪氨酸激酶抑制剂，可以阻断肿瘤细胞发生和发展，临床上用于进展性、转移性甲状腺髓样癌(MTC)患者的治疗(汤仲明.2012年美国FDA批准药物简介.国际药学研究杂志,2013,40(1):111-123)。目前有较多的喹啉类抗肿瘤先导药物处于不同的临床试验阶段，喹啉衍生物得到了越来越多研究者的关注。In 1966, MEWall and MCWani discovered camptothecin, which opened the prelude to the application of quinoline derivatives in anti-tumor research, followed by camptothecin analogs topotecan, irinotecan, ezetacetin, etc. Synthesized and applied to the treatment of cancer; in 2012, the FDA approved the new anti-cancer drug, bosutinib and cabozantini, both of which are derivatives of quinoline, the former being a tyrosine kinase inhibitor Agents, mainly for the treatment of chronic, accelerated adult Ph* chronic myeloid leukemia (CML), which is resistant or intolerant to previous treatments, as a form of inhibition of MET, vascular endothelial growth factor receptor 2 (VEGFR2) and RET Tyrosine kinase inhibitors can block tumor cell development and progression, and are clinically used for the treatment of patients with progressive, metastatic medullary thyroid carcinoma (MTC) (Tang Zhongming. 2012 FDA approved drug profile. International Journal of Pharmaceutical Research , 2013, 40 (1): 111-123). At present, there are many quinoline anti-tumor lead drugs in different clinical trial stages, and quinoline derivatives have attracted more and more researchers' attention.
目前仍然需要寻找新型的具有抗肿瘤活性的喹啉化合物以供临床应用。There is still a need to find novel quinoline compounds with antitumor activity for clinical use.
发明内容Summary of the invention
本发明的一个目的是提供新的具有抗肿瘤活性的喹啉衍生物。发明人意外地发现，本发明的以下式I化合物具有优异的抗肿瘤活性，本发明基于此发现而得以完成。It is an object of the present invention to provide novel quinoline derivatives having antitumor activity. The inventors have unexpectedly discovered that the compounds of the following formula I of the present invention have excellent antitumor activity, and the present invention has been completed based on this finding.
在第一方面，本发明提供了一种喹啉衍生物，其是以下式I化合物：In a first aspect, the invention provides a quinoline derivative which is a compound of formula I below:
Figure PCTCN2017084929-appb-000001
Figure PCTCN2017084929-appb-000001
或其可药用盐，其中Or a pharmaceutically acceptable salt thereof, wherein
R是一个、两个或三个各自独立地选自以下的基团：任选取代的氢、卤素、羟基、氨基、烷基、烷氧基、烷酰基氧基、烷基硫基、烷基氨基、氰基、硝基、羧基、磺酰基、烷基磺酰基、芳基磺酰基、杂芳基磺酰基、酰氨基、烷氧基羰基或烷基酰基，R is one, two or three groups each independently selected from the group consisting of: optionally substituted hydrogen, halogen, hydroxy, amino, alkyl, alkoxy, alkanoyloxy, alkylthio, alkyl Amino, cyano, nitro, carboxy, sulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, acylamino, alkoxycarbonyl or alkyl acyl,
R1是任选取代的烷基、烯基或炔基，R 1 is an optionally substituted alkyl, alkenyl or alkynyl group,
当存在时所述任选的取代基各自独立地选自芳基、杂芳基、杂环基、烷基芳基、烷基杂芳基、烷 基杂环基、氨基、烷基氨基、酰胺基、烷基酰基氨基、羟基、烷氧基、烷基酰基、烷基酰基氧基、巯基、烷基硫基，所述任选的取代基可进一步被取代；和When present, the optional substituents are each independently selected from the group consisting of aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl, alkane a heterocyclic group, an amino group, an alkylamino group, an amide group, an alkyl acylamino group, a hydroxy group, an alkoxy group, an alkyl acyl group, an alkyl acyloxy group, a decyl group, an alkylthio group, said optional substituent Further replaced; and
W选自NH、O或S。W is selected from NH, O or S.
在一个实施方案中，至少一个所述R选自：任选取代的卤素、烷氧基、烷酰基氧基、烷基硫基、烷基氨基、氰基、硝基、羧基、磺酰基、烷基磺酰基、芳基磺酰基、杂芳基磺酰基、酰氨基、烷氧基羰基或烷基酰基，优选地，至少一个所述R选自：任选取代的氰基、硝基、羧基、磺酰基、烷基磺酰基、芳基磺酰基、杂芳基磺酰基、酰氨基、烷氧基羰基或烷基酰基。In one embodiment, at least one of said R is selected from the group consisting of: optionally substituted halogen, alkoxy, alkanoyloxy, alkylthio, alkylamino, cyano, nitro, carboxy, sulfonyl, alkane a sulfamoyl group, an arylsulfonyl group, a heteroarylsulfonyl group, an acylamino group, an alkoxycarbonyl group or an alkyl acyl group, preferably at least one of said R is selected from the group consisting of an optionally substituted cyano group, a nitro group, a carboxyl group, Sulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, amido, alkoxycarbonyl or alkylacyl.
在一个具体实施方案中，至少一个所述R是硝基、甲氧基、氟、氯或溴。In a particular embodiment, at least one of said R is nitro, methoxy, fluoro, chloro or bromo.
在另一个实施方案中，所述R1是任选取代的C2-C12烷基、C3-C12烯基或C3-C12炔基，例如是乙基、丙基、丁基、戊基、己基、庚基、辛基、壬基、癸基、烯丙基、烯丁基、炔丙基、或炔丁基。In another embodiment, the R 1 is optionally substituted C 2 -C 12 alkyl, C 3 -C 12 alkenyl or C 3 -C 12 alkynyl, for example ethyl, propyl, butyl, pentyl, hexyl, Heptyl, octyl, decyl, decyl, allyl, enbutyl, propargyl, or alkynyl butyl.
在一个具体实施方案中，所述R1是任选取代的芳烷基或杂芳基烷基，优选地是芳基甲基、芳基乙基、芳基丙基，例如是苯甲基、苯乙基、苯基丙基、苯基丁基；所述芳基烷基或杂芳基烷基任选地被一个或更多个卤素如氟、氯或溴、烷基、烷氧基、卤代烷基或卤代烷氧基所取代，例如所述R1可以是氟代苯甲基、氟代苯乙基、氟代苯丙基。In a particular embodiment, said R 1 is optionally substituted arylalkyl or heteroarylalkyl, preferably arylmethyl, arylethyl, arylpropyl, for example benzyl, Phenylethyl, phenylpropyl, phenylbutyl; the arylalkyl or heteroarylalkyl group optionally being substituted by one or more halogens such as fluorine, chlorine or bromine, alkyl, alkoxy, Substituted by haloalkyl or haloalkoxy, for example, R 1 may be fluorobenzyl, fluorophenethyl or fluorophenyl.
另一方面，本发明提供一种制备本发明所述喹啉衍生物的方法，其包括：In another aspect, the present invention provides a method of preparing the quinoline derivative of the present invention, which comprises:
1)使式II化合物在碱存在下与R1X接触，1) contacting a compound of formula II with R 1 X in the presence of a base,
Figure PCTCN2017084929-appb-000002
Figure PCTCN2017084929-appb-000002
获得式III化合物，和Obtaining a compound of formula III, and
Figure PCTCN2017084929-appb-000003
Figure PCTCN2017084929-appb-000003
2)使式III化合物在酸存在下与R取代苯胺接触，获得式I化合物，2) contacting a compound of formula III with an R-substituted aniline in the presence of an acid to obtain a compound of formula I,
Figure PCTCN2017084929-appb-000004
Figure PCTCN2017084929-appb-000004
其中，X各自独立地是卤素，R、R1和W如权利要求1-6中所定义，Wherein X is each independently halogen, and R, R 1 and W are as defined in claims 1-6,
所述碱优选地是NaH，和/或所述酸优选地是浓盐酸。The base is preferably NaH, and/or the acid is preferably concentrated hydrochloric acid.
在第三个方面中，本发明提供一种药物组合物，其包含本发明前述的喹啉衍生物以及可药用载体。In a third aspect, the present invention provides a pharmaceutical composition comprising the aforementioned quinoline derivative of the present invention and a pharmaceutically acceptable carrier.
在第四个方面中，本发明还提供所述喹啉衍生物用于制备治疗增生性疾病的药物中的用途。In a fourth aspect, the invention also provides the use of the quinoline derivative for the manufacture of a medicament for the treatment of a proliferative disorder.
在一个实施方案中，所述增生性疾病是恶性肿瘤。具体地，所述增生性疾病可以选自白血病、结直肠癌、肝癌、非小细胞肺癌、卵巢癌、***和胃癌。In one embodiment, the proliferative disorder is a malignant tumor. Specifically, the proliferative disease may be selected from the group consisting of leukemia, colorectal cancer, liver cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, and gastric cancer.
与以上第四个方面相似，本发明还提供治疗增生性疾病的方法，其包括向有此需要的对象施用有效量的本发明喹啉衍生物。Similar to the fourth aspect above, the present invention also provides a method of treating a proliferative disease comprising administering an effective amount of a quinoline derivative of the present invention to a subject in need thereof.
发明人意外地发现，本发明的喹啉衍生物具有优异的抗肿瘤活性，能够用于有效治疗增生性疾病，尤其是恶性肿瘤。 The inventors have unexpectedly found that the quinoline derivative of the present invention has excellent antitumor activity and can be used for effectively treating proliferative diseases, especially malignant tumors.
具体实施方式detailed description
本申请中所用术语具有相关领域中常规解释。特别地，下面给出一些术语在本申请中的具体含义。当这些术语在相关领域有不同解释时，以本申请中的定义为准。The terms used in this application have conventional interpretations in the relevant art. In particular, the specific meanings of some terms in this application are given below. When these terms are interpreted differently in the relevant art, the definitions in this application prevail.
术语“烷基”在本申请中表示直链或支链的饱和烃基，通常所述烷基具有1个或更多个碳原子，例如C1-C12烷基表示具有1-12个碳原子的烷基。类似地，所述烷基还可以是C2-C12烷基、C2-C11烷基、C2-C10烷基、C2-C9烷基、C2-C8烷基、C2-C7烷基、C2-C6烷基、C2-C5烷基、C2-C4烷基，例如是C2烷基(即乙基)、C3烷基(包括正丙基、异丙基)、C4烷基(包括正丁基、异丁基)、C5烷基(包括正戊基、异戊基、新戊基)、C6烷基(包括正己基、各种支链己基)、C7烷基(庚基)、C8烷基(辛基)、C9烷基(壬基)、C10烷基(癸基)、C11烷基(十一烷基)、C12烷基(十二烷基)。此外，在本申请中，当在其他基团中提到烷基时，例如烷氧基、烷酰基、烷氧羰基，其中的烷基具有此处烷基的定义，只不过有些基团(如烷酰基)在计算碳原子数时还包括烷基以外结构上的碳原子。The term "alkyl" as used in the present application denotes a straight or branched saturated hydrocarbon group, usually the alkyl group has 1 or more carbon atoms, for example, a C1-C12 alkyl group means an alkane having 1 to 12 carbon atoms. base. Similarly, the alkyl group may also be a C2-C12 alkyl group, a C2-C11 alkyl group, a C2-C10 alkyl group, a C2-C9 alkyl group, a C2-C8 alkyl group, a C2-C7 alkyl group, a C2-C6 alkane. Base, C2-C5 alkyl, C2-C4 alkyl, for example C2 alkyl (ie ethyl), C3 alkyl (including n-propyl, isopropyl), C4 alkyl (including n-butyl, isobutyl) , C5 alkyl (including n-pentyl, isopentyl, neopentyl), C6 alkyl (including n-hexyl, various branched hexyl), C7 alkyl (heptyl), C8 alkyl (octyl) ), C9 alkyl (fluorenyl), C10 alkyl (fluorenyl), C11 alkyl (undecyl), C12 alkyl (dodecyl). Further, in the present application, when an alkyl group is mentioned in another group, for example, an alkoxy group, an alkanoyl group, an alkoxycarbonyl group, wherein the alkyl group has the definition of the alkyl group herein, but some groups (such as The alkanoyl group also includes a carbon atom on the structure other than the alkyl group when calculating the number of carbon atoms.
术语“烯基”在本申请中表示具有一个或更多个碳碳双键的直链或支链烃基。例如C2-C12烯基、C3-C12烯基、C3-C11烯基、C3-C10烯基、C3-C9烯基、C3-C8烯基、C3-C7烯基、C3-C6烯基、C3-C5烯基、C3-C4烯基、C4-C12烯基、C4-C11烯基、C4-C10烯基、C4-C9烯基、C4-C8烯基、C4-C7烯基、C4-C6烯基、C4-C5烯基。具体地，所述烯基可以是C3烯基(如烯丙基)、C4烯基(如1,3-丁二烯基)、C5烯基、C6烯基、C7烯基、C8烯基、C9烯基、C10烯基、C11烯基、C12烯基。The term "alkenyl" as used in this application denotes a straight or branched chain hydrocarbon radical having one or more carbon-carbon double bonds. For example, C2-C12 alkenyl, C3-C12 alkenyl, C3-C11 alkenyl, C3-C10 alkenyl, C3-C9 alkenyl, C3-C8 alkenyl, C3-C7 alkenyl, C3-C6 alkenyl, C3 -C5 alkenyl, C3-C4 alkenyl, C4-C12 alkenyl, C4-C11 alkenyl, C4-C10 alkenyl, C4-C9 alkenyl, C4-C8 alkenyl, C4-C7 alkenyl, C4-C6 Alkenyl, C4-C5 alkenyl. Specifically, the alkenyl group may be a C3 alkenyl group (such as an allyl group), a C4 alkenyl group (such as a 1,3-butadienyl group), a C5 alkenyl group, a C6 alkenyl group, a C7 alkenyl group, a C8 alkenyl group, C9 alkenyl, C10 alkenyl, C11 alkenyl, C12 alkenyl.
类似地，术语“炔基”在本申请中表示具有一个或更多个碳碳三键的直链或支链烃基。例如C2-C12炔基、C3-C12炔基、C3-C11炔基、C3-C10炔基、C3-C9炔基、C3-C8炔基、C3-C7炔基、C3-C6炔基、C3-C5炔基、C3-C4炔基、C4-C12炔基、C4-C11炔基、C4-C10炔基、C4-C9炔基、C4-C8炔基、C4-C7炔基、C4-C6炔基、C4-C5炔基。具体地，所述炔基可以是C3炔基(如炔丙基)、C4炔基(如1,3-丁二炔基)、C5炔基、C6炔基、C7炔基、C8炔基、C9炔基、C10炔基、C11炔基、C12炔基。Similarly, the term "alkynyl" as used in this application denotes a straight or branched chain hydrocarbon radical having one or more carbon to carbon triple bonds. For example, C2-C12 alkynyl, C3-C12 alkynyl, C3-C11 alkynyl, C3-C10 alkynyl, C3-C9 alkynyl, C3-C8 alkynyl, C3-C7 alkynyl, C3-C6 alkynyl, C3 -C5 alkynyl, C3-C4 alkynyl, C4-C12 alkynyl, C4-C11 alkynyl, C4-C10 alkynyl, C4-C9 alkynyl, C4-C8 alkynyl, C4-C7 alkynyl, C4-C6 Alkynyl, C4-C5 alkynyl. Specifically, the alkynyl group may be a C3 alkynyl group (such as a propargyl group), a C4 alkynyl group (such as a 1,3-butadiynyl group), a C5 alkynyl group, a C6 alkynyl group, a C7 alkynyl group, a C8 alkynyl group, C9 alkynyl, C10 alkynyl, C11 alkynyl, C12 alkynyl.
术语“芳基”在本申请中表示具有环状共轭结构的碳环基团。所述芳基可以具有6个或更多个碳原子，例如C6-C14芳基、C6-C12芳基、C6-C10芳基。具体地所述芳基可以是苯基、萘基、蒽基、菲基。The term "aryl" as used in this application denotes a carbocyclic group having a cyclic conjugated structure. The aryl group may have 6 or more carbon atoms, such as a C6-C14 aryl group, a C6-C12 aryl group, a C6-C10 aryl group. Specifically, the aryl group may be a phenyl group, a naphthyl group, an anthracenyl group or a phenanthryl group.
术语“杂芳基”在本申请中表示在环状共轭结构中具有选自N、O和S的一个或更多个杂原子的环状基团。杂芳基中环原子数可以是5、6、7、8、9、10、11、12、13、14个或更多个。具体地，所述杂芳基可以是吡啶基、噻吩基、吡唑基、嘧啶基、吲哚基、嘌呤基、噻唑基、吗啉基。The term "heteroaryl" as used in the present application denotes a cyclic group having one or more heteroatoms selected from N, O and S in a cyclic conjugated structure. The number of ring atoms in the heteroaryl group may be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or more. Specifically, the heteroaryl group may be a pyridyl group, a thienyl group, a pyrazolyl group, a pyrimidinyl group, a fluorenyl group, a fluorenyl group, a thiazolyl group, or a morpholinyl group.
术语“杂环基”在本申请中表示具有选自N、O和S的一个或更多个杂原子的环状基团，例如哌啶基、哌嗪基、吡咯烷基、吡喃基、氧杂环戊基、二氧六环基。The term "heterocyclyl" as used in the present application denotes a cyclic group having one or more heteroatoms selected from N, O and S, for example piperidinyl, piperazinyl, pyrrolidinyl, pyranyl, Oxocyclopentyl, dioxane.
术语“卤素”在本申请中表示氟、氯、溴、碘。The term "halogen" as used in this application denotes fluoro, chloro, bromo, iodo.
术语“治疗”在本申请中表示使待治疗对象的健康状况得以从疾病状态中缓解、改善、恢复、消除以及预防患病风险和改善疾病预后的任何处理。所述治疗包括但不限于药物治疗、放射治疗、化学治疗、手术治疗和疫苗接种。The term "treatment" as used in this application denotes any treatment that allows the health condition of a subject to be treated to alleviate, ameliorate, restore, eliminate, and prevent the risk of disease and improve the prognosis of the disease. Such treatments include, but are not limited to, medical treatment, radiation therapy, chemotherapy, surgery, and vaccination.
本发明将参考以下实施例进一步解释说明。必须指出的是，这些实施例仅是为了方便技术人员理解本发明的精神和实质，本发明保护范围并不限于这些实施例，而应以所附权利要求书为准。The invention will be further explained with reference to the following examples. It is to be understood that the embodiments are only intended to facilitate the understanding of the spirit and scope of the invention, and the scope of the invention is not limited to the embodiments, but the appended claims.
实施例Example
本发明将参考以下实施例进一步解释说明。必须指出的是，这些实施例仅是为了方便技术人员理解本发明的精神和实质，本发明保护范围并不限于这些实施例，而应以所附权利要求书为准。The invention will be further explained with reference to the following examples. It is to be understood that the embodiments are only intended to facilitate the understanding of the spirit and scope of the invention, and the scope of the invention is not limited to the embodiments, but the appended claims.
以下是本发明所述喹啉衍生物的一般性合成路线图。化合物6a-6e的合成根据现有技术公开的方案(中国专利申请公开CN103864680A，对应申请CN201310652191.5)进行。 The following is a general synthetic route diagram of the quinoline derivative of the present invention. The synthesis of the compound 6a-6e is carried out according to the scheme disclosed in the prior art (Chinese Patent Application Publication No. CN103864680A, corresponding to the application CN201310652191.5).
Figure PCTCN2017084929-appb-000005
Figure PCTCN2017084929-appb-000005
制备实施例1Preparation Example 1
化合物7a-d的通用合成工艺General synthetic process for compound 7a-d
将相应的7-取代-4-喹诺酮6(30mmol)和POCl3(45mL)混合加热回流2h。将反应液冷却至室温后，逐滴滴加到冰水中，再滴加浓NaOH溶液调节pH至6.0～7.0，析出大量固体，过滤，水洗，干燥，可得较纯的7a-d。The corresponding 7-substituted 4-quinolone 6 (30mmol) and POCl 3 (45mL) was heated mixture refluxed for 2h. After cooling the reaction solution to room temperature, it was added dropwise to ice water, and the concentrated NaOH solution was added dropwise to adjust the pH to 6.0-7.0, and a large amount of solid was precipitated, filtered, washed with water, and dried to obtain a relatively pure 7a-d.
制备实施例1.1：4-氯-7-氟喹啉(7a)PREPARATIVE EXAMPLE 1.1: 4-Chloro-7-fluoroquinoline (7a)
以7-氟-4-喹诺酮6a(30mmol)为原料，得白色固体(4.20g，77.1％)。1H NMR(400MHz,CDCl3)δ8.79(d,J＝4.8Hz,1H),8.26(m,1H),7.77(d,J＝9.6Hz,1H),7.48(d,J＝4.8Hz,1H),7.44(d,J＝8.4Hz,1H).13C NMR(100MHz,CDCl3)δ164.7,162.2,151.0,150.03(d,J＝12.8Hz),142.6,126.49(d,J＝10.0Hz),123.4,120.61(d,J＝1.9Hz),118.2,117.9,113.5,113.3.Starting from 7-fluoro-4-quinolone 6a (30 mmol) gave a white solid ( 4. <RTIgt; 1 H NMR (400MHz, CDCl 3 ) δ8.79 (d, J = 4.8Hz, 1H), 8.26 (m, 1H), 7.77 (d, J = 9.6Hz, 1H), 7.48 (d, J = 4.8Hz , 1H), 7.44 (d, J = 8.4 Hz, 1H). 13 C NMR (100 MHz, CDCl 3 ) δ 164.7, 162.2, 151.0, 150.03 (d, J = 12.8 Hz), 142.6, 126.49 (d, J = 10.0) Hz), 123.4, 120.61 (d, J = 1.9 Hz), 118.2, 117.9, 113.5, 113.3.
制备实施例1.2：4,7-二氯喹啉(7b)PREPARATIVE EXAMPLE 1.2: 4,7-Dichloroquinoline (7b)
以7-氯-4-喹诺酮6b(30mmol)为原料，得白色固体(5.02g，85.0％)。ESI-MS m/z 197[M]+.1H NMR(300MHz,CDCl3):δ8.74(1H,d,J＝4.8Hz),8.09–8.15(2H,m),7.54–7.58(1H,m),7.45(1H,d,J＝4.8Hz).13C NMR(75MHz,CDCl3)δ151.0,149.4,142.8,136.7,128.8(2C),125.7,125.1,121.6. Starting from 7-chloro-4-quinolone 6b (30 mmol) gave a white solid (5. ESI-MS m/z 197 [M] + . 1 H NMR (300 MHz, CDCl 3 ): δ 8.74 (1H, d, J = 4.8 Hz), 8.09 - 8.15 (2H, m), 7.54 - 7.58 (1H , m), 7.45 (1H, d, J = 4.8 Hz). 13 C NMR (75 MHz, CDCl 3 ) δ 151.0, 149.4, 142.8, 136.7, 128.8 (2C), 125.7, 125.1, 121.6.
制备实施例1.3：4-氯-7-溴喹啉(7c)PREPARATIVE EXAMPLE 1.3: 4-Chloro-7-bromoquinoline (7c)
以7-溴-4-喹诺酮6c(30mmol)为原料，得白色固体(4.35g，90.3％)。1H NMR(400MHz,CDCl3)δ8.79(d,J＝4.4Hz,1H),8.32(s,1H),8.11(d,J＝8.8Hz,1H),7.74(d,J＝9.2Hz,1H),7.51(d,J＝4.4Hz,1H).13C NMR(100MHz,CDCl3)δ150.9,149.5,142.7,132.0,131.1,125.5,125.2,124.8,121.6.Starting from 7-bromo-4-quinolone 6c (30 mmol) gave a white solid (4.35 g, 90.3%). 1 H NMR (400MHz, CDCl 3 ) δ8.79 (d, J = 4.4Hz, 1H), 8.32 (s, 1H), 8.11 (d, J = 8.8Hz, 1H), 7.74 (d, J = 9.2Hz , 1H), 7.51 (d, J = 4.4 Hz, 1H). 13 C NMR (100 MHz, CDCl 3 ) δ 150.9, 149.5, 142.7, 132.0, 131.1, 125.5, 125.2, 124.8, 121.6.
制备实施例1.4：4-氯-7-甲氧基喹啉(7d)PREPARATIVE EXAMPLE 1.4: 4-Chloro-7-methoxyquinoline (7d)
以7-甲氧基-4-喹诺酮6d(30mmol)为原料，得橙色固体(4.19g，67.8％)。Starting from 7-methoxy-4-quinolone 6d (30 mmol) gave an orange solid (4.19 g, 67.8%).
ESI-MS m/z 194[M+H]+.1H NMR(300MHz,CDCl3):δ8.67(1H,d,J＝4.8Hz),8.09(1H,d,J＝9.0Hz),7.42(1H,d,J＝2.4Hz),7.33(1H,d,J＝4.8Hz),7.28(1H,dd,J＝9.0Hz,J＝2.4Hz),3.97(3H,s).13CNMR(75MHz,CDCl3)δ161.3,151.0,150.2,142.4,125.3,121.7,120.8,119.3,107.7,55.9.ESI-MS m/z 194 [M+H] + . 1 H NMR (300 MHz, CDCl 3 ): δ 8.67 (1H, d, J = 4.8 Hz), 8.09 (1H, d, J = 9.0 Hz), 7.42 (1H, d, J = 2.4 Hz), 7.33 (1H, d, J = 4.8 Hz), 7.28 (1H, dd, J = 9.0 Hz, J = 2.4 Hz), 3.97 (3H, s). 13 CNMR (75MHz, CDCl 3 ) δ161.3, 151.0, 150.2, 142.4, 125.3, 121.7, 120.8, 119.3, 107.7, 55.9.
制备实施例2Preparation Example 2
化合物7e-l的通用合成工艺General synthetic process for compound 7e-1
在250ml的圆底烧瓶中加入4-氯-7-羟基喹啉6e(15mmol)，DMF(70ml)和60％NaH(45mmol)，室温搅拌15min，加入相应的卤代烷烃继续反应，TLC跟踪监测至反应完毕。将反应混合液倒入冰水中停止反应，乙酸乙酯萃取3次，合并有机相，再分别水洗，饱和食盐水洗，无水硫酸钠干燥。过滤，减压浓缩至干，柱层析除去反应杂质，用流动相二氯甲烷:甲醇＝200:1、二氯甲烷:甲醇＝100:1洗脱，收集目标产物，减压浓缩至干。4-Chloro-7-hydroxyquinoline 6e (15 mmol), DMF (70 ml) and 60% NaH (45 mmol) were added to a 250 ml round bottom flask, stirred at room temperature for 15 min, and the corresponding halogenated alkane was added to continue the reaction. The reaction is completed. The reaction mixture was poured into ice water to stop the reaction, and the mixture was extracted three times with ethyl acetate. The organic phase was combined, washed with water, brine and dried over anhydrous sodium sulfate. Filtration, concentrating to dryness under reduced pressure, and EtOAc (EtOAc).
制备实施例2.1：4-氯-7-乙氧基喹啉(7e)PREPARATIVE EXAMPLE 2.1: 4-Chloro-7-ethoxyquinoline (7e)
以4-氯-7-羟基喹啉6e(15mmol)和1-溴乙烷(30mmol)为原料，得浅黄色固体(2.11g，68.0％)。Mp 70-71℃.MS(ESI):m/z(M+H)+207.8.1H NMR(300MHz,CDCl3)δ8.66(1H,d,J＝4.7Hz),8.09(1H,d,J＝9.2Hz),7.39(1H,d,J＝1.8Hz),7.32(1H,d,J＝4.7Hz),7.29–7.20(1H,m),4.19(2H,q,J＝6.9Hz),1.50(3H,t,J＝7.0Hz).13C NMR(75MHz,CDCl3)δ160.3,150.6,149.8,142.0,124.9,121.2,120.7,118.8,107.8,63.7,14.6.HRMS(ESI)calcd for C11H11ClNO[M+H]+208.0524,found 208.0515.4-Chloro-7-hydroxyquinoline 6e (15 mmol) and 1-bromoethane (30 mmol) were obtained as a pale yellow solid (21.1 g, 68.0%). Mp 70-71 ° C. MS (ESI): m/z (M+H) + 207.8. 1 H NMR (300 MHz, CDCl 3 ) δ 8.66 (1H, d, J = 4.7 Hz), 8.09 (1H, d , J = 9.2 Hz), 7.39 (1H, d, J = 1.8 Hz), 7.32 (1H, d, J = 4.7 Hz), 7.29 - 7.20 (1H, m), 4.19 (2H, q, J = 6.9 Hz) ), 1.50 (3H, t, J = 7.0 Hz). 13 C NMR (75 MHz, CDCl 3 ) δ 160.3, 150.6, 149.8, 142.0, 124.9, 121.2, 120.7, 118.8, 107.8, 63.7, 14.6. HRMS (ESI) calcd For C 11 H 11 ClNO[M+H] + 208.0524, found 208.0515.
制备实施例2.2：4-氯-7-异丙氧基喹啉(7f)PREPARATIVE EXAMPLE 2.2: 4-Chloro-7-isopropoxyquinoline (7f)
以4-氯-7-羟基喹啉6e(15mmol)和2-溴丙烷(30mmol)为原料，得浅黄色固体(2.08g，62.6％)。Mp 65-66℃.MS(ESI):m/z(M+H)+221.8.1H NMR(300MHz,CDCl3)δ8.65(1H,d,J＝4.7Hz),8.08(1H,d,J＝9.2Hz),7.39(1H,s),7.30(1H,d,J＝4.7Hz),7.27–7.20(1H,m),4.82–4.67(1H,m),1.43(6H,d,J＝6.0Hz).13C NMR(75MHz,CDCl3)δ159.3,150.5,149.7,142.1,125.0,121.5,121.0,118.7,108.8,70.2,21.7.HRMS(ESI)calcd for C12H13ClNO[M+H]+222.0680,found 222.0676.4-Chloro-7-hydroxyquinoline 6e (15 mmol) and 2-bromopropane (30 mmol) were obtained as pale yellow solid (2.08 g, 62.6%). Mp 65-66 ° C. MS (ESI): m/z (M+H) + 221.8. 1 H NMR (300 MHz, CDCl 3 ) δ 8.65 (1H, d, J = 4.7 Hz), 8.08 (1H, d , J = 9.2 Hz), 7.39 (1H, s), 7.30 (1H, d, J = 4.7 Hz), 7.27 - 7.20 (1H, m), 4.82 - 4.67 (1H, m), 1.43 (6H, d, J = 6.0 Hz). 13 C NMR (75 MHz, CDCl 3 ) δ 159.3, 150.5, 149.7, 142.1, 125.0, 121.5, 121.0, 118.7, 108.8, 70.2, 21.7. HRMS (ESI) calcd for C 12 H 13 ClNO [M +H] + 222.0680, found 222.0676.
制备实施例2.3：4-氯-7-烯丙氧基喹啉(7g)PREPARATIVE EXAMPLE 2.3: 4-Chloro-7-allyloxyquinoline (7 g)
以4-氯-7-羟基喹啉6e(15mmol)和烯丙基溴(30mmol)为原料，得浅黄色固体(2.40g，72.8％)。Mp 36-37℃.MS(ESI):m/z(M+H)+219.8.1H NMR(300MHz,CDCl3)δ8.66(1H,d,J＝4.6Hz),8.09(1H,d,J＝9.1Hz),7.41(1H,s),7.29(2H,dd,J＝15.9Hz,J＝6.2Hz),6.10(1H,m),5.48(1H,d,J＝17.2Hz),5.34(1H,d,J＝10.4Hz),4.69(2H,d,J＝4.8Hz).13C NMR(75MHz,CDCl3)δ159.9,150.5,149.9,142.1,132.2,125.1,121.4,120.8,119.0,118.1,108.4,68.94-Chloro-7-hydroxyquinoline 6e (15 mmol) and allyl bromide (30 mmol) were obtained as a pale yellow solid ( 2.40 g, 72.8%). Mp 36-37 ° C. MS (ESI): m/z (M+H) + 219.8. 1 H NMR (300 MHz, CDCl 3 ) δ 8.66 (1H, d, J = 4.6 Hz), 8.09 (1H, d , J = 9.1 Hz), 7.41 (1H, s), 7.29 (2H, dd, J = 15.9 Hz, J = 6.2 Hz), 6.10 (1H, m), 5.48 (1H, d, J = 17.2 Hz), 5.34 (1H, d, J = 10.4 Hz), 4.69 (2H, d, J = 4.8 Hz). 13 C NMR (75 MHz, CDCl 3 ) δ 159.9, 150.5, 149.9, 142.1, 132.2, 125.1, 121.4, 120.8, 119.0 ,118.1,108.4,68.9
制备实施例2.4：4-氯-7-正丁氧基喹啉(7h)PREPARATIVE EXAMPLE 2.4: 4-Chloro-7-n-butoxyquinoline (7h)
以4-氯-7-羟基喹啉6e(15mmol)和1-溴丁烷(30mmol)为原料，得白色固体(2.22g,63.0％)。Mp37-38℃.MS(ESI):m/z(M+H)+236.1.1H NMR(300MHz,CDCl3)δ8.65(1H,d,J＝4.8Hz),8.08(1H,d,J＝9.2Hz),7.39(1H,d,J＝1.9Hz),7.31(1H,d,J＝4.8Hz),7.29–7.23(1H,m),4.12(2H,t,J＝6.5Hz),1.92–1.79(2H,m),1.62–1.47(2H,m),1.00(3H,t,J＝7.3Hz).13C NMR(75MHz,CDCl3)δ160.5,150.7,149.8,142.0,124.9,121.2,120.8,118.8,108.0,68.0,31.0,19.2,13.84-Chloro-7-hydroxyquinoline 6e (15 mmol) and 1-bromobutane (30 mmol) were obtained as a white solid (2. 2 g, 63.0%). Mp37-38 ° C. MS (ESI): m/z (M+H) + 236.1. 1 H NMR (300 MHz, CDCl 3 ) δ 8.65 (1H, d, J = 4.8 Hz), 8.08 (1H, d, J = 9.2 Hz), 7.39 (1H, d, J = 1.9 Hz), 7.31 (1H, d, J = 4.8 Hz), 7.29 - 7.23 (1H, m), 4.12 (2H, t, J = 6.5 Hz) , 1.92 - 1.79 (2H, m), 1.62 - 1.47 (2H, m), 1.00 (3H, t, J = 7.3 Hz). 13 C NMR (75 MHz, CDCl 3 ) δ 160.5, 150.7, 149.8, 142.0, 124.9, 121.2, 120.8, 118.8, 108.0, 68.0, 31.0, 19.2, 13.8
制备实施例2.5：4-氯-7-正辛氧基喹啉(7i)PREPARATIVE EXAMPLE 2.5: 4-Chloro-7-n-octyloxyquinoline (7i)
以4-氯-7-羟基喹啉6e(15mmol)和1-碘代辛烷(45mmol)为原料，得淡黄色固体(2.51g，57.4％)。1H NMR(400MHz,CDCl3)δ8.68(1H,d,J＝4.8Hz),8.11(1H,d,J＝9.2Hz),7.41(1H,s),7.33(1H,d,J＝4.8Hz),7.27(1H,d,J＝4.8Hz),4.12(2H,t,J＝6.4Hz),1.92–1.81(2H,m),1.55–1.45(2H,m),1.42–1.22(8H,m),0.89(3H,t,J＝6.4Hz).4-Chloro-7-hydroxyquinoline 6e (15 mmol) and 1-iodooctane (45 mmol) were obtained as a pale yellow solid (2.51 g, 57.4%). 1 H NMR (400 MHz, CDCl 3 ) δ 8.68 (1H, d, J = 4.8 Hz), 8.11 (1H, d, J = 9.2 Hz), 7.41 (1H, s), 7.33 (1H, d, J = 4.8 Hz), 7.27 (1H, d, J = 4.8 Hz), 4.12 (2H, t, J = 6.4 Hz), 1.92 - 1.81 (2H, m), 1.55 - 1.45 (2H, m), 1.42 - 1.22 ( 8H, m), 0.89 (3H, t, J = 6.4 Hz).
制备实施例2.6：4-氯-7-苄氧基喹啉(7j)Preparation Example 2.6: 4-Chloro-7-benzyloxyquinoline (7j)
以4-氯-7-羟基喹啉6e(15mmol)和溴化苄(30mmol)为原料，得白色固体(2.11g，52.2％)。Mp 87-88℃.MS(ESI):m/z(M+H)+269.8.1H NMR(300MHz,CDCl3)δ8.67(1H,d,J＝4.7Hz),8.12(1H,d,J＝9.2Hz),7.52–7.30(8H,m),5.21(2H,s).13C NMR(75MHz,CDCl3)δ160.2,150.7,150.0,142.2,135.9,128.5,128.1,127.5,125.2,121.6,120.9,119.2,108.7,70.3.HRMS(ESI)calcd for C16H13ClNO[M+H]+270.0680,found 270.0678.4-Chloro-7-hydroxyquinoline 6e (15 mmol) and benzyl bromide (30 mmol) were obtained as a white solid (21.1 g, 52.2%). Mp 87-88 ° C. MS (ESI): m/z (M+H) + 269.8. 1 H NMR (300 MHz, CDCl 3 ) δ 8.67 (1H, d, J = 4.7 Hz), 8.12 (1H, d , J = 9.2 Hz), 7.52 - 7.30 (8H, m), 5.21 (2H, s). 13 C NMR (75 MHz, CDCl 3 ) δ 160.2, 150.7, 150.0, 142.2, 135.9, 128.5, 128.1, 127.5, 125.2, 121.6, 120.9, 119.2, 108.7, 70.3. HRMS (ESI) calcd for C 16 H 13 ClNO [M+H] + 270.0680, found 270.0678.
制备实施例2.7：4-氯-7-((4’-氟苄基)氧基)喹啉(7k)Preparation Example 2.7: 4-Chloro-7-((4'-fluorobenzyl)oxy)quinoline (7k)
以4-氯-7-羟基喹啉6e(15mmol)和4-氟溴化苄(30mmol)为原料，得黄色固体(2.80g,65.1％)。Mp 98-99℃.MS(ESI):m/z(M+H)+287.9.1H NMR(300MHz,CDCl3)δ8.67(1H,d,J＝4.8Hz),8.12(1H,d,J＝9.2Hz),7.49–7.42(3H,m),7.36–7.30(2H,m),7.08(2H,t,J＝8.7Hz),5.17(2H,s).13C NMR(75MHz,CDCl3)δ162.4(d,J＝246.4Hz),159.9,150.6,150.0,142.2,131.7(d,J＝2.2Hz),129.4(d,J＝8.1Hz),125.2,121.6,120.8,119.2,115.44(d,J＝21.5Hz),108.6,69.5.HRMS(ESI)calcd for C16H12ClFNO[M+H]+288.0586,found 288.0587.4-Chloro-7-hydroxyquinoline 6e (15 mmol) and 4-fluorobenzyl bromide (30 mmol) were obtained as a yellow solid (yield: 2.80 g, 65.1%). Mp 98-99 ° C. MS (ESI): m/z (M+H) + 287.9. 1 H NMR (300 MHz, CDCl 3 ) δ 8.67 (1H, d, J = 4.8 Hz), 8.12 (1H, d , J = 9.2 Hz), 7.49 - 7.42 (3H, m), 7.36 - 7.30 (2H, m), 7.08 (2H, t, J = 8.7 Hz), 5.17 (2H, s). 13 C NMR (75 MHz, CDCl 3 ) δ 162.4 (d, J = 246.4 Hz), 159.9, 150.6, 150.0, 142.2, 131.7 (d, J = 2.2 Hz), 129.4 (d, J = 8.1 Hz), 125.2, 121.6, 120.8, 119.2 , 115.44 (d, J = 21.5 Hz), 108.6, 69.5. HRMS (ESI) calcd for C 16 H 12 ClFNO [M+H] + 288.0586, found 288.0587.
制备实施例2.8：4-氯-7-((3’-苯丙基)氧基)喹啉(7l)PREPARATIVE EXAMPLE 2.8: 4-Chloro-7-((3'-phenylpropyl)oxy)quinoline (7l)
以4-氯-7-羟基喹啉6e(15mmol)和1-溴-3-苯基丙烷(45mmol)为原料，得浅黄色固体(2.22g，49.8％)。Mp 84-85℃.MS(ESI):m/z(M+H)+283.8.1H NMR(300MHz,CDCl3)δ8.64(1H,d,J＝4.0Hz),8.07(1H,d,J＝9.1Hz),7.40(1H,s),7.36–7.19(7H,m),4.34(2H,t,J＝6.7Hz),3.18(2H,t,J＝6.7Hz).13CNMR(75MHz,CDCl3)δ160.1150.6,149.8,142.0,137.7,128.7,128.3,126.4,124.9,121.3,120.7,118.9,108.1,68.7,35.4.4-Chloro-7-hydroxyquinoline 6e (15 mmol) and 1-bromo-3-phenylpropane (45 mmol) were obtained as pale yellow solid (2.22 g, 49.8%). Mp 84-85 ° C. MS (ESI): m/z (M+H) + 283.8. 1 H NMR (300 MHz, CDCl 3 ) δ 8.64 (1H, d, J = 4.0 Hz), 8.07 (1H, d , J = 9.1 Hz), 7.40 (1H, s), 7.36 - 7.19 (7H, m), 4.34 (2H, t, J = 6.7 Hz), 3.18 (2H, t, J = 6.7 Hz). 13 CNMR ( 75MHz, CDCl 3 ) δ160.1150.6, 149.8, 142.0, 137.7, 128.7, 128.3, 126.4, 124.9, 121.3, 120.7, 118.9, 108.1, 68.7, 35.4.
制备实施例3Preparation Example 3
化合物8-51的通用合成工艺General synthetic process for compound 8-51
在100ml的圆底烧瓶中加入4-氯-7-取代喹啉7(2mmol)，丙酮(20ml)和相应的芳香胺(8mmol)，室温搅拌下滴加浓盐酸(15滴)，加热回流反应12h，TLC跟踪监测至反应完毕，将反应液冷却至室温，倒入冰水中，氢氧化钠溶液调节pH至9，乙酸乙酯萃取3次，合并有机相，分别水洗，饱和食盐水洗各一次，有机相用无水硫酸钠干燥，过滤，减压浓缩至干，柱层析除去反应杂质，用流动相PE：EA＝4：1、PE：EA＝3：1、PE：EA＝2：1洗脱，收集目标产物，减压浓缩至干，即得目标产物8-51。其中4-chloro-7-substituted quinoline 7 (2 mmol), acetone (20 ml) and the corresponding aromatic amine (8 mmol) were added to a 100 ml round bottom flask, and concentrated hydrochloric acid (15 drops) was added dropwise with stirring at room temperature, and refluxed under reflux. 12h, TLC tracking monitoring until the reaction is completed, the reaction solution is cooled to room temperature, poured into ice water, adjusted to pH 9 with sodium hydroxide solution, extracted with ethyl acetate 3 times, combined with organic phase, washed with water, and washed once with saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered and evaporated to dryness. Elution, collection of the target product, and concentration to dryness under reduced pressure afforded the desired product 8-51. among them
制备实施例3.1：4-((3’-氟苯基)氨基)-7-氟喹啉(化合物8)的合成Preparation Example 3.1: Synthesis of 4-((3'-fluorophenyl)amino)-7-fluoroquinoline (Compound 8)
以4-氯-7-氟喹啉7a(1.5mmol)和间氟苯胺(8mmol)为原料，得白色固体(0.37g,96.3％)。Mp191.1-191.7℃.1H NMR(400MHz,CDCl3)δ8.61(1H,d,J＝5.2Hz),7.95–7.72(1H,m),7.69(1H,d,J＝10.4Hz),7.40–7.30(2H,m),7.07–7.01(3H,m),6.89(1H,t,J＝8.0Hz),6.64(1H,s).13C NMR(100MHz,DMSO-d6)δ164.0,163.7,161.6,161.2,151.9,150.23(d,J＝12.5Hz),147.2,142.65(d,J＝10.3Hz),130.88(d,J＝9.7Hz),125.15(d,J＝10.1Hz),117.40(d,J＝2.3Hz),117.2,114.7,114.5,112.38(d,J＝19.4Hz),110.0,109.8,108.5,108.2,102.4.4-chloro-7-fluoroquinoline 7a (1.5 mmol) and m-fluoroaniline (8 mmol) were obtained as a white solid (0.37 g, 96.3%). Mp191.1-191.7 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.61 (1H, d, J = 5.2 Hz), 7.95 - 7.72 (1H, m), 7.69 (1H, d, J = 10.4 Hz) , 7.40 - 7.30 (2H, m), 7.07 - 7.01 (3H, m), 6.89 (1H, t, J = 8.0 Hz), 6.64 (1H, s). 13 C NMR (100 MHz, DMSO-d 6 ) δ 164 .0,163.7,161.6,161.2,151.9,150.23(d,J=12.5Hz),147.2,142.65(d,J=10.3Hz),130.88(d,J=9.7Hz),125.15(d,J=10.1Hz) , 117.40 (d, J = 2.3 Hz), 117.2, 114.7, 114.5, 112.38 (d, J = 19.4 Hz), 110.0, 109.8, 108.5, 108.2, 102.4.
制备实施例3.2：4-((3’-氯苯基)氨基)-7-氟喹啉(化合物9)的合成PREPARATIVE EXAMPLE 3.2 Synthesis of 4-((3'-Chlorophenyl)amino)-7-fluoroquinoline (Compound 9)
以4-氯-7-氟喹啉7a(1.5mmol)和间氯苯胺(8mmol)为原料，得白色固体(0.31g,76.0％)。Mp223.0-223.4℃.1H NMR(400MHz,CDCl3)δ8.61(1H,d,J＝5.6Hz),7.94–7.91(1H,m),7.71–7.68(1H,m),7.37–7.29(3H,m),7.17(2H,d,J＝8.0Hz),7.01(1H,d,J＝5.2Hz),6.61(1H,s).13C NMR(100MHz,DMSO-d6)δ163.7,161.2,151.9,150.20(d,J＝12.5Hz),147.2,142.3,133.7,130.9,125.09(d,J＝10.1Hz),123.1,121.3,120.0,117.1,114.8,114.64(d,J＝24.7Hz),112.39(d,J＝19.5Hz),102.2.4-chloro-7-fluoroquinoline 7a (1.5 mmol) and m-chloroaniline (8 mmol) were obtained as a white solid (0.31 g, 76.0%). Mp223.0-223.4 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.61 (1H, d, J = 5.6 Hz), 7.94 - 7.91 (1H, m), 7.71 - 7.68 (1H, m), 7.37 - 7.29 (3H, m), 7.17 (2H, d, J = 8.0 Hz), 7.01 (1H, d, J = 5.2 Hz), 6.61 (1H, s). 13 C NMR (100 MHz, DMSO-d 6 ) δ 163 .7,161.2,151.9,150.20(d,J=12.5Hz),147.2,142.3,133.7,130.9,125.09(d,J=10.1Hz),123.1,121.3,120.0,117.1,114.8,114.64(d,J=24.7 Hz), 112.39 (d, J = 19.5 Hz), 102.2.
制备实施例3.3：4-((3’-溴苯基)氨基)-7-氟喹啉(化合物10)的合成Preparation Example 3.3: Synthesis of 4-((3'-bromophenyl)amino)-7-fluoroquinoline (Compound 10)
以4-氯-7-氟喹啉7a(1.5mmol)和间溴苯胺(8mmol)为原料，得白色固体(0.22g,46.2％)。Mp234.5-235.0℃.1H NMR(400MHz,DMSO-d6)δ9.20(1H,s),8.54(1H,d,J＝5.2Hz),8.47–8.43(1H,m),7.65–7.62(1H,m),7.58–7.45(2H,m),7.44–7.27(3H,m),7.02(1H,d,J＝5.2Hz).13C NMR(100MHz,DMSO-d6)δ163.7,161.2,151.9,150.17(d,J＝12.5Hz),147.2,142.4,131.2,126.0,125.09(d,J＝10.1Hz),124.2,122.1,120.4,117.1,114.8,114.5,112.37(d,J＝19.5Hz),102.2.4-chloro-7-fluoroquinoline 7a (1.5 mmol) and m-bromoaniline (8 mmol) were obtained as a white solid (0.22 g, 46.2%). Mp234.5-235.0 ° C. 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.20 (1H, s), 8.54 (1H, d, J = 5.2 Hz), 8.47 - 8.43 (1H, m), 7.65 - 7.62 (1H, m), 7.58 - 7.45 (2H, m), 7.44 - 7.27 (3H, m), 7.02 (1H, d, J = 5.2 Hz). 13 C NMR (100 MHz, DMSO-d 6 ) δ 163. 7,161.2,151.9,150.17 (d, J=12.5 Hz), 147.2, 142.4, 131.2, 126.0, 125.09 (d, J = 10.1 Hz), 124.2, 122.1, 120.4, 117.1, 114.8, 114.5, 112.37 (d, J = 19.5Hz), 102.2.
制备实施例3.4：4-((3’-硝基苯基)氨基)-7-氟喹啉(化合物11)的合成Preparation Example 3.4: Synthesis of 4-((3'-nitrophenyl)amino)-7-fluoroquinoline (Compound 11)
以4-氯-7-氟喹啉7a(1.5mmol)和间硝基苯胺(8mmol)为原料，得黄色固体(0.29g,68.3％)。Mp231.9-232.5℃.1H NMR(400MHz,DMSO-d6)δ9.47(1H,s),8.59(1H,d,J＝5.2Hz),8.47–8.44(1H,m),8.16(1H,s),7.92(1H,d,J＝7.6Hz),7.83(1H,d,J＝7.6Hz),7.67(2H,t,J＝8.4Hz),7.56–7.52(1H,m),7.15(1H,d,J＝4.8Hz).13C NMR(100MHz,DMSO-d6)δ163.7,161.3,151.9,150.1,148.6,146.6,142.3,130.6,126.8,125.14(d,J＝10.1Hz),117.30(d,J＝7.7Hz),115.0,114.8,112.41(d,J＝19.0Hz),102.7.4-Chloro-7-fluoroquinoline 7a (1.5 mmol) and m-nitroaniline (8 mmol) were obtained as a yellow solid (0.29 g, 68.3%). Mp231.9-232.5 ° C. 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.47 (1H, s), 8.59 (1H, d, J = 5.2 Hz), 8.47 - 8.44 (1H, m), 8.16 ( 1H, s), 7.92 (1H, d, J = 7.6 Hz), 7.83 (1H, d, J = 7.6 Hz), 7.67 (2H, t, J = 8.4 Hz), 7.56 - 7.52 (1H, m), 7.15 (1H, d, J = 4.8 Hz). 13 C NMR (100 MHz, DMSO-d 6 ) δ 163.7, 161.3, 151.9, 150.1, 148.6, 146.6, 142.3, 130.6, 126.8, 125.14 (d, J = 10.1 Hz) , 117.30 (d, J = 7.7 Hz), 115.0, 114.8, 112.41 (d, J = 19.0 Hz), 102.7.
制备实施例3.5：4-((3’-甲氧基苯基)氨基)-7-氟喹啉(化合物12)的合成Preparation Example 3.5: Synthesis of 4-((3'-methoxyphenyl)amino)-7-fluoroquinoline (Compound 12)
以4-氯-7-氟喹啉7a(1.5mmol)和间甲氧基苯胺(8mmol)为原料，得白色固体(0.35g,76.6％)。Mp213.9-214.7℃.1H NMR(400MHz,CDCl3)δ8.57(1H,d,J＝5.6Hz),7.95–7.92(1H,m),7.69–7.66(1H,m),7.35–7.29(2H,m),7.01(1H,d,J＝5.2Hz),6.88(1H,d,J＝8.0Hz),6.84(1H,s),6.77–6.74(1H,m),6.65(1H,s),3.83(3H,s).13C NMR(100MHz,DMSO-d6)δ163.6,161.2,160.2,151.9,150.23(d,J＝12.4Hz),147.9,141.6,130.1,125.10(d,J＝10.1Hz),116.9,114.48(d,J＝3.5Hz),114.2,112.33(d,J＝19.4Hz),109.5,108.1,101.7,55.1.4-chloro-7-fluoroquinoline 7a (1.5 mmol) and m-methoxyaniline (8 mmol) were obtained as a white solid (0.35 g, 76.6%). Mp213.9-214.7 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.57 (1H, d, J = 5.6 Hz), 7.95 - 7.92 (1H, m), 7.69 - 7.66 (1H, m), 7.35 - 7.29 (2H, m), 7.01 (1H, d, J = 5.2 Hz), 6.88 (1H, d, J = 8.0 Hz), 6.84 (1H, s), 6.77 - 6.74 (1H, m), 6.65 (1H) , s), 3.83 (3H, s). 13 C NMR (100MHz, DMSO-d 6 ) δ 163.6, 161.2, 160.2, 151.9, 150.23 (d, J = 12.4 Hz), 147.9, 141.6, 130.1, 125.10 (d, J = 10.1 Hz), 116.9, 114.48 (d, J = 3.5 Hz), 114.2, 112.33 (d, J = 19.4 Hz), 109.5, 108.1, 101.7, 55.1.
制备实施例3.6：4-((3’-甲氧基苯基)氨基)-7-氯喹啉(化合物13)的合成Preparation Example 3.6: Synthesis of 4-((3'-methoxyphenyl)amino)-7-chloroquinoline (Compound 13)
以4-氯-7-氯喹啉7b(1.5mmol)和间甲氧基苯胺(8mmol)为原料，得白色固体(0.33g,产率77.3％)。Mp 213.7-214.1℃.1H NMR(400MHz,CDCl3)δ8.56(1H,d,J＝5.2Hz),8.04(1H,s),7.88(1H,d,J＝9.2Hz),7.45(1H,d,J＝8.8Hz),7.33(1H,t,J＝8.0Hz),7.02(1H,d,J＝5.6Hz),6.88(1H,d,J＝8.4Hz),6.85(1H,s),6.76(1H,d,J＝8.0Hz),6.70(1H,s),3.83(3H,s).13C NMR(101MHz,DMSO-d6)δ160.2,151.9,149.4,147.9,141.4,134.0,130.2,127.6,125.0,124.5,118.4,114.5,109.6,108.1,102.3,55.1.4-chloro-7-chloroquinoline 7b (1.5 mmol) and m-methoxyaniline (8 mmol) were obtained as a white solid (0.33 g, yield 77.3%). Mp 213.7-214.1 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.56 (1H, d, J = 5.2 Hz), 8.04 (1H, s), 7.88 (1H, d, J = 9.2 Hz), 7.45 ( 1H, d, J = 8.8 Hz), 7.33 (1H, t, J = 8.0 Hz), 7.02 (1H, d, J = 5.6 Hz), 6.88 (1H, d, J = 8.4 Hz), 6.85 (1H, s), 6.76 (1H, d, J = 8.0 Hz), 6.70 (1H, s), 3.83 (3H, s). 13 C NMR (101 MHz, DMSO-d 6 ) δ 160.2, 151.9, 149.4, 147.9, 141.4, 134.0, 130.2, 127.6, 125.0, 124.5, 118.4, 114.5, 109.6, 108.1, 102.3, 55.1.
制备实施例3.7：4-((3’-氟苯基)氨基)-7-氯喹啉(化合物14)的合成Preparation Example 3.7: Synthesis of 4-((3'-fluorophenyl)amino)-7-chloroquinoline (Compound 14)
以4-氯-7-氯喹啉7b(1.5mmol)和间氟苯胺(8mmol)为原料，得白色固体(0.40g,97.8％)。Mp209.3-209.6℃.1H NMR(400MHz,CDCl3)δ8.61(1H,d,J＝5.2Hz),8.05(1H,d,J＝1.6Hz),7.87(1H,d,J＝8.8Hz),7.47(1H,dd,J＝8.8,1.6Hz),7.40–7.34(1H,m),7.07–7.00(3H,m),6.91–6.85(1H,m),6.68(1H,s).13C NMR(100MHz,DMSO-d6)δ163.9,161.5,152.0,149.5,147.1,142.50(d,J＝10.4Hz),134.1,130.94(d,J＝9.7Hz),127.6,125.2,124.5,118.6,117.43(d,J＝2.3Hz),110.1,109.9,108.5,108.2,103.0.4-chloro-7-chloroquinoline 7b (1.5 mmol) and m-fluoroaniline (8 mmol) were obtained as a white solid (0.40 g, 97.8%). Mp 209.3-209.6 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.61 (1H, d, J = 5.2 Hz), 8.05 (1H, d, J = 1.6 Hz), 7.87 (1H, d, J = 8.8 Hz), 7.47 (1H, dd, J = 8.8, 1.6 Hz), 7.40 - 7.34 (1H, m), 7.07 - 7.00 (3H, m), 6.91 - 6.85 (1H, m), 6.68 (1H, s 13 C NMR (100 MHz, DMSO-d 6 ) δ 163.9, 161.5, 152.0, 149.5, 147.1, 142.50 (d, J = 10.4 Hz), 134.1, 130.94 (d, J = 9.7 Hz), 127.6, 125.2, 124.5 , 118.6, 117.43 (d, J = 2.3 Hz), 110.1, 109.9, 108.5, 108.2, 103.0.
制备实施例3.8：4-((3’-硝基苯基)氨基)-7-氯喹啉(化合物15)的合成Preparation Example 3.8: Synthesis of 4-((3'-nitrophenyl)amino)-7-chloroquinoline (Compound 15)
以4-氯-7-氯喹啉7b(1.5mmol)和间硝基苯胺(8mmol)为原料，得白色固体(0.28g,62.3％)。Mp234-237℃.1H NMR(400MHz,DMSO-d6)δ9.48(1H,s),8.59(1H,d,J＝5.2Hz),8.40(1H,d,J＝9.2Hz),8.16(1H,s),7.99–7.88(2H,m),7.83(1H,d,J＝8.0Hz),7.70–7.60(2H,m),7.18(1H,d,J＝4.8Hz).13CNMR(100MHz,DMSO-d6)δ151.9,149.5,148.6,146.6,142.2,134.3,130.7,127.7,126.8,125.5,124.5,118.8,117.4,115.1,103.3.4-chloro-7-chloroquinoline 7b (1.5 mmol) and m-nitroaniline (8 mmol) were obtained as a white solid (0.28 g, 62.3%). Mp234-237 ℃. 1 H NMR (400MHz , DMSO-d 6) δ9.48 (1H, s), 8.59 (1H, d, J = 5.2Hz), 8.40 (1H, d, J = 9.2Hz), 8.16 (1H, s), 7.99 - 7.88 (2H, m), 7.83 (1H, d, J = 8.0 Hz), 7.70 - 7.60 (2H, m), 7.18 (1H, d, J = 4.8 Hz). 13 CNMR (100MHz, DMSO-d 6 ) δ151.9, 149.5, 148.6, 146.6, 142.2, 134.3, 130.7, 127.7, 126.8, 125.5, 124.5, 118.8, 117.4, 115.1, 103.3.
制备实施例3.9：4-((3’-氟苯基)氨基)-7-溴喹啉(化合物16)的合成Preparation Example 3.9: Synthesis of 4-((3'-fluorophenyl)amino)-7-bromoquinoline (Compound 16)
以4-氯-7-溴喹啉7c(2mmol)和间氟苯胺(8mmol)为原料，得白色固体(0.52g,82.3％)。Mp 212.5-214.0℃.1H NMR(400MHz,CDCl3)δ8.60(1H,d,J＝5.2Hz),8.23(1H,s),7.80(1H,d,J＝9.2Hz),7.60(1H,d,J＝8.8Hz),7.40–7.34(1H,dd,J＝14.8,7.9Hz),7.08–7.00(3H,m),6.91–6.87(1H,m),6.68(1H,s).13CNMR(101MHz,DMSO-d6)δ163.9,161.5,152.0,149.8,147.1,142.45(d,J＝10.6Hz),130.95(d,J＝9.5Hz),127.8,124.5,122.8,118.9,117.40(d,J＝2.3Hz),110.1,109.9,108.4,108.2,103.0.4-chloro-7-bromoquinoline 7c (2 mmol) and m-fluoroaniline (8 mmol) were obtained as a white solid (0.52 g, 82.3%). Mp 212.5-214.0 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.60 (1H, d, J = 5.2 Hz), 8.23 (1H, s), 7.80 (1H, d, J = 9.2 Hz), 7.60 ( 1H, d, J = 8.8 Hz), 7.40 - 7.34 (1H, dd, J = 14.8, 7.9 Hz), 7.08 - 7.00 (3H, m), 6.91 - 6.87 (1H, m), 6.68 (1H, s) 13 C NMR (101 MHz, DMSO-d 6 ) δ 163.9, 161.5, 152.0, 149.8, 147.1, 142.45 (d, J = 10.6 Hz), 130.95 (d, J = 9.5 Hz), 127.8, 124.5, 122.8, 118.9, 117.40 (d, J = 2.3 Hz), 110.1, 109.9, 108.4, 108.2, 103.0.
制备实施例3.10：4-((3’-氯苯基)氨基)-7-溴喹啉(化合物17)的合成Preparation Example 3.10: Synthesis of 4-((3'-chlorophenyl)amino)-7-bromoquinoline (Compound 17)
以4-氯-7-溴喹啉7c(1.5mmol)和间氯苯胺(8mmol)为原料，得白色固体(0.34g,68.3％)。Mp229.0-229.7℃.1H NMR(400MHz,CDCl3)δ8.60(1H,d,J＝5.2Hz),8.24(1H,s),7.79(1H,d,J＝8.8Hz),7.63–7.58(1H,m),7.35(1H,t,J＝8.0Hz),7.30(1H,s),7.17(2H,d,J＝8.0Hz),7.04(1H,d,J＝5.2Hz),6.62(1H,s).13C NMR(100MHz,DMSO-d6)δ151.9,149.7,147.2,142.2,133.7,130.9,127.8,124.5,123.2,122.8,121.2,120.0,118.9,102.9.4-chloro-7-bromoquinoline 7c (1.5 mmol) and m-chloroaniline (8 mmol) were obtained as a white solid (0.34 g, 68.3%). Mp229.0-229.7°C. 1 H NMR (400MHz, CDCl 3 ) δ 8.60 (1H, d, J = 5.2 Hz), 8.24 (1H, s), 7.79 (1H, d, J = 8.8 Hz), 7.63 –7.58(1H,m), 7.35(1H,t,J=8.0Hz), 7.30(1H,s), 7.17(2H,d,J=8.0Hz),7.04(1H,d,J=5.2Hz) , 6.62 (1H, s). 13 C NMR (100MHz, DMSO-d 6 ) δ 151.9, 149.7, 147.2, 142.2, 133.7, 130.9, 127.8, 124.5, 123.2, 122.8, 121.2, 120.0, 118.9, 102.9.
制备实施例3.11：4-((3’-溴苯基)氨基)-7-溴喹啉(化合物18)的合成Preparation Example 3.11: Synthesis of 4-((3'-bromophenyl)amino)-7-bromoquinoline (Compound 18)
以4-氯-7-溴喹啉7c(1.5mmol)和间溴苯胺(8mmol)为原料，得白色固体(0.39g,69.2％)。Mp238.5-239.9℃.1H NMR(400MHz,CDCl3)δ8.61(1H,d,J＝5.2Hz),8.24(1H,s),7.78(1H,d,J＝8.8Hz),7.62(1H,d,J＝8.0Hz),7.46(s,1H,),7.34–7.29(2H,m),7.22(1H,d,J＝7.6Hz),7.03(1H,d,J＝5.2Hz),6.57(1H,s).13C NMR(100MHz,DMSO-d6)δ151.7,149.6,147.3,142.3,131.2,130.8,127.8,126.2,124.5,124.2,122.9,122.1,120.5,118.8,102.8.4-chloro-7-bromoquinoline 7c (1.5 mmol) and m-bromoaniline (8 mmol) were obtained as a white solid (0.39 g, 69.2%). Mp238.5-239.9 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.61 (1H, d, J = 5.2 Hz), 8.24 (1H, s), 7.78 (1H, d, J = 8.8 Hz), 7.62 (1H, d, J = 8.0 Hz), 7.46 (s, 1H,), 7.34 - 7.29 (2H, m), 7.22 (1H, d, J = 7.6 Hz), 7.03 (1H, d, J = 5.2 Hz) ), 6.57 (1H, s). 13 C NMR (100MHz, DMSO-d 6 ) δ 151.7, 149.6, 147.3, 142.3, 131.2, 130.8, 127.8, 126.2, 124.5, 124.2, 122.9, 122.1, 120.5, 118.8, 102.8.
制备实施例3.12：4-((3’-硝基苯基)氨基)-7-溴喹啉(化合物19)的合成Preparation Example 3.12: Synthesis of 4-((3'-nitrophenyl)amino)-7-bromoquinoline (Compound 19)
以4-氯-7-溴喹啉7c(2mmol)和间硝基苯胺(8mmol)为原料，得黄色固体(0.74g,97.2％)。Mp222.0-223.4℃.1H NMR(400MHz,DMSO-d6)δ9.50(1H,s),8.58(1H,d,J＝4.8Hz),8.33(1H,d,J＝8.8Hz),8.14(2H,d,J＝11.2Hz),7.93(1H,d,J＝8.4Hz),7.83(1H,d,J＝8.0Hz),7.76(1H,d,J＝8.8Hz),7.67(1H,t,J＝8.0Hz),7.20(1H,d,J＝4.4Hz).13C NMR(101MHz,DMSO-d6)δ151.7,149.6,148.5,146.6,142.2,130.8,130.6,128.0,126.8,124.5,123.0,119.0,117.3,115.1,103.3.4-Chloro-7-bromoquinoline 7c (2 mmol) and m-nitroaniline (8 mmol) were obtained as a yellow solid (0.74 g, 97.2%). Mp222.0-223.4°C. 1 H NMR (400MHz, DMSO-d 6 ) δ 9.50 (1H, s), 8.58 (1H, d, J = 4.8 Hz), 8.33 (1H, d, J = 8.8 Hz) , 8.14 (2H, d, J = 11.2 Hz), 7.93 (1H, d, J = 8.4 Hz), 7.83 (1H, d, J = 8.0 Hz), 7.76 (1H, d, J = 8.8 Hz), 7.67 (1H, t, J = 8.0 Hz), 7.20 (1H, d, J = 4.4 Hz). 13 C NMR (101 MHz, DMSO-d 6 ) δ 151.7, 149.6, 148.5, 146.6, 142.2, 130.8, 130.6, 128.0, 126.8, 124.5, 123.0, 119.0, 117.3, 115.1, 103.3.
制备实施例3.13：4-((3’-甲氧基苯基)氨基)-7-溴喹啉(化合物20)的合成Preparation Example 3.13: Synthesis of 4-((3'-methoxyphenyl)amino)-7-bromoquinoline (Compound 20)
以4-氯-7-溴喹啉7c(2mmol)和间甲氧基苯胺(8mmol)为原料，得浅绿色固体(0.30g,63.3％)。Mp215.4-216.4℃.1H NMR(400MHz,CDCl3)δ8.56(1H,d,J＝5.2Hz),8.22(1H,s),7.80(1H,d,J＝8.8Hz), 7.58(1H,d,J＝8.8Hz),7.33(1H,t,J＝8.0Hz),7.04(1H,d,J＝5.2Hz),6.88(1H,d,J＝8.0Hz),6.84(1H,s),6.76(1H,d,J＝8.4Hz),6.65(1H,s),3.83(3H,s).13C NMR(100MHz,DMSO-d6)δ160.2,151.8,149.8,147.9,141.4,130.9,130.1,127.5,124.5,122.6,118.7,114.4,109.5,108.0,102.4,55.1.4-Chloro-7-bromoquinoline 7c (2 mmol) and m-methoxyaniline (8 mmol) were obtained as a pale green solid (0.30 g, 63.3%). Mp215.4-216.4 ℃. 1 H NMR (400MHz , CDCl 3) δ8.56 (1H, d, J = 5.2Hz), 8.22 (1H, s), 7.80 (1H, d, J = 8.8Hz), 7.58 (1H, d, J = 8.8 Hz), 7.33 (1H, t, J = 8.0 Hz), 7.04 (1H, d, J = 5.2 Hz), 6.88 (1H, d, J = 8.0 Hz), 6.84 (1H) , s), 6.76 (1H, d, J = 8.4 Hz), 6.65 (1H, s), 3.83 (3H, s). 13 C NMR (100 MHz, DMSO-d 6 ) δ 160.2, 151.8, 149.8, 147.9, 141.4 , 130.9, 130.1, 127.5, 124.5, 122.6, 118.7, 114.4, 109.5, 108.0, 102.4, 55.1.
制备实施例3.14：4-((3’-氟苯基)氨基)-7-甲氧基喹啉(化合物21)的合成Preparation Example 3.14: Synthesis of 4-((3'-fluorophenyl)amino)-7-methoxyquinoline (Compound 21)
以4-氯-7-甲氧基喹啉7d(1mmol)和间氟苯胺(8mmol)为原料，得白色固体(0.12g,44.8％)。Mp238-239℃.1H NMR(400MHz,DMSO-d6)δ8.46(1H,d,J＝5.6Hz),8.33(1H,d,J＝8.8Hz),7.51–7.43(1H,m),7.30–7.19(4H,m),7.02–6.97(1H,m),6.94(1H,d,J＝6.0Hz),3.93(3H,s).13C NMR(100MHz,DMSO-d6)δ162.74(d,J＝241.0Hz),160.0,150.9(d,J＝4.7Hz),146.7,143.1(d,J＝10.3Hz),130.8(d,J＝9.7Hz),123.5,116.9(2C),114.7,109.4,109.2,107.8(d,J＝6.5Hz),107.6,101.7,55.3.4-chloro-7-methoxyquinoline 7d (1 mmol) and m-fluoroaniline (8 mmol) were obtained as a white solid (0.12 g, 44.8%). Mp 238-239 ° C. 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.46 (1H, d, J = 5.6 Hz), 8.33 (1H, d, J = 8.8 Hz), 7.51 - 7.43 (1H, m) , 7.30 - 7.19 (4H, m), 7.02 - 6.97 (1H, m), 6.94 (1H, d, J = 6.0 Hz), 3.93 (3H, s). 13 C NMR (100 MHz, DMSO-d 6 ) δ 162 .74 (d, J = 241.0 Hz), 160.0, 150.9 (d, J = 4.7 Hz), 146.7, 143.1 (d, J = 10.3 Hz), 130.8 (d, J = 9.7 Hz), 123.5, 116.9 (2C ), 114.7, 109.4, 109.2, 107.8 (d, J = 6.5 Hz), 107.6, 101.7, 55.3.
制备实施例3.15：4-((3’-溴苯基)氨基)-7-甲氧基喹啉(化合物22)的合成Preparation Example 3.15: Synthesis of 4-((3'-bromophenyl)amino)-7-methoxyquinoline (Compound 22)
以4-氯-7-甲氧基喹啉7d(1mmol)和间溴苯胺(8mmol)为原料，得白色固体(0.22g,67.1％)。Mp>250℃.1H NMR(400MHz,DMSO-d6)δ9.01(1H,s),8.46(1H,d,J＝5.2Hz),8.23(1H,d,J＝9.2Hz),7.51(1H,s),7.38–7.25(4H,m),7.22–7.19(1H,m),6.94(1H,d,J＝5.2Hz),3.91(3H,s).13C NMR(100MHz,DMSO-d6)δ160.0,151.0,146.6,142.9,131.2,125.4,123.6,123.5,122.0,119.9,117.0,114.7,107.8,101.5,55.3.4-chloro-7-methoxyquinoline 7d (1 mmol) and m-bromoaniline (8 mmol) were obtained as a white solid (0.22 g, 67.1%). Mp > 250 ° C. 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.01 (1H, s), 8.46 (1H, d, J = 5.2 Hz), 8.23 (1H, d, J = 9.2 Hz), 7.51 (1H, s), 7.38 - 7.25 (4H, m), 7.22 - 7.19 (1H, m), 6.94 (1H, d, J = 5.2 Hz), 3.91 (3H, s). 13 C NMR (100 MHz, DMSO -d 6 ) δ160.0, 151.0, 146.6, 142.9, 131.2, 125.4, 123.6, 123.5, 122.0, 119.9, 117.0, 114.7, 107.8, 101.5, 55.3.
制备实施例3.16：4-((3’-硝基苯基)氨基)-7-甲氧基喹啉(化合物23)的合成Preparation Example 3.16: Synthesis of 4-((3'-nitrophenyl)amino)-7-methoxyquinoline (Compound 23)
以4-氯-7-甲氧基喹啉7d(1mmol)和间硝基苯胺(8mmol)为原料，得黄色固体(0.12g,40.7％)。Mp200-201℃.1H NMR(400MHz,DMSO-d6)δ9.34(1H,s),8.51(1H,d,J＝4.8Hz),8.26(1H,d,J＝9.2Hz),8.13(1H,t,J＝2.0Hz),7.88(1H,dd,J＝8.0,2.4Hz),7.80(1H,dd,J＝8.0,1.6Hz),7.64(1H,t,J＝8.0Hz),7.33(1H,d,J＝2.4Hz),7.24(1H,dd,J＝9.2,2.8Hz),7.07(1H,d,J＝5.2Hz),3.93(3H,s).13C NMR(100MHz,DMSO-d6)δ160.2,150.9,148.6,146.1,142.8,130.6,126.3,123.6,117.3,116.7,114.9,114.4,107.8,102.1,55.4.4-Chloro-7-methoxyquinoline 7d (1 mmol) and m-nitrophenylamine (8 mmol) were obtained as a yellow solid (0.12 g, 40.7%). Mp200-201 ℃. 1 H NMR (400MHz , DMSO-d 6) δ9.34 (1H, s), 8.51 (1H, d, J = 4.8Hz), 8.26 (1H, d, J = 9.2Hz), 8.13 (1H, t, J = 2.0 Hz), 7.88 (1H, dd, J = 8.0, 2.4 Hz), 7.80 (1H, dd, J = 8.0, 1.6 Hz), 7.64 (1H, t, J = 8.0 Hz) , 7.33 (1H, d, J = 2.4 Hz), 7.24 (1H, dd, J = 9.2, 2.8 Hz), 7.07 (1H, d, J = 5.2 Hz), 3.93 (3H, s). 13 C NMR ( 100 MHz, DMSO-d 6 ) δ 160.2, 150.9, 148.6, 146.1, 142.8, 130.6, 126.3, 123.6, 117.3, 116.7, 114.9, 114.4, 107.8, 102.1, 55.4.
制备实施例3.17：4-((3’-羟基苯基)氨基)-7-甲氧基喹啉(化合物24)的合成Preparation Example 3.17: Synthesis of 4-((3'-hydroxyphenyl)amino)-7-methoxyquinoline (Compound 24)
以4-氯-7-甲氧基喹啉7d(1mmol)和间羟基苯胺(8mmol)为原料，得白色固体(0.07g,26.3％)。Mp248-249℃.1H NMR(400MHz,DMSO-d6)δ9.50(1H,s),8.79(1H,s),8.38(1H,d,J＝5.2Hz),8.26(1H,d,J＝9.2Hz),7.25(1H,d,J＝2.4Hz),7.22–7.14(2H,m),6.85(1H,d,J＝5.2Hz),6.78–6.76(2H,m),6.54–6.52(1H,m),3.90(3H,s).13C NMR(100MHz,DMSO-d6)δ160.0,158.2,150.8,147.6,141.8,130.0,123.6,116.5,114.4,112.8,110.7,109.0,107.7,100.9,55.3.4-chloro-7-methoxyquinoline 7d (1 mmol) and m-hydroxyaniline (8 mmol) were obtained as a white solid (0.07 g, 26.3%). Mp248-249 ℃. 1 H NMR (400MHz , DMSO-d 6) δ9.50 (1H, s), 8.79 (1H, s), 8.38 (1H, d, J = 5.2Hz), 8.26 (1H, d, J = 9.2 Hz), 7.25 (1H, d, J = 2.4 Hz), 7.22 - 7.14 (2H, m), 6.85 (1H, d, J = 5.2 Hz), 6.78 - 6.76 (2H, m), 6.54 - 6.52 (1H, m), 3.90 (3H, s). 13 C NMR (100MHz, DMSO-d 6 ) δ 160.0, 158.2, 150.8, 147.6, 141.8, 130.0, 123.6, 116.5, 114.4, 112.8, 110.7, 109.0, 107.7 , 100.9, 55.3.
制备实施例3.18：4-((3’-甲氧基苯基)氨基)-7-甲氧基喹啉(化合物25)的合成Preparation Example 3.18: Synthesis of 4-((3'-methoxyphenyl)amino)-7-methoxyquinoline (Compound 25)
以4-氯-7-甲氧基喹啉7d(1.5mmol)和间甲氧基苯胺(8mmol)为原料，得白色固体(0.34g,81.0％)。Mp 221.0-222.3℃.1H NMR(400MHz,CDCl3)δ8.50(1H,d,J＝5.2Hz),7.82(1H,d,J＝9.2Hz),7.38(1H,s),7.31(1H,t,J＝8.0Hz),7.15(1H,d,J＝9.2Hz),6.96(1H,d,J＝5.2Hz),6.88(1H,d,J＝8.0Hz),6.84(1H,s),6.72(1H,d,J＝8.0Hz),6.61(1H,s),3.95(3H,s),3.82(3H,s).13C NMR(100MHz,DMSO-d6)δ160.2,160.1,150.7,150.6,147.6,141.9,130.1,123.6,116.7,114.4,114.2,109.1,107.7,107.6,101.0,55.3,55.1.4-chloro-7-methoxyquinoline 7d (1.5 mmol) and m-methoxyaniline (8 mmol) were obtained as a white solid (0.34 g, 81.0%). Mp 221.0-222.3 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.50 (1H, d, J = 5.2 Hz), 7.82 (1H, d, J = 9.2 Hz), 7.38 (1H, s), 7.31 ( 1H, t, J = 8.0 Hz), 7.15 (1H, d, J = 9.2 Hz), 6.96 (1H, d, J = 5.2 Hz), 6.88 (1H, d, J = 8.0 Hz), 6.84 (1H, s), 6.72 (1H, d, J = 8.0 Hz), 6.61 (1H, s), 3.95 (3H, s), 3.82 (3H, s). 13 C NMR (100 MHz, DMSO-d 6 ) δ 160.2, 160.1 , 150.7, 150.6, 147.6, 141.9, 130.1, 123.6, 116.7, 114.4, 114.2, 109.1, 107.7, 107.6, 101.0, 55.3, 55.1.
制备实施例3.19：4-((3’,4’-二氯苯基)氨基)-7-甲氧基喹啉(化合物26)的合成Preparation Example 3.19: Synthesis of 4-((3',4'-dichlorophenyl)amino)-7-methoxyquinoline (Compound 26)
以4-氯-7-甲氧基喹啉7d(1mmol)和3,4-二氯苯胺(8mmol)为原料，得浅黄色固体(0.13g,40.9％)。Mp 216-218℃.1H NMR(400MHz,DMSO-d6)δ9.10(1H,s),8.48(1H,d,J＝5.2Hz),8.22(1H,d,J＝9.2 Hz),7.59(1H,d,J＝8.8Hz),7.54(1H,d,J＝2.4Hz),7.35–7.30(2H,m),7.22(1H,dd,J＝9.2,2.4Hz),6.97(1H,d,J＝5.2Hz),3.92(3H,s).13C NMR(100MHz,DMSO-d6)δ160.1,150.8,146.4,141.6,131.5,131.0,124.0,123.5,122.2,120.8,117.1,114.8,107.7,102.0,55.3.4-chloro-7-methoxyquinoline 7d (1 mmol) and 3,4-dichloroaniline (8 mmol) were obtained as pale yellow solid (0.13 g, 40.9%). Mp 216-218 ℃. 1 H NMR ( 400MHz, DMSO-d 6) δ9.10 (1H, s), 8.48 (1H, d, J = 5.2Hz), 8.22 (1H, d, J = 9.2 Hz), 7.59 (1H, d, J = 8.8 Hz), 7.54 (1H, d, J = 2.4 Hz), 7.35 - 7.30 (2H, m), 7.22 (1H, dd, J = 9.2, 2.4 Hz), 6.97 (1H) , d, J = 5.2 Hz), 3.92 (3H, s). 13 C NMR (100 MHz, DMSO-d 6 ) δ 160.1, 150.8, 146.4, 141.6, 131.5, 131.0, 124.0, 123.5, 122.2, 120.8, 117.1, 114.8 , 107.7, 102.0, 55.3.
制备实施例3.20：4-((3’-氟苯基)氨基)-7-乙氧基喹啉(化合物27)的合成Preparation Example 3.20: Synthesis of 4-((3'-fluorophenyl)amino)-7-ethoxyquinoline (Compound 27)
以4-氯-7-乙氧基喹啉7e(1.2mmol)和间氟苯胺(8mmol)为原料，得白色固体(0.24g,70.9％)。Mp223.2-224.4℃.1H NMR(400MHz,CDCl3)δ8.54(1H,d,J＝5.2Hz),7.82(1H,d,J＝9.2Hz),7.37–7.31(2H,m),7.15(1H,dd,J＝9.2,2.0Hz),7.05–6.97(3H,m),6.86–6.82(1H,m),6.71(1H,s),4.17(2H,q,J＝6.8Hz),1.49(3H,t,J＝6.8Hz).13C NMR(100MHz,DMSO-d6)δ163.9,161.5,159.3,150.87(d,J＝6.4Hz),146.6,143.09(d,J＝10.5Hz),130.82(d,J＝9.7Hz),123.5,117.2,116.84(d,J＝2.3Hz),114.6,109.4,109.2,108.3,107.8,107.6,101.7,63.3,14.5.4-chloro-7-ethoxyquinoline 7e (1.2 mmol) and m-fluoroaniline (8 mmol) were obtained as a white solid (0.24 g, 70.9%). Mp223.2-224.4°C. 1 H NMR (400MHz, CDCl 3 ) δ 8.54 (1H, d, J = 5.2 Hz), 7.82 (1H, d, J = 9.2 Hz), 7.37 - 7.31 (2H, m) , 7.15 (1H, dd, J=9.2, 2.0 Hz), 7.05–6.97 (3H, m), 6.86–6.82 (1H, m), 6.71 (1H, s), 4.17 (2H, q, J=6.8Hz) ), 1.49 (3H, t, J = 6.8 Hz). 13 C NMR (100 MHz, DMSO-d 6 ) δ 163.9, 161.5, 159.3, 150.87 (d, J = 6.4 Hz), 146.6, 143.09 (d, J = 10.5) Hz), 130.82 (d, J = 9.7 Hz), 123.5, 117.2, 116.84 (d, J = 2.3 Hz), 114.6, 109.4, 109.2, 108.3, 107.8, 107.6, 101.7, 63.3, 14.5.
制备实施例3.21：4-((3’-甲氧基苯基)氨基)-7-乙氧基喹啉(化合物28)的合成Preparation Example 3.21: Synthesis of 4-((3'-methoxyphenyl)amino)-7-ethoxyquinoline (Compound 28)
以4-氯-7-乙氧基喹啉7e(1.2mmol)和间甲氧基苯胺(8mmol)为原料，得白色固体(0.34g,96.3％)。Mp 176.4-177.9℃.1H NMR(400MHz,CDCl3)δ8.50(1H,d,J＝5.2Hz),7.81(1H,d,J＝9.2Hz),7.37–7.29(2H,m),7.15(1H,dd,J＝9.2,2.4Hz),6.96(1H,d,J＝5.2Hz),6.88–6.84(2H,m),6.72(1H,d,J＝6.8Hz),6.57(1H,s),4.19(2H,q,J＝6.8Hz),3.83(3H,s),1.50(3H,t,J＝6.8Hz).13C NMR(100MHz,CDCl3)δ160.8,160.1,151.1,151.0,147.7,141.6,130.5,121.5,118.4,114.7,114.6,109.8,108.7,108.2,101.8,63.8,55.5,14.8.4-chloro-7-ethoxyquinoline 7e (1.2 mmol) and m-methoxyaniline (8 mmol) were obtained as a white solid (0.34 g, 96.3%). Mp 176.4-177.9 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.50 (1H, d, J = 5.2 Hz), 7.81 (1H, d, J = 9.2 Hz), 7.37 - 7.29 (2H, m), 7.15 (1H, dd, J = 9.2, 2.4 Hz), 6.96 (1H, d, J = 5.2 Hz), 6.88 - 6.84 (2H, m), 6.72 (1H, d, J = 6.8 Hz), 6.57 (1H) , s), 4.19 (2H, q, J = 6.8 Hz), 3.83 (3H, s), 1.50 (3H, t, J = 6.8 Hz). 13 C NMR (100 MHz, CDCl 3 ) δ 160.8, 160.1, 151.1, 151.0, 147.7, 141.6, 130.5, 121.5, 118.4, 114.7, 114.6, 109.8, 108.7, 108.2, 101.8, 63.8, 55.5, 14.8.
制备实施例3.22：4-((3’-硝基苯基)氨基)-7-乙氧基喹啉(化合物29)的合成Preparation Example 3.22: Synthesis of 4-((3'-nitrophenyl)amino)-7-ethoxyquinoline (Compound 29)
以4-氯-7-乙氧基喹啉7e(1.2mmol)和间硝基苯胺(8mmol)为原料，得黄色固体(0.22g,59.4％)。Mp 184.9-185.6℃.1H NMR(400MHz,CDCl3)δ8.59(1H,d,J＝5.2Hz),8.10(1H,s),7.95(1H,d,J＝7.6Hz),7.86(1H,d,J＝9.2Hz),7.60–7.52(2H,m),7.39(1H,s),7.22–7.15(1H,m),7.00(1H,d,J＝5.2Hz),6.88(1H,s),4.17(2H,q,J＝6.8Hz),1.49(3H,t,J＝6.8Hz).13C NMR(100MHz,DMSO-d6)δ159.4,150.8,148.6,146.1,142.8,130.6,126.2,123.5,117.5,116.7,114.8,114.4,108.3,102.1,63.3,14.5.4-Chloro-7-ethoxyquinoline 7e (1.2 mmol) and m-nitroaniline (8 mmol) were obtained as a yellow solid (0.22 g, 59.4%). Mp 184.9-185.6 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.59 (1H, d, J = 5.2 Hz), 8.10 (1H, s), 7.95 (1H, d, J = 7.6 Hz), 7.86 ( 1H, d, J = 9.2 Hz), 7.60 - 7.52 (2H, m), 7.39 (1H, s), 7.22 - 7.15 (1H, m), 7.00 (1H, d, J = 5.2 Hz), 6.88 (1H) , s), 4.17 (2H, q, J = 6.8 Hz), 1.49 (3H, t, J = 6.8 Hz). 13 C NMR (100 MHz, DMSO-d 6 ) δ 159.4, 150.8, 148.6, 146.1, 142.8, 130.6 , 126.2, 123.5, 117.5, 116.7, 114.8, 114.4, 108.3, 102.1, 63.3, 14.5.
制备实施例3.23：4-((3’-氟苯基)氨基)-7-异丙氧基喹啉(化合物30)的合成Preparation Example 3.23: Synthesis of 4-((3'-fluorophenyl)amino)-7-isopropoxyquinoline (Compound 30)
以4-氯-7-异丙氧基喹啉7f(1.5mmol)和间氟苯胺(8mmol)为原料，得白色固体(0.27g,61.4％)。Mp>250℃.1H NMR(400MHz,CDCl3)δ8.54(1H,d,J＝5.2Hz),7.81(1H,d,J＝9.2Hz),7.38–7.31(2H,m),7.13(1H,d,J＝9.2Hz),7.04–6.97(3H,m),6.84(1H,t,J＝8.0Hz),6.62(1H,s),4.77–4.71(1H,m),1.42(6H,d,J＝6.0Hz).13C NMR(100MHz,DMSO-d6)δ164.0,161.5,158.2,150.78(d,J＝10.7Hz),146.7,143.09(d,J＝10.6Hz),130.86(d,J＝9.8Hz),123.7,117.8,116.88(d,J＝2.1Hz),114.5,109.4,109.2,107.8,107.6,101.6,69.4,21.7.4-chloro-7-isopropoxyquinoline 7f (1.5 mmol) and m-fluoroaniline (8 mmol) were obtained as a white solid (0.27 g, 61.4%). Mp > 250 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.54 (1H, d, J = 5.2 Hz), 7.81 (1H, d, J = 9.2 Hz), 7.38 - 7.31 (2H, m), 7.13 (1H, d, J = 9.2 Hz), 7.04 - 6.97 (3H, m), 6.84 (1H, t, J = 8.0 Hz), 6.62 (1H, s), 4.77 - 4.71 (1H, m), 1.42 ( 6H, d, J = 6.0 Hz). 13 C NMR (100 MHz, DMSO-d 6 ) δ 164.0, 161.5, 158.2, 150.78 (d, J = 10.7 Hz), 146.7, 143.09 (d, J = 10.6 Hz), 130.86 (d, J = 9.8 Hz), 123.7, 117.8, 116.88 (d, J = 2.1 Hz), 114.5, 109.4, 109.2, 107.8, 107.6, 101.6, 69.4, 21.7.
制备实施例3.24：4-((3’-甲氧基)氨基)-7-异丙氧基喹啉(化合物31)的合成Preparation Example 3.24: Synthesis of 4-((3'-methoxy)amino)-7-isopropoxyquinoline (Compound 31)
以4-氯-7-异丙氧基喹啉7f(1.5mmol)和间甲氧基苯胺(8mmol)为原料，得淡黄色固体(0.34g,73.9％)。Mp 155.3-156.1℃.1H NMR(400MHz,CDCl3)δ8.49(d,J＝5.2Hz,1H,),7.82(d,J＝9.2Hz,1H,),7.37(s,1H,),7.30(t,J＝8.0Hz,1H,),7.12(dd,J＝9.2,2.0Hz,1H,),6.94(d,J＝5.2Hz,1H,),6.88–6.84(m,2H,),6.72(d,J＝8.4Hz,1H,),6.62(s,1H,NH),4.77–4.71(m,1H,OCH(CH3)2),3.82(s,3H,OCH3),1.42(d,J＝6.0Hz,6H,OCH(CH3)2).13C NMR(100MHz,CDCl3)δ160.8,159.0,151.12,151.0,147.6,141.6,130.5,121.5,119.2,114.7,114.4,109.8,109.7,108.2,101.7,70.1,55.5,22.0.4-Chloro-7-isopropoxyquinoline 7f (1.5 mmol) and m-methoxyaniline (8 mmol) were obtained as pale yellow solid (0.34 g, 73.9%). Mp 155.3-156.1 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.49 (d, J = 5.2 Hz, 1H,), 7.82 (d, J = 9.2 Hz, 1H,), 7.37 (s, 1H,) , 7.30 (t, J = 8.0 Hz, 1H,), 7.12 (dd, J = 9.2, 2.0 Hz, 1H,), 6.94 (d, J = 5.2 Hz, 1H,), 6.88 - 6.84 (m, 2H, ), 6.72 (d, J = 8.4 Hz, 1H,), 6.62 (s, 1H, NH), 4.77 - 4.71 (m, 1H, OCH(CH 3 ) 2 ), 3.82 (s, 3H, OCH 3 ), 1.42 (d, J = 6.0 Hz, 6H, OCH(CH 3 ) 2 ). 13 C NMR (100 MHz, CDCl 3 ) δ 160.8, 159.0, 151.12, 151.0, 147.6, 141.6, 130.5, 121.5, 119.2, 114.7, 114.4, 109.8, 109.7, 108.2, 101.7, 70.1, 55.5, 22.0.
制备实施例3.25：4-((3’-硝基苯基)氨基)-7-异丙氧基喹啉(化合物32)的合成Preparation Example 3.25: Synthesis of 4-((3'-nitrophenyl)amino)-7-isopropoxyquinoline (Compound 32)
以4-氯-7-异丙氧基喹啉7f(1.5mmol)和间硝基苯胺(8mmol)为原料，得黄色固体(0.20g,50.0％)。Mp 204.6-206.5℃.1H NMR(400MHz,CDCl3)δ8.56(1H,d,J＝5.2Hz),8.08(1H,s),7.99(1H,d,J＝9.2Hz),7.90(1H,d,J＝8.0Hz),7.60(1H,d,J＝8.0Hz),7.49(1H,t,J＝8.0Hz),7.31(1H,s),7.08(1H,d,J＝8.8Hz),6.99(1H,d,J＝4.8Hz),4.60–4.54(1H,m),1.32(6H,d,J＝6.0Hz).13C NMR(100MHz,CDCl3)δ159.3,151.2,151.0,149.3,146.6,142.5,130.4,126.8,122.1,119.81,118.0,115.6,115.0,109.6,102.7,70.2,21.9.4-Chloro-7-isopropoxyquinoline 7f (1.5 mmol) and m-nitroaniline (8 mmol) were obtained as a yellow solid (0.20 g, 50.0%). Mp 204.6-206.5 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.56 (1H, d, J = 5.2 Hz), 8.08 (1H, s), 7.99 (1H, d, J = 9.2 Hz), 7.90 ( 1H,d,J=8.0Hz), 7.60(1H,d,J=8.0Hz), 7.49(1H,t,J=8.0Hz),7.31(1H,s),7.08(1H,d,J=8.8 Hz), 6.99 (1H, d, J = 4.8 Hz), 4.60 - 4.54 (1H, m), 1.32 (6H, d, J = 6.0 Hz). 13 C NMR (100 MHz, CDCl 3 ) δ 159.3, 151.2, 151.0 , 149.3, 146.6, 142.5, 130.4, 126.8, 122.1, 119.81, 118.0, 115.6, 115.0, 109.6, 102.7, 70.2, 21.9.
制备实施例3.26：4-((3’-氟苯基)氨基)-7-烯丙氧基喹啉(化合物33)的合成Preparation Example 3.26: Synthesis of 4-((3'-fluorophenyl)amino)-7-allyloxyquinoline (Compound 33)
以4-氯-7-烯丙氧基喹啉7g(1.5mmol)和间氟苯胺(8mmol)为原料，得白色固体(0.10g,22.7％)。Mp 206.2-207.3℃.1H NMR(400MHz,CDCl3)δ8.55(1H,d,J＝5.2Hz),7.83(1H,d,J＝9.2Hz),7.39–7.32(2H,m),7.19(1H,d,J＝9.2Hz),7.05–6.98(3H,m),6.85(1H,t,J＝8.0Hz),6.63(1H,s),6.17–6.08(1H,m),5.49(1H,d,J＝17.2Hz),5.35(1H,d,J＝10.8Hz),4.69(2H,d,J＝5.2Hz).13C NMR(100MHz,DMSO-d6)δ164.0,161.5,158.9,150.92(d,J＝22.2Hz),150.47–149.81(m),146.6,143.07(d,J＝10.1Hz),133.4,130.87(d,J＝9.7Hz),123.6,117.7,117.2,116.89(d,J＝2.3Hz),114.8,109.32(d,J＝21.1Hz),109.18–108.97(m),108.9,107.9,107.6,101.8,68.3.4-chloro-7-allyloxyquinoline 7g (1.5mmol) and m-fluoroaniline (8mmol) were obtained as a white solid (0.10 g, 22.7%). Mp 206.2-207.3 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.55 (1H, d, J = 5.2 Hz), 7.83 (1H, d, J = 9.2 Hz), 7.39 - 7.32 (2H, m), 7.19 (1H, d, J = 9.2 Hz), 7.05 - 6.98 (3H, m), 6.85 (1H, t, J = 8.0 Hz), 6.63 (1H, s), 6.17 - 6.08 (1H, m), 5.49 (1H, d, J = 17.2 Hz), 5.35 (1H, d, J = 10.8 Hz), 4.69 (2H, d, J = 5.2 Hz). 13 C NMR (100 MHz, DMSO-d 6 ) δ 164.0, 161.5, 158.9, 150.92 (d, J = 22.2 Hz), 150.47 - 149.81 (m), 146.6, 143.07 (d, J = 10.1 Hz), 133.4, 130.87 (d, J = 9.7 Hz), 123.6, 117.7, 117.2, 116.89 (d, J = 2.3 Hz), 114.8, 109.32 (d, J = 21.1 Hz), 109.18 - 108.97 (m), 108.9, 107.9, 107.6, 101.8, 68.3.
制备实施例3.27：4-((3’-甲氧基苯基)氨基)-7-烯丙氧基喹啉(化合物34)的合成Preparation Example 3.27: Synthesis of 4-((3'-methoxyphenyl)amino)-7-allyloxyquinoline (Compound 34)
以4-氯-7-烯丙氧基喹啉7g(1.5mmol)和间甲氧基苯胺(8mmol)为原料，得白色固体(0.10g,21.8％)。Mp 174.6-175.4℃.1H NMR(400MHz,CDCl3)δ8.47(1H,d,J＝5.6Hz),7.85(1H,d,J＝9.2Hz),7.37(1H,d,J＝2.4Hz),7.31(1H,t,J＝8.0Hz),7.18(1H,dd,J＝9.2,2.4Hz),6.95(1H,d,J＝5.2Hz),6.90–6.85(2H,m),6.74–6.71(1H,m),6.16–6.06(1H,m),5.48(1H,d,J＝17.2),5.34(1H,d,J＝10.4),4.66(2H,d,J＝5.2Hz),3.82(3H,s).13C NMR(100MHz,CDCl3)δ160.9,159.6,151.3,151.0,147.6,141.5,132.9,130.5,121.5,118.4,118.3,114.8,114.7,109.8,109.3,108.2,101.9,69.0,55.5.4-chloro-7-allyloxyquinoline 7g (1.5mmol) and m-methoxyaniline (8mmol) were obtained as a white solid (0.10 g, 21.8%). Mp 174.6-175.4 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.47 (1H, d, J = 5.6 Hz), 7.85 (1H, d, J = 9.2 Hz), 7.37 (1H, d, J = 2.4 Hz), 7.31 (1H, t, J = 8.0 Hz), 7.18 (1H, dd, J = 9.2, 2.4 Hz), 6.95 (1H, d, J = 5.2 Hz), 6.90 - 6.85 (2H, m), 6.74–6.71(1H,m), 6.16–6.06(1H,m), 5.48(1H,d,J=17.2), 5.34(1H,d,J=10.4),4.66(2H,d,J=5.2Hz ), 3.82 (3H, s). 13 C NMR (100MHz, CDCl 3 ) δ 160.9, 159.6, 151.3, 151.0, 147.6, 141.5, 132.9, 130.5, 121.5, 118.4, 118.3, 114.8, 114.7, 109.8, 109.3, 108.2, 101.9, 69.0, 55.5.
制备实施例3.28：4-((3’-硝基苯基)氨基)-7-烯丙氧基喹啉(化合物35)的合成Preparation Example 3.28: Synthesis of 4-((3'-nitrophenyl)amino)-7-allyloxyquinoline (Compound 35)
以4-氯-7-烯丙氧基喹啉7g(1.5mmol)和间硝基苯胺(8mmol)为原料，得黄色固体(0.44g,92.1％)。Mp 159.8-161.4℃.1H NMR(400MHz,CDCl3)δ8.59(1H,d,J＝4.8Hz),8.10(1H,s),7.95(1H,d,J＝8.0Hz),7.89(1H,d,J＝5.2Hz),7.60–7.52(2H,m),7.39(1H,s),7.21(1H,d,J＝8.8Hz),7.01(1H,d,J＝5.1Hz),6.14–6.04(1H,m),5.47(1H,d,J＝17.2Hz),5.33(1H,d,J＝10.4Hz),4.64(2H,d,J＝5.2Hz).13CNMR(100MHz,DMSO-d6)δ159.0,151.0,148.6,146.1,142.8,133.4,130.6,126.2,123.6,117.7,117.5,116.7,115.0,114.4,108.9,102.2,68.4.4-Chloro-7-allyloxyquinoline 7g (1.5mmol) and m-nitroaniline (8mmol) were obtained as a yellow solid (0.44 g, 92.1%). Mp 159.8-161.4 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.59 (1H, d, J = 4.8 Hz), 8.10 (1H, s), 7.95 (1H, d, J = 8.0 Hz), 7.89 ( 1H, d, J = 5.2 Hz), 7.60 - 7.52 (2H, m), 7.39 (1H, s), 7.21 (1H, d, J = 8.8 Hz), 7.01 (1H, d, J = 5.1 Hz), 6.14–6.04(1H,m), 5.47(1H,d,J=17.2Hz), 5.33(1H,d,J=10.4Hz), 4.64(2H,d,J=5.2Hz). 13 CNMR(100MHz, DMSO-d 6 ) δ 159.0, 151.0, 148.6, 146.1, 142.8, 133.4, 130.6, 126.2, 123.6, 117.7, 117.5, 116.7, 115.0, 114.4, 108.9, 102.2, 68.4.
制备实施例3.29：4-((3’-氟苯基)氨基)-7-正丁氧基喹啉(化合物36)的合成Preparation Example 3.29: Synthesis of 4-((3'-fluorophenyl)amino)-7-n-butoxyquinoline (Compound 36)
以4-氯-7-正丁氧基喹啉7h(1mmol)和间氟苯胺(8mmol)为原料，得淡黄色固体(0.11g,32.2％)。1HNMR(400MHz,DMSO-d6)δ9.05(1H,s),8.45(1H,d,J＝5.6Hz),8.24(1H,d,J＝9.2Hz),7.41(1H,dd,J＝15.2,8.0Hz),7.28(1H,d,J＝2.4Hz),7.21–7.13(3H,m),6.97(1H,d,J＝5.6Hz),6.92–6.87(1H,m),4.12(2H,t,J＝6.4Hz),1.82–1.73(2H,m),1.52–1.45(2H,m),0.97(3H,t,J＝7.2Hz).13C NMR(100MHz,DMSO-d6)δ162.7(d,J＝240.9Hz),159.4,150.8(d,J＝4.8Hz),146.6,143.1(d,J＝10.6Hz),130.8(d,J＝9.7Hz),123.5,117.2,116.8,114.6,109.4,109.3(d,J＝20.9Hz),108.3,107.7(d,J＝24.0Hz),101.7,67.3,30.6,18.8,13.7.4-Chloro-7-n-butoxyquinoline 7h (1 mmol) and m-fluoroaniline (8 mmol) were obtained as pale yellow solid (0.11 g, 32.2%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.05 (1H, s), 8.45 (1H, d, J = 5.6 Hz), 8.24 (1H, d, J = 9.2 Hz), 7.41 (1H, dd, J =15.2, 8.0 Hz), 7.28 (1H, d, J = 2.4 Hz), 7.21 - 7.13 (3H, m), 6.97 (1H, d, J = 5.6 Hz), 6.92 - 6.87 (1H, m), 4.12 (2H, t, J = 6.4 Hz), 1.82 - 1.73 (2H, m), 1.52 - 1.45 (2H, m), 0.97 (3H, t, J = 7.2 Hz). 13 C NMR (100 MHz, DMSO-d) 6 ) δ 162.7 (d, J = 240.9 Hz), 159.4, 150.8 (d, J = 4.8 Hz), 146.6, 143.1 (d, J = 10.6 Hz), 130.8 (d, J = 9.7 Hz), 123.5, 117.2, 116.8, 114.6, 109.4, 109.3 (d, J = 20.9 Hz), 108.3, 107.7 (d, J = 24.0 Hz), 101.7, 67.3, 30.6, 18.8, 13.7.
制备实施例3.30：4-((3’-溴苯基)氨基)-7-正丁氧基喹啉(化合物37)的合成Preparation Example 3.30: Synthesis of 4-((3'-bromophenyl)amino)-7-n-butoxyquinoline (Compound 37)
以4-氯-7-正丁氧基喹啉7h(1mmol)和间溴苯胺(8mmol)为原料，得白色固体(0.24g,64.7％)。1H NMR(400MHz,DMSO-d6)δ9.01(1H,s),8.45(1H,d,J＝5.2Hz),8.23(1H,d,J＝9.2Hz),7.50(1H,s),7.38– 7.31(2H,m),7.28–7.24(2H,m),7.19(1H,dd,J＝9.2,2.4Hz),6.93(1H,d,J＝5.2Hz),4.12(2H,t,J＝6.4Hz),1.81–1.74(2H,m),1.54–1.45(2H,m),0.97(3H,q,J＝7.2Hz).13C NMR(100MHz,DMSO-d6)δ159.4,150.9,146.6,142.9,131.1,125.3,123.5,122.0,119.8,117.2,114.6,108.4,101.5,67.3,30.6,18.8,13.7.制备实施例3.31：4-((3’-甲氧基苯基)氨基)-7-正丁氧基喹啉(化合物38)的合成 4-Chloro-7-n-butoxyquinoline 7h (1 mmol) and m-bromoaniline (8 mmol) were obtained as a white solid (0.24 g, 64.7%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.01 (1H, s), 8.45 (1H, d, J = 5.2 Hz), 8.23 (1H, d, J = 9.2 Hz), 7.50 (1H, s) , 7.38– 7.31(2H,m), 7.28–7.24(2H,m), 7.19(1H,dd,J=9.2,2.4Hz), 6.93(1H,d,J=5.2Hz), 4.12(2H,t , J = 6.4 Hz), 1.81 - 1.74 (2H, m), 1.54 - 1.45 (2H, m), 0.97 (3H, q, J = 7.2 Hz). 13 C NMR (100 MHz, DMSO-d 6 ) δ 159. 4,150.9,146.6,142.9,131.1,125.3,123.5,122.0,119.8,117.2,114.6,108.4,101.5,67.3,30.6,18.8,13.7. Preparation Example 3.31: 4-((3'-methoxyphenyl) Synthesis of Amino)-7-n-Butoxyquinoline (Compound 38)
以4-氯-7-正丁氧基喹啉7h(1mmol)和间甲氧基苯胺(8mmol)为原料，得白色固体(0.31g,62.9％)。Mp 166.0-167.0℃.1H NMR(400MHz,CDCl3)δ8.49(1H,d,J＝5.2Hz),7.82(1H,d,J＝9.2Hz),7.36(1H,d,J＝2.0Hz),7.30(1H,t,J＝8.0Hz),7.15(1H,dd,J＝9.2,2.4Hz),6.95(1H,d,J＝5.6Hz),6.87(1H,d,J＝8.0Hz),6.84(1H,s),6.73–6.71(1H,m),6.64(1H,s),4.11(2H,t,J＝6.4Hz),3.82(3H,s),1.88–1.81(2H,m),1.58–1.49(2H,m),1.00(3H,t,J＝7.2Hz).13C NMR(100MHz,CDCl3)δ160.7,160.2,151.1,147.8,141.7,130.4,121.7,118.3,114.7,114.6,109.6,108.6,108.2,101.7,67.9,55.4,31.2,19.4,14.00.4-Chloro-7-n-butoxyquinoline 7h (1 mmol) and m-methoxyaniline (8 mmol) were obtained as a white solid (0.31 g, 62.9%). Mp 166.0-167.0 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.49 (1H, d, J = 5.2 Hz), 7.82 (1H, d, J = 9.2 Hz), 7.36 (1H, d, J = 2.0 Hz), 7.30 (1H, t, J = 8.0 Hz), 7.15 (1H, dd, J = 9.2, 2.4 Hz), 6.95 (1H, d, J = 5.6 Hz), 6.87 (1H, d, J = 8.0) Hz), 6.84 (1H, s), 6.73–6.71 (1H, m), 6.64 (1H, s), 4.11 (2H, t, J = 6.4 Hz), 3.82 (3H, s), 1.88–1.81 (2H) , m), 1.58 - 1.49 (2H, m), 1.00 (3H, t, J = 7.2 Hz). 13 C NMR (100 MHz, CDCl 3 ) δ 160.7, 160.2, 151.1, 147.8, 141.7, 130.4, 121.7, 118.3, 114.7, 114.6, 109.6, 108.6, 108.2, 101.7, 67.9, 55.4, 31.2, 19.4, 14.00.
制备实施例3.32：4-((3’-硝基苯基)氨基)-7-正丁氧基喹啉(化合物39)的合成Preparation Example 3.32: Synthesis of 4-((3'-nitrophenyl)amino)-7-n-butoxyquinoline (Compound 39)
以4-氯-7-正丁氧基喹啉7h(1mmol)和间硝基苯胺(8mmol)为原料，得黄色固体(0.07g,20.8％)。Mp 70-71℃.1H NMR(400MHz,DMSO-d6)δ9.31(1H,s),8.50(1H,t,J＝5.2Hz),8.25(1H,d,J＝9.2Hz),8.13(1H,s),7.88–7.86(1H,m),7.80–7.78(1H,m),7.64(1H,t,J＝8.0Hz),7.31(1H,d,J＝2.4Hz),7.23(1H,dd,J＝9.2,2.4Hz),7.06(1H,d,J＝4.8Hz),4.13(2H,t,J＝6.4Hz),1.81–1.74(2H,m),1.54–1.45(2H,m),0.97(3H,t,J＝7.2Hz).13C NMR(100MHz,DMSO-d6)δ159.6,150.9,148.6,146.0,142.8,130.6,126.2,123.5,117.5,116.6,114.9,114.3,108.4,102.1,67.4,30.6,18.8,13.7.4-Chloro-7-n-butoxyquinoline 7h (1 mmol) and m-nitroaniline (8 mmol) were obtained as a yellow solid (0.07 g, 20.8%). Mp 70-71 ℃. 1 H NMR ( 400MHz, DMSO-d 6) δ9.31 (1H, s), 8.50 (1H, t, J = 5.2Hz), 8.25 (1H, d, J = 9.2Hz), 8.13(1H,s), 7.88–7.86(1H,m), 7.80–7.78(1H,m), 7.64(1H,t,J=8.0Hz), 7.31(1H,d,J=2.4Hz), 7.23 (1H, dd, J = 9.2, 2.4 Hz), 7.06 (1H, d, J = 4.8 Hz), 4.13 (2H, t, J = 6.4 Hz), 1.81 - 1.74 (2H, m), 1.54 - 1.45 ( 2H, m), 0.97 (3H, t, J = 7.2 Hz). 13 C NMR (100MHz, DMSO-d 6 ) δ 159.6, 150.9, 148.6, 146.0, 142.8, 130.6, 126.2, 123.5, 117.5, 116.6, 114.9, 114.3, 108.4, 102.1, 67.4, 30.6, 18.8, 13.7.
制备实施例3.33：4-((3’-甲氧基苯基)氨基)-7-正辛氧基喹啉(化合物40)的合成Preparation Example 3.33: Synthesis of 4-((3'-methoxyphenyl)amino)-7-n-octyloxyquinoline (Compound 40)
以4-氯-7-正辛氧基喹啉7i(1mmol)和间甲氧基苯胺(8mmol)为原料，得白色固体(0.26g,68.7％)。Mp 136.8-138.4℃.1H NMR(400MHz,CDCl3)δ8.49(1H,d,J＝5.2Hz),7.81(1H,d,J＝8.8Hz),7.36(1H,s),7.30(1H,t,J＝8.0Hz),7.15(1H,dd,J＝9.2,2.0Hz),6.95(1H,d,J＝5.2Hz),6.88–6.84(2H,m),6.72(1H,d,J＝8.4Hz),6.64(1H,s),4.10(2H,t,J＝6.4Hz),3.82(3H,s),1.89–1.82(2H,m),1.53–1.46(2H,m),1.34–1.26(8H,m),0.89(3H,t,J＝6.4Hz).13C NMR(100MHz,CDCl3)δ160.8,160.2,151.08,151.01,147.7,141.6,130.4,121.5,118.4,114.7,114.6,109.7,108.6,108.2,101.8,68.3,55.5,32.0,29.5,29.4,29.2,26.2,22.8,14.3.4-chloro-7-n-octyloxyquinoline 7i (1 mmol) and m-methoxyaniline (8 mmol) were obtained as a white solid (0.26 g, 68.7%). Mp 136.8-138.4 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.49 (1H, d, J = 5.2 Hz), 7.81 (1H, d, J = 8.8 Hz), 7.36 (1H, s), 7.30 ( 1H, t, J = 8.0 Hz), 7.15 (1H, dd, J = 9.2, 2.0 Hz), 6.95 (1H, d, J = 5.2 Hz), 6.88 - 6.84 (2H, m), 6.72 (1H, d , J = 8.4 Hz), 6.64 (1H, s), 4.10 (2H, t, J = 6.4 Hz), 3.82 (3H, s), 1.89 - 1.82 (2H, m), 1.53 - 1.46 (2H, m) , 1.34 - 1.26 (8H, m), 0.89 (3H, t, J = 6.4 Hz). 13 C NMR (100 MHz, CDCl 3 ) δ 160.8, 160.2, 151.08, 151.01, 147.7, 141.6, 130.4, 121.5, 118.4, 114.7 , 114.6, 109.7, 108.6, 108.2, 101.8, 68.3, 55.5, 32.0, 29.5, 29.4, 29.2, 26.2, 22.8, 14.3.
制备实施例3.34：4-((3’-氟苯基)氨基)-7-正辛氧基喹啉(化合物41)的合成Preparation Example 3.34: Synthesis of 4-((3'-fluorophenyl)amino)-7-n-octyloxyquinoline (Compound 41)
以4-氯-7-正辛氧基喹啉7i(1mmol)和间氟苯胺(8mmol)为原料，得灰色固体(0.48g,87.4％)。Mp184.4-185.0℃.1H NMR(400MHz,CDCl3)δ8.53(1H,d,J＝5.2Hz),7.81(1H,d,J＝9.2Hz),7.37–7.31(2H,m),7.16(1H,d,J＝9.2Hz),7.05–6.97(3H,m),6.84(1H,t,J＝8.0Hz),6.67(1H,s),4.10(2H,t,J＝6.4Hz),1.89–1.82(2H,m),1.51–1.46(2H,m),1.39–1.30(8H,m),0.89(3H,t,J＝6.8Hz).13C NMR(100MHz,DMSO-d6)δ163.4,161.5,159.4,151.0,146.6,130.85(d,J＝9.8Hz),123.5,117.2,116.8,114.6,109.27(d,J＝21.1Hz),108.94–108.72(m),108.4,107.97–107.80(m),107.66(d,J＝24.1Hz),101.7,67.6,31.2,28.9,28.7,28.6,25.6,22.1,14.0.4-chloro-7-n-octyloxyquinoline 7i (1 mmol) and m-fluoroaniline (8 mmol) were obtained as a white solid (0.48 g, 87.4%). Mp 184.4-185.0 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.53 (1H, d, J = 5.2 Hz), 7.81 (1H, d, J = 9.2 Hz), 7.37 - 7.31 (2H, m) , 7.16 (1H, d, J = 9.2 Hz), 7.05 - 6.97 (3H, m), 6.84 (1H, t, J = 8.0 Hz), 6.67 (1H, s), 4.10 (2H, t, J = 6.4 Hz), 1.89–1.82 (2H, m), 1.51–1.46 (2H, m), 1.39–1.30 (8H, m), 0.89 (3H, t, J = 6.8 Hz). 13 C NMR (100 MHz, DMSO- d 6 ) δ 163.4, 161.5, 159.4, 151.0, 146.6, 130.85 (d, J = 9.8 Hz), 123.5, 117.2, 116.8, 114.6, 109.27 (d, J = 21.1 Hz), 108.94 - 108.72 (m), 108.4, 107.97–107.80(m), 107.66 (d, J=24.1 Hz), 101.7, 67.6, 31.2, 28.9, 28.7, 28.6, 25.6, 22.1, 14.0.
制备实施例3.35：4-((3’-硝基苯基)氨基)-7-正辛氧基喹啉(化合物42)的合成Preparation Example 3.35: Synthesis of 4-((3'-nitrophenyl)amino)-7-n-octyloxyquinoline (Compound 42)
以4-氯-7-正辛氧基喹啉7i(1mmol)和间硝基苯胺(8mmol)为原料，得白色固体(0.11g,28.0％)。Mp 131.0-132.7℃.1H NMR(400MHz,CDCl3)δ8.59(1H,d,J＝4.8Hz),8.11(1H,s),7.95(1H,d,J＝8.0Hz),7.85(1H,d,J＝9.2Hz),7.60–7.52(2H,m),7.39(1H,s),7.19(1H,d,J＝9.2Hz),7.00(1H,d,J＝5.2Hz),4.10(2H,t,J＝6.8Hz),1.90–1.81(2H,m),1.53–1.46(2H,m),1.34–1.27(8H,m),0.89(3H,t,J＝5.6Hz).13C NMR(100MHz,DMSO-d6)δ159.6,150.9,148.6,146.1,142.8,130.6,126.2,123.5,117.5,116.6, 114.4,108.3,102.1,67.8,31.2,28.8,28.7,28.6,25.6,22.1,14.0.4-chloro-7-n-octyloxyquinoline 7i (1 mmol) and m-nitroaniline (8 mmol) were obtained as white crystals (0.11 g, 28.0%). Mp 131.0-132.7 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.59 (1H, d, J = 4.8 Hz), 8.11 (1H, s), 7.95 (1H, d, J = 8.0 Hz), 7.85 ( 1H, d, J = 9.2 Hz), 7.60 - 7.52 (2H, m), 7.39 (1H, s), 7.19 (1H, d, J = 9.2 Hz), 7.00 (1H, d, J = 5.2 Hz), 4.10(2H,t,J=6.8Hz), 1.90–1.81(2H,m), 1.53–1.46(2H,m), 1.34–1.27(8H,m),0.89(3H,t,J=5.6Hz) 13 C NMR (100 MHz, DMSO-d 6 ) δ 159.6, 150.9, 148.6, 146.1, 142.8, 130.6, 126.2, 123.5, 117.5, 116.6, 114.4, 108.3, 102.1, 67.8, 31.2, 28.8, 28.7, 28.6, 25.6, 22.1, 14.0.
制备实施例3.36：4-((3’-氟苯基)氨基)-7-苄氧基喹啉(化合物43)的合成Preparation Example 3.36: Synthesis of 4-((3'-fluorophenyl)amino)-7-benzyloxyquinoline (Compound 43)
以4-氯-7-苄氧基喹啉7j(1.5mmol)和间氟苯胺(8mmol)为原料，得灰白色固体(0.43g,83.3％)。Mp 225.4-226.4℃.1H NMR(400MHz,CDCl3)δ8.55(1H,d,J＝5.2Hz),7.84(1H,d,J＝9.2Hz),7.50–7.47(3H,m),7.41(2H,t,J＝7.2Hz),7.37–7.30(2H,m),7.25–7.23(1H,m,),7.04–6.92(3H,m),6.87–6.83(1H,m),6.66(1H,s),5.20(2H,s).13C NMR(100MHz,DMSO-d6)δ163.9,161.5,159.0,151.0,150.8,146.59(s),143.04(d,J＝10.5Hz),136.8,130.83(d,J＝9.7Hz),128.4,127.82(d,J＝13.3Hz),123.6,117.3,116.84(d,J＝2.2Hz),114.8,109.4,109.2,107.8,107.6,101.8,69.4.4-Chloro-7-benzyloxyquinoline 7j (1.5 mmol) and m-fluoroaniline (8 mmol) were obtained as pale white solid (0.43 g, 83.3%). Mp 225.4-226.4 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.55 (1H, d, J = 5.2 Hz), 7.84 (1H, d, J = 9.2 Hz), 7.50 - 7.47 (3H, m), 7.41 (2H, t, J = 7.2 Hz), 7.37 - 7.30 (2H, m), 7.25 - 7.23 (1H, m,), 7.04 - 6.92 (3H, m), 6.87 - 6.83 (1H, m), 6.66 (1H, s), 5.20 (2H, s). 13 C NMR (100MHz, DMSO-d 6 ) δ 163.9, 161.5, 159.0, 151.0, 150.8, 146.59 (s), 144.04 (d, J = 10.5 Hz), 136.8 , 130.83 (d, J = 9.7 Hz), 128.4, 127.82 (d, J = 13.3 Hz), 123.6, 117.3, 116.84 (d, J = 2.2 Hz), 114.8, 109.4, 109.2, 107.8, 107.6, 101.8, 69.4 .
制备实施例3.37：4-((3’-甲氧基苯基)氨基)-7-苄氧基喹啉(化合物44)的合成Preparation Example 3.37: Synthesis of 4-((3'-methoxyphenyl)amino)-7-benzyloxyquinoline (Compound 44)
以4-氯-7-苄氧基喹啉7j(1.5mmol)和间甲氧基苯胺(8mmol)为原料，得白色固体(0.42g,78.6％)。Mp 200.4-201.6℃.1H NMR(400MHz,CDCl3)δ8.51(1H,d,J＝5.2Hz),7.84(1H,d,J＝9.2Hz),7.49(3H,t,J＝8.0Hz),7.41(2H,t,J＝7.6Hz),7.37–7.28(3H,m),7.24(1H,dd,J＝9.2,1.6Hz),6.96(1H,d,J＝5.2Hz),6.89–6.84(2H,m),6.72(1H,d,J＝6.8Hz),6.59(1H,s),5.21(2H,s),3.82(3H,s).13C NMR(100MHz,CDCl3)δ160.8,159.8,151.3,151.0,147.7,141.5,136.6,130.5,128.8,128.3,127.9,121.6,118.4,114.8,109.8,109.4,108.3,102.0,70.2,55.5.4-chloro-7-benzyloxyquinoline 7j (1.5 mmol) and m-methoxyaniline (8 mmol) were obtained as a white solid (0.42 g, 78.6%). Mp 200.4-201.6 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.51 (1H, d, J = 5.2 Hz), 7.84 (1H, d, J = 9.2 Hz), 7.49 (3H, t, J = 8.0 Hz), 7.41 (2H, t, J = 7.6 Hz), 7.37 - 7.28 (3H, m), 7.24 (1H, dd, J = 9.2, 1.6 Hz), 6.96 (1H, d, J = 5.2 Hz), 6.89–6.84 (2H, m), 6.72 (1H, d, J = 6.8 Hz), 6.59 (1H, s), 5.21 (2H, s), 3.82 (3H, s). 13 C NMR (100 MHz, CDCl 3 ) δ 160.8, 159.8, 151.3, 151.0, 147.7, 141.5, 136.6, 130.5, 128.8, 128.3, 127.9, 121.6, 118.4, 114.8, 109.8, 109.4, 108.3, 102.0, 70.2, 55.5.
制备实施例3.38：4-((3’-硝基苯基)氨基)-7-苄氧基喹啉(化合物45)的合成Preparation Example 3.38: Synthesis of 4-((3'-nitrophenyl)amino)-7-benzyloxyquinoline (Compound 45)
以4-氯-7-苄氧基喹啉7j(1.2mmol)和间硝基苯胺(8mmol)为原料，得黄色固体(0.27g,60.5％)。Mp 192.0-193.4℃.1H NMR(400MHz,CDCl3)δ8.60(1H,d,J＝5.2Hz),8.10(1H,s),7.95(1H,d,J＝7.6Hz),7.88(1H,d,J＝9.2Hz),7.62–7.46(5H,m),7.40(2H,t,J＝6.8Hz),7.36–7.33(1H,m),7.28(1H,s),7.01(1H,d,J＝5.2Hz),6.88(1H,s),5.19(2H,s).13C NMR(100MHz,DMSO-d6)δ159.2,151.00,148.6,146.1,142.8,136.7,130.6,128.4,127.9,127.8,126.2,123.6,117.6,116.7,115.0,114.4,109.1,102.2,69.4.4-Chloro-7-benzyloxyquinoline 7j (1.2 mmol) and m-nitroaniline (8 mmol) were obtained as a yellow solid (0.27 g, 60.5%). Mp 192.0-193.4 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.60 (1H, d, J = 5.2 Hz), 8.10 (1H, s), 7.95 (1H, d, J = 7.6 Hz), 7.88 ( 1H,d,J=9.2Hz), 7.62–7.46(5H,m), 7.40(2H,t,J=6.8Hz), 7.36–7.33(1H,m), 7.28(1H,s),7.01(1H , d, J = 5.2 Hz), 6.88 (1H, s), 5.19 (2H, s). 13 C NMR (100 MHz, DMSO-d 6 ) δ 159.2, 151.00, 148.6, 146.1, 142.8, 136.7, 130.6, 128.4, 127.9, 127.8, 126.2, 123.6, 117.6, 116.7, 115.0, 114.4, 109.1, 102.2, 69.4.
制备实施例3.39：4-((3’-氟苯基)氨基)-7-((4’-氟苄基)氧基)喹啉(化合物46)的合成Preparation Example 3.39: Synthesis of 4-((3'-fluorophenyl)amino)-7-((4'-fluorobenzyl)oxy)quinoline (Compound 46)
以4-氯-7-((4’-氟苄基)氧基)喹啉7k(1mmol)和间氟苯胺(8mmol)为原料，得淡黄色固体(0.16g,44.2％)。Mp 232.4-233.1℃.1H NMR(400MHz,DMSO-d6)δ9.07(1H,s),8.46(1H,d,J＝4.8Hz),8.28(1H,d,J＝9.2Hz),7.66–7.52(2H,m),7.44–7.38(2H,m),7.29–7.14(5H,m),6.99(1H,d,J＝5.2Hz),6.90(1H,t,J＝8.0Hz),5.27(2H,s).13C NMR(100MHz,DMSO-d6)δ164.0,163.0,161.5,160.6,159.0,151.93–151.15(m),150.88(d,J＝24.8Hz),146.68(s),143.07(d,J＝10.2Hz),133.01(d,J＝2.9Hz),130.84(d,J＝9.7Hz),130.04(d,J＝8.3Hz),123.7,117.2,116.87(d,J＝2.1Hz),115.4,115.2,114.9,109.71–109.06(m),109.06–108.74(m),107.9,107.6,101.8,68.7.4-Chloro-7-((4'-fluorobenzyl)oxy)quinoline 7k (1 mmol) and m-fluoroaniline (8 mmol) were obtained as pale yellow solid (0.16 g, 44.2%). Mp 232.4-233.1 ℃. 1 H NMR ( 400MHz, DMSO-d 6) δ9.07 (1H, s), 8.46 (1H, d, J = 4.8Hz), 8.28 (1H, d, J = 9.2Hz), 7.66–7.52(2H,m), 7.44–7.38(2H,m), 7.29–7.14(5H,m),6.99(1H,d,J=5.2Hz),6.90(1H,t,J=8.0Hz) , 5.27 (2H, s). 13 C NMR (100 MHz, DMSO-d 6 ) δ 164.0, 163.0, 161.5, 160.6, 159.0, 151.93-115.15 (m), 150.88 (d, J = 24.8 Hz), 146.68 (s) , 143.07 (d, J = 10.2 Hz), 133.01 (d, J = 2.9 Hz), 130.84 (d, J = 9.7 Hz), 130.04 (d, J = 8.3 Hz), 123.7, 117.2, 116.87 (d, J =2.1 Hz), 115.4, 115.2, 114.9, 109.71–109.06 (m), 109.06–108.74 (m), 107.9, 107.6, 101.8, 68.7.
制备实施例3.40：4-((3’-甲氧基苯基)氨基)-7-((4’-氟苄基)氧基)喹啉(化合物47)的合成Preparation Example 3.40: Synthesis of 4-((3'-methoxyphenyl)amino)-7-((4'-fluorobenzyl)oxy)quinoline (Compound 47)
以4-氯-7-((4’-氟苄基)氧基)喹啉7k(1mmol)和间甲氧基苯胺(8mmol)为原料，得白色固体(0.22g,58.8％)。Mp206.4-206.9℃.1H NMR(400MHz,CDCl3)δ8.50(1H,d,J＝5.2Hz),7.86(1H,d,J＝9.2Hz),7.47–7.42(3H,m),7.30(1H,t,J＝8.0Hz),7.20(1H,dd,J＝8.8,2.4Hz),7.08(2H,t,J＝8.8Hz),6.97(1H,d,J＝5.2Hz),6.87(1H,d,J＝8.0Hz),6.84(1H,s),6.75–6.71(2H,m),5.13(2H,s),3.81(3H,s).13C NMR(100MHz,CDCl3)δ163.9,161.5,160.8,159.6,151.4,151.0,147.7,141.5,132.34(d,J＝3.1Hz),130.5,129.70(d,J＝8.2Hz),121.8,118.3,115.8,115.6,114.84(d,J＝15.2Hz),109.8,109.3,108.3,102.0,69.5,55.5.4-chloro-7-((4'-fluorobenzyl)oxy)quinoline 7k (1 mmol) and m-methoxyaniline (8 mmol) were obtained as a white solid (0.22 g, 58.8%). Mp206.4-206.9 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.50 (1H, d, J = 5.2 Hz), 7.86 (1H, d, J = 9.2 Hz), 7.47 - 7.42 (3H, m) , 7.30 (1H, t, J = 8.0 Hz), 7.20 (1H, dd, J = 8.8, 2.4 Hz), 7.08 (2H, t, J = 8.8 Hz), 6.97 (1H, d, J = 5.2 Hz) , 6.87 (1H, d, J = 8.0 Hz), 6.84 (1H, s), 6.75 - 6.71 (2H, m), 5.13 (2H, s), 3.81 (3H, s). 13 C NMR (100 MHz, CDCl 3 ) δ163.9, 161.5, 160.8, 159.6, 151.4, 151.0, 147.7, 141.5, 132.34 (d, J = 3.1 Hz), 130.5, 129.70 (d, J = 8.2 Hz), 121.8, 118.3, 115.8, 115.6, 114.84 ( d, J = 15.2 Hz), 109.8, 109.3, 108.3, 102.0, 69.5, 55.5.
制备实施例3.41：4-((3’-硝基苯基)氨基)-7-((4’-氟苄基)氧基)喹啉(化合物48)的合成Preparation Example 3.41: Synthesis of 4-((3'-nitrophenyl)amino)-7-((4'-fluorobenzyl)oxy)quinoline (Compound 48)
以4-氯-7-((4’-氟苄基)氧基)喹啉7k(1mmol)和间硝基苯胺(8mmol)为原料，得黄色固体(0.15g,38.5％)。Mp 187-188℃.1H NMR(400MHz,CDCl3)δ8.60(1H,d,J＝5.2Hz),8.12–8.11(1H,m),7.97(1H,d,J＝7.6Hz),7.88(1H,d,J＝9.2Hz),7.60–7.52(2H,m),7.49–7.46(3H,m),7.28(1H,s),7.10(2H,t,J＝8.4Hz),7.02(1H,d,J＝5.2Hz),5.17(2H,s).13C NMR(100MHz,DMSO-d6)δ161.8(d,J＝242.2Hz),159.1,150.9,148.6,146.2,142.8,133.0(d,J＝2.9Hz),130.6,130.1(d,J＝8.3Hz),126.3,123.7,117.6,116.8,115.3(d,J＝21.3Hz),115.0,114.5,109.0,102.2,68.7.4-Chloro-7-((4'-fluorobenzyl)oxy)quinoline 7k (1 mmol) and m-nitroaniline (8 mmol) were obtained as a yellow solid (0.15 g, 38.5%). Mp 187-188 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.60 (1H, d, J = 5.2 Hz), 8.12 - 8.11 (1H, m), 7.97 (1H, d, J = 7.6 Hz), 7.88 (1H, d, J = 9.2 Hz), 7.60 - 7.52 (2H, m), 7.49 - 7.46 (3H, m), 7.28 (1H, s), 7.10 (2H, t, J = 8.4 Hz), 7.02 (1H, d, J = 5.2 Hz), 5.17 (2H, s). 13 C NMR (100 MHz, DMSO-d 6 ) δ 161.8 (d, J = 242.2 Hz), 159.1, 150.9, 148.6, 146.2, 142.8 , 133.0 (d, J = 2.9 Hz), 130.6, 130.1 (d, J = 8.3 Hz), 126.3, 123.7, 117.6, 116.8, 115.3 (d, J = 21.3 Hz), 115.0, 114.5, 109.0, 102.2, 68.7 .
制备实施例3.42：4-((3’-氟苯基)氨基)-7-((3’-苯丙基)氧基)喹啉(化合物49)的合成Preparation Example 3.42: Synthesis of 4-((3'-fluorophenyl)amino)-7-((3'-phenylpropyl)oxy)quinoline (Compound 49)
以4-氯-7-((3’-苯丙基)氧基)喹啉7l(1.5mmol)和间氟苯胺(8mmol)为原料，得白色固体(0.33g,59.1％)。Mp 190.1-192.1℃.1H NMR(400MHz,CDCl3)δ8.54(1H,d,J＝5.6Hz),7.81(1H,d,J＝9.2Hz),7.36–7.28(5H,m),7.24–7.18(3H,m),7.05–6.98(3H,m),6.85(1H,t,J＝8.0Hz),6.56(1H,s),4.13(2H,t,J＝6.4Hz),2.86(2H,t,J＝7.6Hz),2.23–2.16(2H,m).13C NMR(100MHz,CDCl3)δ164.9,162.5,159.8,151.17(d,J＝18.6Hz),147.0,142.25(d,J＝10.1Hz),132.8,131.00(d,J＝9.6Hz),128.6,121.5,118.8,118.4,117.34(d,J＝2.7Hz),115.0,111.0,110.8,109.3,109.0,108.8,102.4,69.1,32.4,30.9.4-chloro-7-((3'-phenylpropyl)oxy)quinoline 7l (1.5 mmol) and m-fluoroaniline (8 mmol) were obtained as a white solid (0.33 g, 59.1%). Mp 190.1-192.1 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.54 (1H, d, J = 5.6 Hz), 7.81 (1H, d, J = 9.2 Hz), 7.36 - 7.28 (5H, m), 7.24–7.18(3H,m), 7.05–6.98(3H,m), 6.85(1H,t,J=8.0Hz), 6.56(1H,s), 4.13(2H,t,J=6.4Hz),2.86 (2H, t, J = 7.6 Hz), 2.23 - 2.16 (2H, m). 13 C NMR (100 MHz, CDCl 3 ) δ 164.9, 162.5, 159.8, 151.17 (d, J = 18.6 Hz), 147.0, 142.25 (d , J = 10.1 Hz), 132.8, 131.00 (d, J = 9.6 Hz), 128.6, 121.5, 118.8, 118.4, 117.34 (d, J = 2.7 Hz), 115.0, 111.0, 110.8, 109.3, 109.0, 108.8, 102.4 , 69.1, 32.4, 30.9.
制备实施例3.43：4-((3’-甲氧基苯基)氨基)-7-((3’-苯丙基)氧基)喹啉(化合物50)的合成Preparation Example 3.43: Synthesis of 4-((3'-methoxyphenyl)amino)-7-((3'-phenylpropyl)oxy)quinoline (Compound 50)
以4-氯-7-((3’-苯丙基)氧基)喹啉7l(1.5mmol)和间甲氧基苯胺(8mmol)为原料，得棕色固体(0.30g,52.0％)。Mp 158.9-161.0℃.1H NMR(400MHz,CDCl3)δ8.44(d,J＝5.2Hz,1H,),7.85(d,J＝9.2Hz,1H,),7.34–7.28(m,5H,),7.24–7.15(m,3H,),6.92–6.86(m,3H,),6.73(d,J＝8.8Hz,1H,),4.11(t,J＝6.4Hz,2H,OCH2CH2CH2Ph),3.83(s,3H,OCH3),2.85(t,J＝7.6Hz,2H,OCH2CH2CH2Ph),2.21–2.14(m,2H,OCH2CH2CH2Ph).13C NMR(100MHz,CDCl3)δ160.9,160.2,151.3,151.1,147.4,141.6,141.5,130.6,128.7,128.6,126.2,121.2,118.5,114.7,114.6,109.9,109.0,108.2,101.9,67.4,55.6,32.4,30.9.4-Chloro-7-((3'-phenylpropyl)oxy)quinoline 7l (1.5 mmol) and m-methoxyaniline (8 mmol) were obtained as a brown solid (0.30 g, 52.0%). Mp 158.9-161.0 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.44 (d, J = 5.2 Hz, 1H,), 7.85 (d, J = 9.2 Hz, 1H,), 7.34 - 7.28 (m, 5H) ,), 7.24–7.15 (m, 3H,), 6.92–6.86 (m, 3H,), 6.73 (d, J=8.8 Hz, 1H,), 4.11 (t, J=6.4 Hz, 2H, OCH 2 CH 2 CH 2 Ph), 3.83 (s, 3H, OCH 3 ), 2.85 (t, J = 7.6 Hz, 2H, OCH 2 CH 2 CH 2 Ph), 2.21 - 2.14 (m, 2H, OCH 2 CH 2 CH 2 Ph). 13 C NMR (100 MHz, CDCl 3 ) δ 160.9, 160.2, 151.3, 151.1, 147.4, 141.6, 141.5, 130.6, 128.7, 128.6, 126.2, 121.2, 118.5, 114.7, 114.6, 109.9, 109.0, 108.2, 101.9, 67.4, 55.6, 32.4, 30.9.
制备实施例3.44：4-((3’-硝基苯基)氨基)-7-((3’-苯丙基)氧基)喹啉(化合物51)的合成Preparation Example 3.44: Synthesis of 4-((3'-nitrophenyl)amino)-7-((3'-phenylpropyl)oxy)quinoline (Compound 51)
以4-氯-7-((3’-苯丙基)氧基)喹啉7l(1.5mmol)和间硝基苯胺(8mmol)为原料，得黄色固体(0.26g,43.4％)。Mp 149.1-150.3℃.1H NMR(400MHz,CDCl3)δ8.60(1H,d,J＝5.2Hz),8.11(1H,s),7.96(1H,d,J＝8.0Hz),7.84(1H,d,J＝9.2Hz),7.59–7.52(2H,m),7.38(1H,s),7.33–7.27(2H,m),7.24–7.19(4H,m),7.01(1H,d,J＝5.2Hz),6.75(1H,s),4.12(2H,t,J＝6.4Hz),2.86(2H,t,J＝7.6Hz),2.24–2.14(2H,m).13C NMR(100MHz,DMSO-d6)δ159.5,151.0,148.6,146.0,142.8,141.4,130.6,128.4,126.2,125.9,123.6,117.5,116.7,115.0,114.4,108.5,102.2,67.0,31.5,30.3.4-Chloro-7-((3'-phenylpropyl)oxy)quinoline 7l (1.5 mmol) and m-nitrophenylamine (8 mmol) were obtained as a yellow solid (0.26 g, 43.4%). Mp 149.1-150.3 ° C. 1 H NMR (400 MHz, CDCl 3 ) δ 8.60 (1H, d, J = 5.2 Hz), 8.11 (1H, s), 7.96 (1H, d, J = 8.0 Hz), 7.84 ( 1H, d, J = 9.2 Hz), 7.59 - 7.52 (2H, m), 7.38 (1H, s), 7.33 - 7.27 (2H, m), 7.24 - 7.19 (4H, m), 7.01 (1H, d, J = 5.2 Hz), 6.75 (1H, s), 4.12 (2H, t, J = 6.4 Hz), 2.86 (2H, t, J = 7.6 Hz), 2.24 - 2.14 (2H, m). 13 C NMR ( 100 MHz, DMSO-d 6 ) δ 159.5, 151.0, 148.6, 146.0, 142.8, 141.4, 130.6, 128.4, 126.2, 125.9, 123.6, 117.5, 116.7, 115.0, 114.4, 108.5, 102.2, 67.0, 31.5, 30.3.
下表1示出了本发明化合物8-51编号与结构式和基本参数的对应关系。Table 1 below shows the correspondence between the compound 8-51 number of the present invention and the structural formula and basic parameters.
表1.化合物8-51结构和基本参数Table 1. Structure and basic parameters of compound 8-51
Figure PCTCN2017084929-appb-000006
Figure PCTCN2017084929-appb-000006
Figure PCTCN2017084929-appb-000007
Figure PCTCN2017084929-appb-000007
Figure PCTCN2017084929-appb-000008
Figure PCTCN2017084929-appb-000008
Figure PCTCN2017084929-appb-000009
Figure PCTCN2017084929-appb-000009
Figure PCTCN2017084929-appb-000010
Figure PCTCN2017084929-appb-000010
Figure PCTCN2017084929-appb-000011
Figure PCTCN2017084929-appb-000011
测试实施例1Test Example 1
体外抗肿瘤活性试验In vitro antitumor activity test
本发明所述喹啉衍生物作为治疗癌症的药物的药理研究。所有测试的化合物在试验前均制备成盐酸盐形式，以临床上常用的抗肿瘤药物－顺铂和伯舒替尼作为阳性对照药物。The quinoline derivative of the present invention is used as a pharmacological study for a medicament for treating cancer. All tested compounds were prepared as the hydrochloride salt prior to the test, using the commonly used anti-tumor drugs, cisplatin and besibutinib, as positive control drugs.
分别选用人直肠癌细胞系(HCT116)、人肝癌细胞系(HepG2)、人非小细胞肺癌细胞系(A549和NCI-H1650)、人卵巢癌细胞系(A2780)、人***细胞(Hela)、人胃癌细胞系(BGC-823)、等人肿瘤细胞系，采用MTT法进行测试。具体方法如下:按照标准培养方法培养各种细胞系，分别将生长状态良好、处于对数生长期的细胞系以5×104个/ml的浓度接种于96孔板，每孔接种160μl，随后将96孔板置于37℃、含5％CO2的培养箱中培养24小时，弃旧液，换新鲜培养液，加入灭菌处理的喹啉衍生物，继续培养48小时后，然后弃去培养液，每孔加20ul含5mg/ml MTT的RPMI-1640培养液，继续培养4小时，小心除去上清后，每孔加入200μl的DMSO，振荡约10min溶解沉淀，随后用酶标仪检测OD值，波长490nm。用下式求出每一样品浓度下的细胞存活率。Human rectal cancer cell line (HCT116), human hepatoma cell line (HepG2), human non-small cell lung cancer cell line (A549 and NCI-H1650), human ovarian cancer cell line (A2780), human cervical cancer cell line (Hela) Human gastric cancer cell line (BGC-823), and other human tumor cell lines were tested by MTT assay. The specific method is as follows: various cell lines are cultured according to standard culture methods, and cell lines in good growth state and in logarithmic growth phase are inoculated into 96-well plates at a concentration of 5×10 4 /ml, and 160 μl is inoculated per well, followed by The 96-well plate was incubated in an incubator containing 5% CO 2 at 37 ° C for 24 hours, the old solution was discarded, the fresh culture solution was replaced, the sterilized quinoline derivative was added, and the culture was continued for 48 hours, and then discarded. The culture medium was added with 20 ul of RPMI-1640 medium containing 5 mg/ml MTT per well, and the culture was continued for 4 hours. After carefully removing the supernatant, 200 μl of DMSO was added to each well, and the precipitate was dissolved by shaking for about 10 minutes, and then the OD was detected by a microplate reader. Value, wavelength 490 nm. The cell viability at each sample concentration was determined by the following formula.
存活率％＝样品组平均OD值/对照组平均OD值×100％Survival rate % = average OD value of the sample group / average OD value of the control group × 100%
以细胞存活率对药物浓度对数作图，按作图法求出每个样品的IC50值，结果见下表2。 The cell survival rate was plotted against the logarithm of the drug concentration, and the IC 50 value of each sample was determined by the mapping method. The results are shown in Table 2 below.
表2.化合物8-51体外抗肿瘤活性评价结果(IC50,μM)Table 2. Evaluation results of in vitro antitumor activity of compound 8-51 (IC 50 , μM)
Figure PCTCN2017084929-appb-000012
Figure PCTCN2017084929-appb-000012
Figure PCTCN2017084929-appb-000013
Figure PCTCN2017084929-appb-000013
Figure PCTCN2017084929-appb-000014
Figure PCTCN2017084929-appb-000014
制备实施例4：化合物9a-c的通用合成工艺Preparation Example 4: General Synthesis Process for Compound 9a-c
在100mL的圆底烧瓶中加入化合物6e(10mmol)和DMF(30ml)以及K2CO3(12mmol)，搅拌溶解，随后加入相应的卤化物(12mmol)，60℃搅拌2h，TLC跟踪至反应完毕。将反应混合液倒入冰水中，乙酸乙酯(EA)萃取3次，合并有机相，有机相水洗3次，饱和食盐水洗1次，无水硫酸钠干燥。过滤，减压浓缩至干，柱层析除去反应杂质，流动相分别为乙酸乙酯:石油醚＝8:1、乙酸乙酯:石油醚＝4:1，收集目标产物，减压浓缩至干，得化合物9a-c。Compound 6e (10 mmol) and DMF (30 ml) and K 2 CO 3 (12 mmol) were added to a 100 mL round bottom flask, stirred and dissolved, then the corresponding halide (12 mmol) was added, stirred at 60 ° C for 2 h, and the reaction was completed by TLC. . The reaction mixture was poured into ice water, and the mixture was extracted with EtOAc (EtOAc). Filtration, concentrating to dryness under reduced pressure, and the residue was removed by column chromatography. The mobile phase was ethyl acetate: petroleum ether = 8:1, ethyl acetate: petroleum ether = 4:1. , gave compound 9a-c.
制备实施例4.1:4-氯-7-((3’,4’,5’-三甲氧基)苄氧基)喹啉(9a)的合成Preparation Example 4.1: Synthesis of 4-chloro-7-((3',4',5'-trimethoxy)benzyloxy)quinoline (9a)
以4-氯-7-羟基喹啉6e(10mmol)和3,4,5-三甲氧基苄氯(12mmol)为原料，得白色固体(3.02g，产率:84.5％)。Mp:100.0-100.6℃.MS(ESI):m/z 359.90[M+H]+.1H NMR(400MHz,CDCl3)δ8.64(m,1H,ArH),8.13(m,1H,ArH),7.57(d,J＝4.8Hz,1H,ArH),7.54–7.46(m,1H,ArH),7.38(m,1H,ArH),6.72(s,2H,ArH),5.15(s,2H,PhCH2O-),3.89(s,6H,-OCH3),3.86(s,3H,-OCH3).13C NMR(101MHz,CDCl3)δ160.29,153.52,150.17,137.94,133.85,131.59,128.11,125.45,123.14,121.27,121.04,119.40,108.78,104.81(2C),70.67,60.86,56.18(2C).4-Chloro-7-hydroxyquinoline 6e (10 mmol) and 3,4,5-trimethoxybenzyl chloride (12 mmol) were obtained as a white solid (yield:: Mp: 100.0-100.6 ℃ .MS (ESI) :. M / z 359.90 [M + H] + 1 H NMR (400MHz, CDCl 3) δ8.64 (m, 1H, ArH), 8.13 (m, 1H, ArH ), 7.57 (d, J = 4.8 Hz, 1H, ArH), 7.54 - 7.46 (m, 1H, ArH), 7.38 (m, 1H, ArH), 6.72 (s, 2H, ArH), 5.15 (s, 2H) , PhCH 2 O-), 3.89 (s, 6H, -OCH 3 ), 3.86 (s, 3H, -OCH 3 ). 13 C NMR (101 MHz, CDCl 3 ) δ 160.29, 153.52, 150.17, 137.94, 133.85, 131.59, 128.11, 125.45, 123.14, 121.27, 121.04, 119.40, 108.78, 104.81 (2C), 70.67, 60.86, 56.18 (2C).
制备实施例4.2：4-氯-7-((3’,4’-二甲氧基)苄氧基)喹啉(9b)的合成Preparation Example 4.2: Synthesis of 4-chloro-7-((3',4'-dimethoxy)benzyloxy)quinoline (9b)
以4-氯-7-羟基喹啉6e(10mmol)和3,4-二甲氧基苄氯(12mmol)为原料，得白色固体(2.53g，产率:77.8％)。Mp:124.5-125.8℃.MS(ESI):m/z 329.85[M+H]+.1H NMR(400MHz,CDCl3)δ8.64(dd,J＝18.0,9.2Hz,1H,ArH),8.12(dd,J＝18.0,9.2Hz,1H,ArH),7.56(d,J＝4.4Hz,1H,ArH),7.52(d,J＝7.2Hz,1H,ArH),7.39–7.35(m,1H,ArH),7.05(d,J＝8.4Hz,1H,ArH),7.02(s,1H,ArH),6.90(d,J＝8.0Hz,1H,ArH),5.15(s,2H,-OCH2Ph),3.92(s,3H,-OCH3),3.90(s,3H,-OCH3).13C NMR(101MHz,CDCl3)δ160.42,150.14,150.05,149.22,149.14,128.46,128.03,125.38,123.05,121.39,121.17,120.65,119.31,111.14,108.68,70.49,55.96,55.93.4-chloro-7-hydroxyquinoline 6e (10 mmol) and 3,4-dimethoxybenzyl chloride (12 mmol) were obtained as a white solid (yield: Mp: 124.5-125.8 ° C. MS (ESI): m/z: 329.85 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.64 (dd, J = 18.0, 9.2 Hz, 1H, ArH), 8.12 (dd, J = 18.0, 9.2 Hz, 1H, ArH), 7.56 (d, J = 4.4 Hz, 1H, ArH), 7.52 (d, J = 7.2 Hz, 1H, ArH), 7.39 - 7.35 (m, 1H, ArH), 7.05 (d, J = 8.4 Hz, 1H, ArH), 7.02 (s, 1H, ArH), 6.90 (d, J = 8.0 Hz, 1H, ArH), 5.15 (s, 2H, -OCH) 2 Ph), 3.92 (s, 3H, -OCH 3 ), 3.90 (s, 3H, -OCH 3 ). 13 C NMR (101 MHz, CDCl 3 ) δ 160.42, 150.14, 150.05, 149.22, 149.14, 128.46, 128.03, 125.38 , 123.05, 121.39, 121.17, 120.65, 119.31, 111.14, 108.68, 70.49, 55.96, 55.93.
制备实施例4.3：4-氯-7-((4-甲氧基)苄氧基)喹啉(9c)的合成Preparation Example 4.3: Synthesis of 4-chloro-7-((4-methoxy)benzyloxy)quinoline (9c)
以4-氯-7-羟基喹啉6e(10mmol)和4-甲氧基苄氯(12mmol)为原料，得白色固体(2.59g，产率:86.6％)。Mp:120.8-122.2℃.MS(ESI):m/z 299.90[M+H]+.1H NMR(400MHz,CDCl3)δ8.63(dd,J＝18.4,9.2Hz,1H,ArH),8.10(dd,J＝18.4,9.2Hz,1H,ArH),7.54(d,J＝4.6Hz,1H,ArH),7.53-7.48(m,1H,ArH),7.42(d,J＝8.0Hz,2H,ArH),7.36–7.32(m,1H,ArH),6.94(d,J＝8.0Hz,2H,ArH),5.15(s,2H,-OCH2Ph),3.82(s,3H,-OCH3).13C NMR(101MHz,CDCl3)δ160.43,159.68,150.20,150.09,129.51(2C),128.11,127.99,125.33,123.01,121.40,121.17,119.26,114.12,108.70,70.18,55.32.4-chloro-7-hydroxyquinoline 6e (10 mmol) and 4-methoxybenzyl chloride (12 mmol) were obtained as white crystals (yield: Mp: 120.8-122.2 ° C. MS (ESI): m/z 299.90 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.63 (dd, J = 18.4, 9.2 Hz, 1H, ArH), 8.10 (dd, J = 18.4, 9.2 Hz, 1H, ArH), 7.54 (d, J = 4.6 Hz, 1H, ArH), 7.53 - 7.48 (m, 1H, ArH), 7.42 (d, J = 8.0 Hz, 2H, ArH), 7.36 - 7.32 (m, 1H, ArH), 6.94 (d, J = 8.0 Hz, 2H, ArH), 5.15 (s, 2H, -OCH 2 Ph), 3.82 (s, 3H, -OCH) 3 ). 13 C NMR (101 MHz, CDCl 3 ) δ 160.43, 159.68, 150.20, 150.09, 129.51 (2C), 128.11, 127.99, 125.33, 123.01, 121.40, 121.17, 119.26, 114.12, 108.70, 70.18, 55.32.
制备实施例5：化合物52-68的合成工艺Preparation Example 5: Synthesis Process of Compound 52-68
Figure PCTCN2017084929-appb-000015
Figure PCTCN2017084929-appb-000015
制备实施例5.1：化合物52,53,56,57,58,62,63,66,68的通用合成工艺Preparation Example 5.1: General synthetic procedure for compounds 52, 53, 56, 57, 58, 62, 63, 66, 68
在100mL的圆底烧瓶中加入4-氯-7-取代喹啉(1mmol)，丙酮(10mL)和相应的芳香胺(4mmol)，室温搅拌下滴加浓盐酸(15滴)，加热回流反应，TLC跟踪监测至反应完毕。反应液冷却至室温，转入500mL烧杯中，加入适量冰水，滴加氢氧化钠溶液调节pH至碱性，乙酸乙酯萃取3次，合并有机相，水及饱和食盐水洗各一次，无水硫酸钠干燥。过滤，减压浓缩至干，柱层析除去反应杂质，流动相PE：EA＝4：1、PE：EA＝3：1、PE：EA＝2：1洗脱，收集目标产物，减压浓缩至干。4-chloro-7-substituted quinoline (1 mmol), acetone (10 mL) and the corresponding aromatic amine (4 mmol) were added to a 100 mL round bottom flask, and concentrated hydrochloric acid (15 drops) was added dropwise with stirring at room temperature, and the mixture was heated to reflux. The TLC was monitored until the reaction was completed. The reaction solution was cooled to room temperature, transferred to a 500 mL beaker, and an appropriate amount of ice water was added thereto, and the sodium hydroxide solution was added dropwise to adjust the pH to be alkaline, and the ethyl acetate was extracted three times, and the organic phase was combined, washed with water and saturated brine, and dried. Dry over sodium sulfate. Filtration, concentration to dryness under reduced pressure, and removal of the reaction impurities by column chromatography, mobile phase PE: EA = 4:1, PE: EA = 3:1, PE: EA = 2:1 elution, the target product was collected, concentrated under reduced pressure To the dry.
制备实施例5.1.1：4-((3’-硝基苯基)氨基)-7-羟基喹啉(52)的合成Preparation Example 5.1.1: Synthesis of 4-((3'-nitrophenyl)amino)-7-hydroxyquinoline (52)
以4-氯-7-羟基喹啉6e(1mmol)与3-硝基苯胺(1.2mmol)为原料，得黄色固体(0.20g，产率:72.8％)。Mp:＞250℃.MS(ESI):m/z 281.90[M+H]+.1H NMR(400MHz,DMSO)δ10.18(s,1H,ArOH),9.29(s,1H,NH),8.43(d,J＝4.4Hz,1H,ArH),8.18(d,J＝8.8Hz,1H,ArH),8.11(s,1H,ArH),7.87(d,J＝8.0Hz,1H,ArH),7.78(d,J＝8.0Hz,1H,ArH),7.64(t,J＝8.0Hz,1H,ArH),7.19(s,1H,ArH),7.12(d,J＝9.2Hz,1H,ArH),6.99(s,1H,ArH).13C NMR(101MHz,DMSO)δ159.12,151.04,150.90,149.04,146.80,143.43,131.03,126.74,124.14,117.87,117.10,114.87,114.60,110.69,101.95.4-Chloro-7-hydroxyquinoline 6e (1 mmol) and 3-nitroaniline (1.2 mmol) were obtained as a yellow solid (0.20 g, yield: 72.8%). Mp: &gt; 250 ° C. MS (ESI): m/z 281.90 [M+H] + . 1 H NMR (400 MHz, DMSO) δ 10.18 (s, 1H, ArOH), 9.29 (s, 1H, NH), 8.43 (d, J = 4.4 Hz, 1H, ArH), 8.18 (d, J = 8.8 Hz, 1H, ArH), 8.11 (s, 1H, ArH), 7.87 (d, J = 8.0 Hz, 1H, ArH) , 7.78 (d, J = 8.0 Hz, 1H, ArH), 7.64 (t, J = 8.0 Hz, 1H, ArH), 7.19 (s, 1H, ArH), 7.12 (d, J = 9.2 Hz, 1H, ArH) ), 6.99 (s, 1H, ArH). 13 C NMR (101 MHz, DMSO) δ 159.12, 151.04, 150.90, 149.04, 146.80, 143.43, 131.03, 126.74, 124.14, 117.87, 117.10, 114.87, 114.60, 110.69, 101.95.
制备实施例5.1.2：4-((3’-甲氧基苯基)氨基)-7-羟基喹啉(53)的合成Preparation Example 5.1.2: Synthesis of 4-((3'-methoxyphenyl)amino)-7-hydroxyquinoline (53)
以4-氯-7-羟基喹啉6e(1mmol)与3-甲氧基苯胺(1.2mmol)为原料，得黄色固体(0.18g，产率:66.5％)。Mp:148.9-150.8℃.MS(ESI):m/z 266.95[M+H]+.1H NMR(400MHz,DMSO)δ9.08(s,1H,NH),8.33(d,J＝5.6Hz,1H,ArH),8.24(d,J＝8.8Hz,1H,ArH),7.32(t,J＝8.0Hz,1H,ArH),7.16(s,1H,ArH),7.09(d,J＝9.2Hz,1H,ArH),6.94(d,J＝8.0Hz,1H,ArH),6.90(s,1H,ArH),6.81(d,J＝5.6Hz,1H,ArH),6.73(d,J＝8.4Hz,1H,ArH),3.77(s,3H,-OCH3).13C NMR(101MHz,DMSO)δ160.58,159.47,149.89,149.83,148.87,142.08,130.55,124.29,117.59,114.92,113.65,109.80,109.69,108.47,100.57,55.55.4-Chloro-7-hydroxyquinoline 6e (1 mmol) and 3-methoxyaniline (1.2 mmol) were obtained as a yellow solid (0.18 g, yield: 66.5%). Mp: 148.9-150.8 ° C. MS (ESI): m/z 266.95 [M+H] + . 1 H NMR (400 MHz, DMSO) δ 9.08 (s, 1H, NH), 8.33 (d, J = 5.6 Hz , 1H, ArH), 8.24 (d, J = 8.8 Hz, 1H, ArH), 7.32 (t, J = 8.0 Hz, 1H, ArH), 7.16 (s, 1H, ArH), 7.09 (d, J = 9.2 Hz, 1H, ArH), 6.94 (d, J = 8.0 Hz, 1H, ArH), 6.90 (s, 1H, ArH), 6.81 (d, J = 5.6 Hz, 1H, ArH), 6.73 (d, J = 8.4 Hz, 1H, ArH), 3.77 (s, 3H, -OCH 3 ). 13 C NMR (101 MHz, DMSO) δ 160.58, 159.47, 149.89, 149.83, 148.87, 142.08, 130.55, 124.29, 117.59, 114.92, 113.65, 109.80 , 109.69, 108.47, 100.57, 55.55.
制备实施例5.1.3：4-((4’-硝基苯基)氨基)-7-((3’-苯基)丙氧基)喹啉(56)的合成Preparation Example 5.1.3: Synthesis of 4-((4'-nitrophenyl)amino)-7-((3'-phenyl)propoxy)quinoline (56)
以4-氯-7-((3’-苯基)丙氧基)喹啉7l(1mmol)与4-硝基苯胺(1.2mmol)为原料，得黄色固体(0.23g，产率:58.3％)。Mp:131.6-133.5℃.MS(ESI):m/z 400.00[M+H]+.1H NMR(400MHz,CDCl3)δ8.64(d,J＝ 5.2Hz,1H,ArH),8.24(d,J＝8.8Hz,2H,ArH),7.87(d,J＝9.2Hz,1H,ArH),7.39(d,J＝2.0Hz,1H,ArH),7.33-7.28(m,4H,ArH),7.25–7.18(m,4H,ArH),7.17(d,J＝5.2Hz,1H,ArH),4.11(t,J＝6.4Hz,2H,-OCH2CH2CH2Ph),2.85(t,J＝7.6Hz,2H,-OCH2CH2CH2Ph),2.26–2.13(m,2H,-OCH2CH2CH2Ph).13C NMR(101MHz,DMSO)δ160.23,150.94,149.43,145.59,141.78,140.77,128.81(4C),126.32(2C),126.06(2C),124.78,118.51,118.12(2C),116.40,108.36,106.32,674-chloro-7-((3'-phenyl)propoxy)quinoline 7l (1mmol) and 4-nitroaniline (1.2mmol) were obtained as a yellow solid (0.23g, yield: 58.3% ). M p : 131.6 - 133.5 ° C. MS (ESI): m/z 40 </RTI> [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.64 (d, J = 5.2 Hz, 1H, ArH), 8.24 (d, J = 8.8 Hz, 2H, ArH), 7.87 (d, J = 9.2 Hz, 1H, ArH), 7.39 (d, J = 2.0 Hz, 1H, ArH), 7.33 - 7.28 (m, 4H, ArH) ), 7.25 - 7.18 (m, 4H, ArH), 7.17 (d, J = 5.2 Hz, 1H, ArH), 4.11 (t, J = 6.4 Hz, 2H, -OCH 2 CH 2 CH 2 Ph), 2.85 ( t, J = 7.6 Hz, 2H, -OCH 2 CH 2 CH 2 Ph), 2.26 - 2.13 (m, 2H, -OCH 2 CH 2 CH 2 Ph). 13 C NMR (101 MHz, DMSO) δ 160.23, 150.94, 149.43 , 145.59, 141.78, 140.77, 128.81 (4C), 126.32 (2C), 126.06 (2C), 124.78, 118.51, 118.12 (2C), 116.40, 108.36, 106.32, 67
制备实施例5.1.4：4-((4’-三氟甲基苯基)氨基)-7-((3’–苯基)丙氧基)喹啉(57)的合成Preparation Example 5.1.4: Synthesis of 4-((4'-trifluoromethylphenyl)amino)-7-((3'-phenyl)propoxy)quinoline (57)
以4-氯-7-((3’–苯基)丙氧基)喹啉7l(1mmol)与4-三氟甲基苯胺(1.2mmol)为原料，得白色固体(0.31g，产率:73.8％)。Mp:170.0-171.9℃.MS(ESI):m/z 423.00[M+H]+.1H NMR(400MHz,CDCl3)δ8.58(d,J＝5.2Hz,1H,ArH),7.84(d,J＝9.2Hz,1H,ArH),7.63(d,J＝8.4Hz,2H,ArH),7.39–7.27(m,5H,ArH),7.26–7.15(m,4H,ArH),7.06(d,J＝5.2Hz,1H,ArH),6.69(s,1H,NH),4.12(t,J＝6.2Hz,2H,-OCH2CH2CH2Ph),2.86(t,J＝7.6Hz,2H,-OCH2CH2CH2Ph),2.26–2.13(m,2H,-OCH2CH2CH2Ph).13C NMR(101MHz,CDCl3)δ160.21(s),151.14,151.01,146.06,144.00,141.31,128.48(2C),128.47(2C),127.34–126.71(m),126.01,125.54,125.22,124.90,121.40,120.13(2C),118.86,115.16,108.78,103.20,67.21,32.19,30.63.4-chloro-7-((3'-phenyl)propoxy)quinoline 7l (1 mmol) and 4-trifluoromethylaniline (1.2 mmol) were obtained as a white solid (0.31 g, yield: 73.8%). Mp: 170.0-171.9 ° C. MS (ESI): m/z 423. </ </RTI> [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.58 (d, J = 5.2 Hz, 1H, ArH), 7.84 ( d, J = 9.2 Hz, 1H, ArH), 7.63 (d, J = 8.4 Hz, 2H, ArH), 7.39 - 7.27 (m, 5H, ArH), 7.26 - 7.15 (m, 4H, ArH), 7.06 ( d, J = 5.2 Hz, 1H, ArH), 6.69 (s, 1H, NH), 4.12 (t, J = 6.2 Hz, 2H, -OCH 2 CH 2 CH 2 Ph), 2.86 (t, J = 7.6 Hz) , 2H, -OCH 2 CH 2 CH 2 Ph), 2.26 - 2.13 (m, 2H, -OCH 2 CH 2 CH 2 Ph). 13 C NMR (101 MHz, CDCl 3 ) δ 160.21 (s), 151.14, 151.11 , 146.06, 144.00, 141.31, 128.48 (2C), 128.47 (2C), 127.34–126.71 (m), 126.01, 125.54, 125.22, 124.90, 121.40, 120.13 (2C), 118.86, 115.16, 108.78, 103.20, 67.21, 32.19 , 30.63.
制备实施例5.1.5：4-((3’-三氟甲基苯基)氨基)-7-((3’–苯基)丙氧基)喹啉(58)的合成Preparation Example 5.1.5: Synthesis of 4-((3'-trifluoromethylphenyl)amino)-7-((3'-phenyl)propoxy)quinoline (58)
以4-氯-7-((3’–苯基)丙氧基)喹啉7l(1mmol)与3-三氟甲基苯胺(1.2mmol)为原料，得白色固体(0.34g，产率:80.4％)。Mp:162.5-164.9℃.MS(ESI):m/z 423.00[M+H]+.1H NMR(400MHz,CDCl3)δ8.54(d,J＝5.2Hz,1H,ArH),7.88(d,J＝9.2Hz,1H,ArH),7.57–7.45(m,3H,ArH),7.40(d,J＝7.2Hz,1H,ArH),7.36(d,J＝2.4Hz,1H,ArH),7.33–7.28(m,2H,ArH),7.27–7.14(m,4H,ArH),6.94(d,J＝5.6Hz,1H,ArH),4.09(t,J＝6.4Hz,2H,-OCH2CH2CH2Ph),2.85(t,J＝7.6Hz,2H,-OCH2CH2CH2Ph),2.24–2.14(m,2H,-OCH2CH2CH2Ph).13C NMR(101MHz,CDCl3)δ160.23,150.84,146.81,141.32,141.03,132.64-131.68(m),130.19,128.49(2C),128.46(2C),126.01,124.69,121.28,120.50,120.47,118.73,118.33,118.29,114.63,108.66,101.98,67.21,32.20,30.64.4-chloro-7-((3'-phenyl)propoxy)quinoline 7l (1 mmol) and 3-trifluoromethylaniline (1.2 mmol) were obtained as a white solid (0.34 g, yield: 80.4%). Mp: 162.5-164.9 ° C. MS (ESI): m/z 422. </RTI> [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.54 (d, J = 5.2 Hz, 1H, ArH), 7.88 ( d, J = 9.2 Hz, 1H, ArH), 7.57 - 7.45 (m, 3H, ArH), 7.40 (d, J = 7.2 Hz, 1H, ArH), 7.36 (d, J = 2.4 Hz, 1H, ArH) , 7.33–7.28 (m, 2H, ArH), 7.27–7.14 (m, 4H, ArH), 6.94 (d, J=5.6 Hz, 1H, ArH), 4.09 (t, J=6.4 Hz, 2H, -OCH 2 CH 2 CH 2 Ph), 2.85 (t, J = 7.6 Hz, 2H, -OCH 2 CH 2 CH 2 Ph), 2.24 - 2.14 (m, 2H, -OCH 2 CH 2 CH 2 Ph). 13 C NMR (101MHz, CDCl 3 ) δ 160.23, 150.84, 144.81, 141.32, 141.03, 132.64-131.68 (m), 130.19, 128.49 (2C), 128.46 (2C), 126.01, 124.69, 121.28, 120.50, 120.47, 118.73, 118.33, 118.29 , 114.63, 108.66, 101.98, 67.21, 32.20, 30.64.
制备实施例5.1.6：4-((3’-硝基苯基)氨基)-7-((3’,4’,5’-三甲氧基)苄氧基)喹啉(62)的合成Preparation Example 5.1.6: Synthesis of 4-((3'-nitrophenyl)amino)-7-((3',4',5'-trimethoxy)benzyloxy)quinoline (62)
以4-氯-7-((3’,4’,5’-三甲氧基)苄氧基)喹啉9a(1mmol)与3-硝基苯胺(1.2mmol)为原料，得黄色固体(0.30g，产率:65.0％)。Mp:66.1-68.0℃.MS(ESI):m/z 462.00[M+H]+.1H NMR(400MHz,CDCl3)δ8.60(d,J＝5.1Hz,1H,ArH),8.12(s,1H,ArH),7.97(d,J＝8.0Hz,1H,ArH),7.90(d,J＝9.2Hz,1H,ArH),7.62–7.49(m,3H,ArH),7.30(s,1H,ArH),7.01(d,J＝5.2Hz,1H,ArH),6.72(s,2H,ArH),5.13(s,2H,-OCH2Ph),3.89(s,6H,-OCH3),3.86(s,3H,-OCH3).13C NMR(101MHz,CDCl3)δ159.86,153.42(2C),150.96,150.91,149.17,146.62,142.27,137.73,131.88,130.25,126.66,122.08,118.75,117.92,115.57,115.34,108.95,104.85(2C),102.77,70.37,60.86,56.12(2C).4-Chloro-7-((3',4',5'-trimethoxy)benzyloxy)quinoline 9a (1 mmol) and 3-nitroaniline (1.2 mmol) were obtained as a yellow solid (0.30) g, yield: 65.0%). Mp: 66.1-68.0 ° C. MS (ESI): m/z 462. </RTI> [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.60 (d, J = 5.1 Hz, 1H, ArH), 8.12 ( s, 1H, ArH), 7.97 (d, J = 8.0 Hz, 1H, ArH), 7.90 (d, J = 9.2 Hz, 1H, ArH), 7.62 - 7.49 (m, 3H, ArH), 7.30 (s, 1H, ArH), 7.01 (d, J = 5.2 Hz, 1H, ArH), 6.72 (s, 2H, ArH), 5.13 (s, 2H, -OCH 2 Ph), 3.89 (s, 6H, -OCH 3 ) , 3.86(s,3H,-OCH 3 ). 13 C NMR (101MHz, CDCl 3 ) δ 159.86, 153.42 (2C), 150.96, 150.91, 149.17, 146.62, 142.27, 137.73, 131.88, 130.25, 126.66, 122.08, 118.75, 117.92, 115.57, 115.34, 108.95, 104.85 (2C), 102.77, 70.37, 60.86, 56.12 (2C).
制备实施例5.1.7：4-((3’-三氟甲基苯基)氨基)-7-((3’,4’,5’-三甲氧基)苄氧基)喹啉(63)的合成PREPARATIVE EXAMPLE 5.1.7: 4-((3'-Trifluoromethylphenyl)amino)-7-((3',4',5'-trimethoxy)benzyloxy)quinoline (63) Synthesis
以4-氯-7-((3’,4’,5’-三甲氧基)苄氧基)喹啉9a(1mmol)与3-三氟甲基苯胺(1.2mmol)为原料，得黄色固体(0.22g，产率:45.0％)。Mp:158.8-159.7℃.MS(ESI):m/z 484.95[M+H]+.1H NMR(400MHz,CDCl3)δ8.55(d,J＝5.2Hz,1H,ArH),7.90(d,J＝9.2Hz,1H,ArH),7.55-7.50(m,2H,ArH),7.48(d,J＝3.2Hz,1H,ArH),7.46(d,J＝2.4Hz,1H,ArH),7.39(d,J＝7.2Hz,1H,ArH),7.24(dd,J＝9.2,2.4Hz,1H,ArH),6.95(d,J＝5.2Hz,1H,ArH),6.70(s,2H,ArH),5.08(s,2H,-OCH2Ph),3.88(s,6H,-OCH3),3.86(s,3H,-OCH3).13C NMR(101MHz,CDCl3)δ159.74,153.46,151.12,151.95,147.01,141.18,137.81,132.56-131.59(m),130.92,130.12,128.80,124.73,121.74,120.39,120.35,118.55,118.38,118.35,109.15,104.85(2C),102.12, 70.37,60.84,56.12(2C).4-Chloro-7-((3',4',5'-trimethoxy)benzyloxy)quinoline 9a (1mmol) and 3-trifluoromethylaniline (1.2mmol) were obtained as a yellow solid (0.22 g, yield: 45.0%). Mp: 158.8-159.7 ° C. MS (ESI): m/z 484.95 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.55 (d, J = 5.2 Hz, 1H, ArH), 7.90 ( d, J = 9.2 Hz, 1H, ArH), 7.55-7.50 (m, 2H, ArH), 7.48 (d, J = 3.2 Hz, 1H, ArH), 7.46 (d, J = 2.4 Hz, 1H, ArH) , 7.39 (d, J = 7.2 Hz, 1H, ArH), 7.24 (dd, J = 9.2, 2.4 Hz, 1H, ArH), 6.95 (d, J = 5.2 Hz, 1H, ArH), 6.70 (s, 2H) , ArH), 5.08 (s, 2H, -OCH 2 Ph), 3.88 (s, 6H, -OCH 3 ), 3.86 (s, 3H, -OCH 3 ). 13 C NMR (101 MHz, CDCl 3 ) δ 159.74, 153.46 , 151.12, 151.95, 147.01, 141.18, 137.81, 132.56-131.59 (m), 130.92, 130.12, 128.80, 124.73, 121.74, 120.39, 120.35, 118.55, 118.38, 118.35, 109.15, 104.85 (2C), 102.12, 70.37, 60.84 , 56.12 (2C).
制备实施例5.1.8：4-((3’-硝基苯基)氨基)-7-((4’-甲氧基)苄氧基)喹啉(66)的合成Preparation Example 5.1.8: Synthesis of 4-((3'-nitrophenyl)amino)-7-((4'-methoxy)benzyloxy)quinoline (66)
以4-氯-7-((3’,4’,5’-三甲氧基)苄氧基)喹啉9a(1mmol)与3-三氟甲基苯胺(1.2mmol)为原料，得黄色固体(0.27g，产率:67.5％)。Mp:197.0-197.8℃.MS(ESI):m/z 401.95[M+H]+.1H NMR(400MHz,DMSO)δ9.33(s,1H,NH),8.50(d,J＝4.8Hz,1H,ArH),8.25(d,J＝9.2Hz,1H,ArH),8.12(s,1H,ArH),7.88(dd,J＝8.1,1.5Hz,1H,ArH),7.79(d,J＝7.6Hz,1H,ArH),7.64(t,J＝8.0Hz,1H,ArH),7.46(d,J＝8.8Hz,2H,ArH),7.41(d,J＝2.0Hz,1H,ArH),7.28(dd,J＝9.2,2.4Hz,1H,ArH),7.07(d,J＝4.4Hz,1H,ArH),6.98(d,J＝8.4Hz,2H,ArH),5.20(s,2H,-OCH2Ph),3.77(s,3H,-OCH3).13C NMR(101MHz,DMSO)δ159.70,159.53,151.35,151.22,149.05,146.60,143.28,131.03,130.05(2C),129.03,126.70,124.04,118.12,117.16,115.47,114.87,114.31(2C),109.52,102.63,69.70,55.55.4-Chloro-7-((3',4',5'-trimethoxy)benzyloxy)quinoline 9a (1mmol) and 3-trifluoromethylaniline (1.2mmol) were obtained as a yellow solid (0.27 g, yield: 67.5%). Mp: 197.0-197.8 ° C. MS (ESI): m/z 401.95 [M+H] + . 1 H NMR (400 MHz, DMSO) δ 9.33 (s, 1H, NH), 8.50 (d, J = 4.8 Hz) , 1H, ArH), 8.25 (d, J = 9.2 Hz, 1H, ArH), 8.12 (s, 1H, ArH), 7.88 (dd, J = 8.1, 1.5 Hz, 1H, ArH), 7.79 (d, J) = 7.6 Hz, 1H, ArH), 7.64 (t, J = 8.0 Hz, 1H, ArH), 7.46 (d, J = 8.8 Hz, 2H, ArH), 7.41 (d, J = 2.0 Hz, 1H, ArH) , 7.28 (dd, J = 9.2, 2.4 Hz, 1H, ArH), 7.07 (d, J = 4.4 Hz, 1H, ArH), 6.98 (d, J = 8.4 Hz, 2H, ArH), 5.20 (s, 2H) , -OCH 2 Ph), 3.77 (s, 3H, -OCH 3 ). 13 C NMR (101 MHz, DMSO) δ 159.70, 159.53, 151.35, 151.22, 149.05, 146.60, 143.28, 131.03, 130.05 (2C), 129.03, 126.70 , 124.04, 118.12, 117.16, 115.47, 114.87, 114.31 (2C), 109.52, 102.63, 69.70, 55.55.
制备实施例5.1.9：4-((3’-三氟甲基苯基)氨基)-7-((4’-甲氧基)苄氧基)喹啉(68)的合成Preparation Example 5.1.9: Synthesis of 4-((3'-trifluoromethylphenyl)amino)-7-((4'-methoxy)benzyloxy)quinoline (68)
以4-氯-7-((3’,4’,5’-三甲氧基)苄氧基)喹啉9a(1mmol)与3-三氟甲基苯胺(1.2mmol)为原料，得黄色固体(0.20g，产率:47.1％)。Mp:196.8-197.7℃.MS(ESI):m/z 425.00[M+H]+.1H NMR(400MHz,CDCl3)δ8.54(d,J＝5.6Hz,1H,ArH),7.86(d,J＝9.2Hz,1H,ArH),7.56–7.45(m,4H,ArH),7.44-7.38(m,3H,ArH),7.22(dd,J＝8.8,2.4Hz,1H,ArH),6.99–6.89(m,3H,ArH),5.11(s,2H,-OCH2Ph),3.82(s,3H,-OCH3).13C NMR(101MHz,DMSO)δ159.64,159.53,151.41,151.24,147.02,142.55,130.90,130.78,130.46,130.04,129.07,(125.90,124.78,123.99,123.20),119.43,119.40,117.93,117.66,117.63,115.29,114.31(2C),109.55,102.02,69.67,55.54.4-Chloro-7-((3',4',5'-trimethoxy)benzyloxy)quinoline 9a (1mmol) and 3-trifluoromethylaniline (1.2mmol) were obtained as a yellow solid (0.20 g, yield: 47.1%). Mp: 196.8 - 197.7 ° C. MS (ESI): m/z 42 </RTI> [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.54 (d, J = 5.6 Hz, 1H, ArH), 7.86 ( d, J = 9.2 Hz, 1H, ArH), 7.56 - 7.45 (m, 4H, ArH), 7.44 - 7.38 (m, 3H, ArH), 7.22 (dd, J = 8.8, 2.4 Hz, 1H, ArH), 6.99–6.89 (m, 3H, ArH), 5.11 (s, 2H, -OCH 2 Ph), 3.82 (s, 3H, -OCH 3 ). 13 C NMR (101 MHz, DMSO) δ 159.64, 159.53, 151.41, 151.24, 147.02, 142.55, 130.90, 130.78, 130.46, 130.04, 129.07, (125.90, 124.78, 123.99, 123.20), 119.43, 119.40, 117.93, 117.66, 117.63, 115.29, 114.31 (2C), 109.55, 102.02, 69.67, 55.54.
制备实施例5.2:化合物54,55,59,60,61,64,65,67的通用合成工艺Preparation Example 5.2: General Synthesis Process for Compounds 54, 55, 59, 60, 61, 64, 65, 67
在100mL的圆底烧瓶中加入相应的4-氯-7-取代喹啉1mmol，乙二醇单甲醚10mL和相应的含取代基的苯胺1.2mmol，吡啶盐酸盐1.5mmol，加热回流反应2h，TLC跟踪监测至反应完毕。反应液冷却转入500mL烧杯中，加入150mL水，调PH至碱性，DCM萃取3次，合并有机相，水洗1次，饱和食盐水洗1次，无水硫酸钠干燥。过滤，减压浓缩至干，柱层析除去反应杂质，用流动相PE：EA＝10：1、PE：EA＝5：1、PE：EA＝2：1洗脱，收集目标产物。In a 100 mL round bottom flask, the corresponding 4-chloro-7-substituted quinoline 1 mmol, ethylene glycol monomethyl ether 10 mL and the corresponding substituted aniline 1.2 mmol, pyridine hydrochloride 1.5 mmol, heated reflux reaction for 2 h were added. , TLC tracking monitoring until the reaction is completed. The reaction solution was cooled and transferred to a 500 mL beaker, and 150 mL of water was added thereto, and the pH was adjusted to be alkaline. The mixture was extracted with DCM three times. The organic phase was combined, washed with water, once with saturated brine and dried over anhydrous sodium sulfate. Filtration, concentration to dryness under reduced pressure, and removal of the reaction impurities by column chromatography, eluting with mobile phase PE: EA = 10:1, PE: EA = 5:1, PE: EA = 2:1.
制备实施例5.2.1：4-((2’-甲氧基-5’-硝基苯基)氨基)-7-((3’–苯基)丙氧基)喹啉(54)的合成Preparation Example 5.2.1: Synthesis of 4-((2'-methoxy-5'-nitrophenyl)amino)-7-((3'-phenyl)propoxy)quinoline (54)
以4-氯-7-((3’–苯基)丙氧基)喹啉7l(1mmol)与2-甲氧基-5-硝基苯基苯胺(1.2mmol)为原料，得黄色固体(0.36g，产率:83.7％)。Mp:139.5-141.4℃.MS(ESI):m/z 430.00[M+H]+.1H NMR(400MHz,CDCl3)δ8.65(d,J＝5.1Hz,1H,ArH),8.35(d,J＝2.4Hz,1H,ArH),7.97(m,1H,ArH),7.87(d,J＝9.2Hz,1H,ArH),7.40(d,J＝2.0Hz,1H,ArH),7.29(m,2H,ArH),7.24(m,2H,ArH),7.22–7.18(m,2H,ArH),7.07–6.95(m,2H,ArH),4.14(t,J＝6.2Hz,2H,-OCH2CH2CH2-),4.07(s,3H,OCH3),2.87(t,J＝7.6Hz,2H,-OCH2CH2CH2-Ph),2.25–2.15(m,2H,-OCH2CH2CH2-Ph).13C NMR(101MHz,CDCl3)δ160.20,154.08,151.22(2C),144.85,141.66,141.32,130.82,128.50(2C),128.47(2C),126.01,121.16,119.01,118.52,115.48,112.55,110.02,109.04,103.16,67.26,56.57,32.22,30.66.4-Chloro-7-((3'-phenyl)propoxy)quinoline 7l (1mmol) and 2-methoxy-5-nitrophenylaniline (1.2mmol) were used as starting materials to give a yellow solid ( 0.36 g, yield: 83.7%). Mp: 139.5-141.4 ℃ .MS (ESI) : m / z 430.00 [M + H] + 1 H NMR (400MHz, CDCl 3) δ8.65 (d, J = 5.1Hz, 1H, ArH), 8.35 (. d, J = 2.4 Hz, 1H, ArH), 7.97 (m, 1H, ArH), 7.87 (d, J = 9.2 Hz, 1H, ArH), 7.40 (d, J = 2.0 Hz, 1H, ArH), 7.29 (m, 2H, ArH), 7.24 (m, 2H, ArH), 7.22 - 7.18 (m, 2H, ArH), 7.07 - 6.95 (m, 2H, ArH), 4.14 (t, J = 6.2 Hz, 2H, -OCH 2 CH 2 CH 2 -), 4.07 (s, 3H, OCH 3 ), 2.87 (t, J = 7.6 Hz, 2H, -OCH 2 CH 2 CH 2 -Ph), 2.25 - 2.15 (m, 2H, -OCH 2 CH 2 CH 2 -Ph). 13 C NMR (101 MHz, CDCl 3 ) δ 160.20, 154.08, 151.22 (2C), 144.85, 141.66, 141.32, 130.82, 128.50 (2C), 128.47 (2C), 126.01, 121.16 , 111.01, 118.52, 115.48, 112.55, 110.02, 109.04, 103.16, 67.26, 56.57, 32.22, 30.66.
制备实施例5.2.2：4-((2’-甲氧基-4’-硝基苯基)氨基)-7-((3’–苯基)丙氧基)喹啉(55)Preparation Example 5.2.2: 4-((2'-Methoxy-4'-nitrophenyl)amino)-7-((3'-phenyl)propoxy)quinoline (55)
以4-氯-7-((3’-甲氧基)丙氧基)喹啉9c(1mmol)与2-甲氧基-4-硝基苯基苯胺(1.2mmol)为原料，得黄色固体(0.26g，产率:61.2％)。Mp:165.4-166.9℃.MS(ESI):m/z 430.00[M+H]+.1H NMR(400MHz,CDCl3):δ8.70(d,J＝4.8Hz,1H,NH),7.93(d,J＝8.8Hz,1H,ArH),7.88(d,J＝9.2Hz,1H,ArH),7.85(s, 1H,ArH),7.45–7.39(m,2H,ArH),7.29(d,J＝7.6Hz,4H,ArH),7.22(m,J＝6.8Hz,4H,ArH),4.14(t,J＝6.4Hz,2H,-OCH2CH2CH2-),4.08(s,3H,OCH3),2.87(t,J＝7.6Hz,2H,-OCH2CH2CH2-Ph),2.21(dt,J＝13.8,6.8Hz,2H,-OCH2CH2CH2-Ph).13C NMR(100MHz,CDCl3)δ159.24,150.19,149.80(2C),146.53,142.65,140.11,139.99,136.43,127.33(2C),124.88,120.44,118.40,116.98,115.23,112.49,107.74,104.98,104.90,66.17,55.27,31.04,29.47,28.54.4-Chloro-7-((3'-methoxy)propoxy)quinoline 9c (1mmol) and 2-methoxy-4-nitrophenylaniline (1.2mmol) were obtained as a yellow solid (0.26 g, yield: 61.2%). Mp: 165.4-166.9 ° C. MS (ESI): m/z 43 </RTI> [M+H] + . 1 H NMR (400 MHz, CDCl3): δ 8.70 (d, J = 4.8 Hz, 1H, NH), 7.93 ( d, J = 8.8 Hz, 1H, ArH), 7.88 (d, J = 9.2 Hz, 1H, ArH), 7.85 (s, 1H, ArH), 7.45 - 7.39 (m, 2H, ArH), 7.29 (d, J = 7.6 Hz, 4H, ArH), 7.22 (m, J = 6.8 Hz, 4H, ArH), 4.14 (t, J = 6.4 Hz, 2H, -OCH 2 CH 2 CH 2 -), 4.08 (s, 3H) , OCH 3 ), 2.87 (t, J = 7.6 Hz, 2H, -OCH 2 CH 2 CH 2 -Ph), 2.21 (dt, J = 13.8, 6.8 Hz, 2H, -OCH 2 CH 2 CH 2 -Ph) 13 C NMR (100 MHz, CDCl 3 ) δ 159.24, 150.19, 149.80 (2C), 146.53, 142.65, 140.11, 139.99, 136.43, 127.33 (2C), 124.88, 120.44, 118.40, 116.98, 115.23, 112.49, 107.74, 104.98, 104.90, 66.17, 55.27, 31.04, 29.47, 28.54.
制备实施例5.2.3：4-((3’,5’-二三氟甲基苯基)氨基)-7-((3’–苯基)丙氧基)喹啉(59)的合成Preparation Example 5.2.3: Synthesis of 4-((3',5'-bistrifluoromethylphenyl)amino)-7-((3'-phenyl)propoxy)quinoline (59)
以4-氯-7-((3’–苯基)丙氧基)喹啉7l(1mmol)与3,5-二三氟甲基苯胺(1.2mmol)为原料，得黄色固体(0.35g，产率:71.4％)。Mp:171.6-172.8℃.MS(ESI):m/z 491.00[M+H]+.1H NMR(400MHz,CDCl3)δ8.63(d,J＝4.8Hz,1H,ArH),7.84(d,J＝9.2Hz,1H,ArH),7.66(s,2H,ArH),7.58(s,1H,ArH),7.39(s,1H,ArH),7.30(t,J＝7.4Hz,2H,ArH),7.25-7.17(m,4H,ArH),7.01(d,J＝4.8Hz,1H,ArH),6.79(s,1H,NH),4.12(t,J＝6.0Hz,2H,-OCH2CH2CH2Ph),2.86(t,J＝7.6Hz,2H-OCH2CH2CH2Ph),2.26–2.13(m,2H,-OCH2CH2CH2Ph).13C NMR(101MHz,CDCl3)δ160.42,151.21,151.02,145.66,142.71,141.27,(133.58,133.25,132.92,132.58(-CF3)2C),128.46(4C),126.02(2C),124.42,121.71,121.45,119.93,119.24,116.29,115.24,108.73,103.30,67.24,32.17,30.59.4-Chloro-7-((3'-phenyl)propoxy)quinoline 7l (1 mmol) and 3,5-ditrifluoromethylaniline (1.2 mmol) were obtained as a yellow solid (0.35 g, Yield: 71.4%). Mp: 171.6-172.8 ° C. MS (ESI): m/z 49 </RTI> [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.63 (d, J = 4.8 Hz, 1H, ArH), 7.84 ( d, J = 9.2 Hz, 1H, ArH), 7.66 (s, 2H, ArH), 7.58 (s, 1H, ArH), 7.39 (s, 1H, ArH), 7.30 (t, J = 7.4 Hz, 2H, ArH), 7.25-7.17 (m, 4H, ArH), 7.01 (d, J = 4.8 Hz, 1H, ArH), 6.79 (s, 1H, NH), 4.12 (t, J = 6.0 Hz, 2H, -OCH) 2 CH 2 CH 2 Ph), 2.86 (t, J = 7.6 Hz, 2H-OCH 2 CH 2 CH 2 Ph), 2.26 - 2.13 (m, 2H, -OCH 2 CH 2 CH 2 Ph). 13 C NMR ( 101MHz, CDCl 3 ) δ160.42, 151.21, 151.22, 145.66, 142.71, 141.27, (133.58, 133.25, 132.92, 132.58 (-CF 3 ) 2C), 128.46 (4C), 126.02 (2C), 124.42, 121.71, 121.45, 119.93 , 119.24, 116.29, 115.24, 108.73, 103.30, 67.24, 32.17, 30.59.
制备实施例5.2.4：4-((4’–氨基苯基)氨基)-7-((3’–苯基)丙氧基)喹啉(60)的合成Preparation Example 5.2.4: Synthesis of 4-((4'-aminophenyl)amino)-7-((3'-phenyl)propoxy)quinoline (60)
以4-氯-7-((3’–苯基)丙氧基)喹啉7l(1mmol)与对苯二胺(1.2mmol)为原料，得黄色固体(0.21g，产率:58.1％)。Mp:193.8-194.1℃.MS(ESI):m/z 370.00[M+H]+.1H NMR(400MHz,DMSO)δ8.60(s,1H,NH),8.27(d,J＝8.8Hz,1H,ArH),8.23(d,J＝5.2Hz,1H),7.34–7.24(m,4H),7.20(d,J＝7.2Hz,1H,ArH),7.16(s,1H,ArH),7.12(d,J＝9.2Hz,1H,ArH),6.98(d,J＝8.0Hz,2H,ArH),6.65(d,J＝8.0Hz,2H,ArH),6.35(d,J＝5.6Hz,1H,ArH),5.09(s,2H,NH),4.09(t,J＝6.0Hz,2H,-OCH2CH2CH2Ph),2.80(t,J＝7.6Hz,2H,-OCH2CH2CH2Ph),2.14-2.04(m,2H,-OCH2CH2CH2Ph).13C NMR(101MHz,DMSO)δ159.58,151.11,150.86,150.40,146.85,141.84,128.82(4C),128.52,126.72(2C),126.32,123.77,116.61,115.01(2C),113.90,108.68,99.26,67.23,31.98,30.77.4-chloro-7-((3'-phenyl)propoxy)quinoline 7l (1 mmol) and p-phenylenediamine (1.2 mmol) were obtained as a yellow solid (0.21 g, yield: 58.1%) . Mp: 193.8-194.1 ℃ .MS (ESI) :. M / z 370.00 [M + H] + 1 H NMR (400MHz, DMSO) δ8.60 (s, 1H, NH), 8.27 (d, J = 8.8Hz , 1H, ArH), 8.23 (d, J = 5.2 Hz, 1H), 7.34 - 7.24 (m, 4H), 7.20 (d, J = 7.2 Hz, 1H, ArH), 7.16 (s, 1H, ArH), 7.12 (d, J = 9.2 Hz, 1H, ArH), 6.98 (d, J = 8.0 Hz, 2H, ArH), 6.65 (d, J = 8.0 Hz, 2H, ArH), 6.35 (d, J = 5.6 Hz) , 1H, ArH), 5.09 (s, 2H, NH), 4.09 (t, J = 6.0 Hz, 2H, -OCH 2 CH 2 CH 2 Ph), 2.80 (t, J = 7.6 Hz, 2H, -OCH 2 CH 2 CH 2 Ph), 2.14-2.04 (m, 2H, -OCH 2 CH 2 CH 2 Ph). 13 C NMR (101 MHz, DMSO) δ 159.58, 151.11, 150.86, 150.40, 146.85, 141.84, 128.82 (4C), 128.52,126.72(2C),126.32,123.77,116.61,115.01(2C),113.90,108.68,99.26,67.23,31.98,30.77.
制备实施例5.2.5：4-((3’–甲氧基苯基)氨基)-7-((3’,4’,5’–三甲氧基)苄氧基)喹啉(61)的合成Preparation Example 5.2.5: 4-((3'-Methoxyphenyl)amino)-7-((3',4',5'-trimethoxy)benzyloxy)quinoline (61) synthesis
以4-氯-7-((3’,4’,5’–三甲氧基)苄氧基)喹啉9a(1mmol)与3-甲氧基苯胺(1.2mmol)为原料，得黄色固体(0.22g，产率:50.8％)。Mp:180.1-180.6℃.MS(ESI):m/z 447.00[M+H]+.1H NMR(400MHz,CDCl3)δ8.50(d,J＝5.2Hz,1H,ArH),7.87(d,J＝9.2Hz,1H,ArH),7.46(s,1H,NH),7.31(t,J＝8.0Hz,1H,ArH),7.23(d,J＝9.2Hz,1H,ArH),6.97(d,J＝5.2Hz,1H,ArH),6.88(d,J＝8.0Hz,1H,ArH),6.85(s,1H,ArH),6.74(s,1H,ArH),6.72(s,3H,ArH),5.11(s,2H,-OCH2Ph),3.89(s,6H,-OCH3),3.86(s,3H,-OCH3),3.82(s,3H,-OCH3).13C NMR(101MHz,CDCl3)δ160.69,159.57,153.44(2C),151.13,150.77,147.54,141.29,137.75,131.98,130.37,121.48,118.21,114.70,114.59,109.69,109.15,108.14,104.80(2C),101.81,70.38,60.87,56.14(2C),55.35.4-Chloro-7-((3',4',5'-trimethoxy)benzyloxy)quinoline 9a (1 mmol) and 3-methoxyaniline (1.2 mmol) were obtained as a yellow solid. 0.22 g, yield: 50.8%). Mp: 180.1 - 180.6 ° C. MS (ESI): m/z 447. 00 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.50 (d, J = 5.2 Hz, 1H, ArH), 7.87 ( d, J = 9.2 Hz, 1H, ArH), 7.46 (s, 1H, NH), 7.31 (t, J = 8.0 Hz, 1H, ArH), 7.23 (d, J = 9.2 Hz, 1H, ArH), 6.97 (d, J = 5.2 Hz, 1H, ArH), 6.88 (d, J = 8.0 Hz, 1H, ArH), 6.85 (s, 1H, ArH), 6.74 (s, 1H, ArH), 6.72 (s, 3H) , ArH), 5.11 (s, 2H, -OCH 2 Ph), 3.89 (s, 6H, -OCH 3 ), 3.86 (s, 3H, -OCH 3 ), 3.82 (s, 3H, -OCH 3 ). 13 C NMR (101 MHz, CDCl 3 ) δ 160.69, 159.57, 153.44 (2C), 151.13, 150.77, 147.54, 141.29, 137.75, 131.98, 130.37, 121.48, 118.21, 114.70, 114.59, 109.69, 109.15, 108.14, 104.80 (2C), 101.81, 70.38, 60.87, 56.14 (2C), 55.35.
制备实施例5.2.6：4-((3’,5’–二三氟甲基苯基)氨基)-7-((3’,4’,5’–三甲氧基)苄氧基)喹啉(64)的合成Preparation Example 5.2.6: 4-((3',5'-Ditrifluoromethylphenyl)amino)-7-((3',4',5'-trimethoxy)benzyloxy)quinaquin Synthesis of porphyrin (64)
以4-氯-7-((3’,4’,5’–三甲氧基)苄氧基)喹啉9a(1mmol)与3’,5’–二三氟甲基苯胺(1.2mmol)为原料，得黄色固体(0.26g，产率:47.1％)。Mp:70.6-72.4℃.MS(ESI):m/z 553.05[M+H]+.1H NMR(400MHz,CDCl3)δ8.64(d,J＝5.2Hz,1H,ArH),7.87(d,J＝9.2Hz,1H,ArH),7.68(s,2H,ArH),7.58(s,1H,ArH),7.50(d,J＝2.0Hz,1H,ArH),7.29(d,J＝2.4Hz,1H,ArH),7.03(d,J＝5.2Hz,1H,ArH),6.72(s,2H,ArH),5.12(s,2H,-OCH2Ph),3.89(s,6H,-OCH3),3.86(s,3H,-OCH3).13C NMR(101MHz,CDCl3)δ159.97,153.46(2C),151.06(2C),145.86,142.74,137.79,(133.52,133.19,132.86,132.53(2C)),131.85,124.43,121.76(2C),120.04,119.12(2C),116.28,115.51,109.12,104.93(2C),103.38,70.46,60.87,56.12(2C). 4-Chloro-7-((3',4',5'-trimethoxy)benzyloxy)quinoline 9a (1mmol) and 3',5'-ditrifluoromethylaniline (1.2mmol) The starting material gave a yellow solid (0.26 g, yield: 47.1%). Mp: 70.6-72.4 ° C. MS (ESI): m/z: 553.05 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.64 (d, J = 5.2 Hz, 1H, ArH), 7.87 ( d, J = 9.2 Hz, 1H, ArH), 7.68 (s, 2H, ArH), 7.58 (s, 1H, ArH), 7.50 (d, J = 2.0 Hz, 1H, ArH), 7.29 (d, J = 2.4 Hz, 1H, ArH), 7.03 (d, J = 5.2 Hz, 1H, ArH), 6.72 (s, 2H, ArH), 5.12 (s, 2H, -OCH 2 Ph), 3.89 (s, 6H, - OCH 3 ), 3.86 (s, 3H, -OCH 3 ). 13 C NMR (101MHz, CDCl 3 ) δ 159.97, 153.46 (2C), 151.06 (2C), 145.86, 142.74, 137.79, (133.52, 133.19, 132.86, 132.53 (2C)), 131.85, 124.43, 121.76 (2C), 120.04, 119.12 (2C), 116.28, 115.51, 109.12, 104.93 (2C), 103.38, 70.46, 60.87, 56.12 (2C).
制备实施例5.2.7：4-((3’–甲氧基苯基)氨基)-7-((3’,4’–二甲氧基)苄氧基)喹啉(65)的合成Preparation Example 5.2.7: Synthesis of 4-((3'-methoxyphenyl)amino)-7-((3',4'-dimethoxy)benzyloxy)quinoline (65)
以4-氯-7-((3’,4’–二甲氧基)苄氧基)喹啉(1mmol)9b与间甲氧基苯胺(1.2mmol)为原料，得黄色固体(0.30g，产率:71.1％)。Mp:172.1-174.0℃.MS(ESI):m/z 417.00[M+H]+.1H NMR(400MHz,CDCl3)δ8.47(d,J＝5.2Hz,1H,ArH),7.86(d,J＝9.2Hz,1H,ArH),7.50(s,1H,ArH),7.32(t,J＝8.0Hz,1H,ArH),7.22(d,J＝8.8Hz,1H,ArH),7.07-7.00(m,2H,ArH),6.95(d,J＝5.2Hz,1H,ArH),6.89(d,J＝8.0Hz,2H,ArH),6.86(s,1H,ArH),6.74(d,J＝8.0Hz,1H,ArH),5.13(s,2H,-OCH2Ph),3.92(s,3H,-OCH3),3.90(s,3H,-OCH3),3.83(s,3H,-OCH3).13C NMR(101MHz,CDCl3)δ160.73,159.79,150.71,150.46,149.19,149.06,147.65,141.21,130.38,128.82,121.39,120.64,118.41,114.61,114.52,111.21,111.17,109.82,108.97,108.18,101.72,70.24,55.95,55.92,55.36.4-Chloro-7-((3',4'-dimethoxy)benzyloxy)quinoline (1 mmol) 9b and m-methoxyaniline (1.2 mmol) were obtained as a yellow solid (0.30 g, Yield: 71.1%). Mp: 172.1-174.0 ° C. MS (ESI): m/z 417. 00 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.47 (d, J = 5.2 Hz, 1H, ArH), 7.86 ( d, J = 9.2 Hz, 1H, ArH), 7.50 (s, 1H, ArH), 7.32 (t, J = 8.0 Hz, 1H, ArH), 7.22 (d, J = 8.8 Hz, 1H, ArH), 7.07 -7.00 (m, 2H, ArH), 6.95 (d, J = 5.2 Hz, 1H, ArH), 6.89 (d, J = 8.0 Hz, 2H, ArH), 6.86 (s, 1H, ArH), 6.74 (d , J=8.0 Hz, 1H, ArH), 5.13 (s, 2H, -OCH 2 Ph), 3.92 (s, 3H, -OCH 3 ), 3.90 (s, 3H, -OCH 3 ), 3.83 (s, 3H) , -OCH 3 ). 13 C NMR (101MHz, CDCl 3 ) δ 160.73, 159.79, 150.71, 150.46, 149.19, 149.06, 147.65, 141.21, 130.38, 128.82, 121.39, 120.64, 118.41, 114.61, 114.52, 111.21, 111.17, 109.82 , 108.97, 108.18, 101.72, 70.24, 55.95, 55.92, 55.36.
制备实施例5.2.8：4-((3’–甲氧基苯基)氨基)-7-((4’–甲氧基)苄氧基)喹啉(67)的合成Preparation Example 5.2.8: Synthesis of 4-((3'-methoxyphenyl)amino)-7-((4'-methoxy)benzyloxy)quinoline (67)
以4-氯-7-((3’–甲氧基)苄氧基)喹啉9c(1mmol)与间甲氧基苯胺(1.2mmol)为原料，得黄色固体(0.32g，产率:57.0％)。Mp:191.4-192.4℃.MS(ESI):m/z 386.95[M+H]+.1H NMR(400MHz,CDCl3)δ8.50(d,J＝5.2Hz,1H,ArH),7.84(d,J＝9.2Hz,1H,ArH),7.46(s,1H,NH),7.41(d,J＝8.4Hz,2H,ArH),7.30(t,J＝8.0Hz,1H,ArH),7.20(d,J＝8.8Hz,1H,ArH),7.02–6.90(m,3H,ArH),6.87(d,J＝8.0Hz,1H,ArH),6.84(s,1H,ArH),6.72(d,J＝8.4Hz,2H,ArH),5.11(s,2H,-OCH2Ph),3.82(s,6H,-OCH3).13C NMR(101MHz,DMSO)δ160.58,159.51,159.48,151.34,151.14,147.89,142.45,130.51,130.05(2C),129.11,123.99,117.49,114.96,114.51,114.31(2C),109.50,109.42,108.04,101.49,69.62,55.56,55.54.4-Chloro-7-((3'-methoxy)benzyloxy)quinoline 9c (1 mmol) and m-methoxyaniline (1.2 mmol) were obtained as a yellow solid (0.32 g, yield: 57.0 %). Mp: 191.4-192.4 ° C. MS (ESI): m/z 386.95 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.50 (d, J = 5.2 Hz, 1H, ArH), 7.84 ( d, J = 9.2 Hz, 1H, ArH), 7.46 (s, 1H, NH), 7.41 (d, J = 8.4 Hz, 2H, ArH), 7.30 (t, J = 8.0 Hz, 1H, ArH), 7.20 (d, J = 8.8 Hz, 1H, ArH), 7.02 - 6.90 (m, 3H, ArH), 6.87 (d, J = 8.0 Hz, 1H, ArH), 6.84 (s, 1H, ArH), 6.72 (d , J = 8.4 Hz, 2H, ArH), 5.11 (s, 2H, -OCH 2 Ph), 3.82 (s, 6H, -OCH 3 ). 13 C NMR (101 MHz, DMSO) δ 160.58, 159.51, 159.48, 151.34, 151.14, 147.89, 142.45, 130.51, 130.05 (2C), 129.11, 123.99, 117.49, 114.96, 114.51, 114.31 (2C), 109.50, 109.42, 108.04, 101.49, 69.62, 55.56, 55.54.
Figure PCTCN2017084929-appb-000016
Figure PCTCN2017084929-appb-000016
制备实施例6：化合物69-81的通用合成工艺Preparation Example 6: General Synthesis Process for Compound 69-81
在100mL的圆底烧瓶中加入4-氯-7-取代喹啉1mmol，DMF(10mL)和相应的苯硫酚1mmol，密封，室温搅拌下反应，TLC跟踪监测至反应完毕。反应液冷却转入500mL烧杯中，加入150mL水，调PH至碱性，DCM萃取3次，合并有机相，水洗3-5次，饱和食盐水洗1次，无水硫酸钠干燥。过滤，减 压浓缩至干，柱层析除去反应杂质，用流动相PE：EA＝6：1、PE：EA＝3：1、PE：EA＝2：1洗脱，收集目标产物。In a 100 mL round bottom flask, 1 mmol of 4-chloro-7-substituted quinoline, DMF (10 mL) and the corresponding thiophenol (1 mmol) were added, sealed, and reacted under stirring at room temperature, and the reaction was completed by TLC. The reaction solution was cooled and transferred to a 500 mL beaker, and 150 mL of water was added thereto, and the pH was adjusted to be alkaline. The mixture was extracted with DCM three times. The organic phase was combined, washed with water 3-5 times, washed with saturated brine and dried over anhydrous sodium sulfate. Filter, subtract The mixture was concentrated to dryness, and the reaction impurities were removed by column chromatography, and eluted with mobile phase PE: EA=6:1, PE:EA=3:1, PE:EA=2:1, and the target product was collected.
制备实施例6.1：4-苯硫基-7–甲氧基喹啉(69)的合成Preparation Example 6.1: Synthesis of 4-phenylthio-7-methoxyquinoline (69)
以4-氯-7甲氧基喹啉7d(1mmol)与苯硫酚(1mmol)为原料，得白色固体(0.21g，产率:78.6％)。Mp:111.6-112.0℃.MS(ESI):m/z 267.85[M+H]+.1H NMR(400MHz,CDCl3)δ8.49(d,J＝4.8Hz,1Hc),8.11(d,J＝9.2Hz,1H,ArH),7.58(m,2H,ArH),7.47(m,3H,ArH),7.40(d,J＝2.4Hz,1H,ArH),7.24(dd,J＝9.2,2.8Hz,1H,ArH),6.65(d,J＝4.8Hz,1H,ArH),3.96(s,3H,-OCH3).13C NMR(101MHz,CDCl3)δ160.85,149.74,149.52,148.17,135.11(2C),129.95(2C),129.88,129.51,124.73,121.15,119.47,116.33,107.82,55.55.4-chloro-7 methoxyquinoline 7d (1 mmol) and thiophenol (1 mmol) were obtained as a white solid (0.21 g, yield: 78.6%). Mp: 111.6-112.0 ° C. MS (ESI): m/z 266.85 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.49 (d, J = 4.8 Hz, 1Hc), 8.11 (d, J = 9.2 Hz, 1H, ArH), 7.58 (m, 2H, ArH), 7.47 (m, 3H, ArH), 7.40 (d, J = 2.4 Hz, 1H, ArH), 7.24 (dd, J = 9.2, 2.8 Hz, 1H, ArH), 6.65 (d, J = 4.8 Hz, 1H, ArH), 3.96 (s, 3H, -OCH 3 ). 13 C NMR (101 MHz, CDCl 3 ) δ 160.85, 149.74, 149.52, 148.17, 135.11(2C), 129.95(2C), 129.88, 129.51, 124.73, 121.15, 119.47, 116.33, 107.82, 55.55.
制备实施例6.2：4-(2’-氨基苯硫基)-7–((3’-苯基)丙氧基)喹啉(70)的合成Preparation Example 6.2: Synthesis of 4-(2'-aminophenylthio)-7-((3'-phenyl)propoxy)quinoline (70)
以4-氯-7-((3’–苯基)丙氧基)喹啉7l(1mmol)与邻氨基苯硫酚(1mmol)为原料，得黄色固体(0.28g，产率:72.5％)。Mp:184.9-186.2℃.MS(ESI):m/z 386.95[M+H]+.1H NMR(400MHz,CDCl3)δ8.40(d,J＝5.2Hz,1H,ArH),7.62(d,J＝7.6Hz,1H,ArH),7.37–7.28(m,5H,ArH),7.25–7.20(m,3H,ArH),7.16(t,J＝7.6Hz,1H,ArH),7.05(d,J＝8.8Hz,1H,ArH),6.89(t,J＝7.6Hz,1H,ArH),6.83(d,J＝5.2Hz,1H,ArH),4.12(t,J＝6.4Hz,2H,-OCH2CH2CH2Ph),2.87(t,J＝7.6Hz,2H,-OCH2CH2CH2Ph),2.25–2.15(m,2H,-OCH2CH2CH2Ph).13C NMR(101MHz,CDCl3)δ160.04,150.93,150.84,145.35,142.07,141.33,136.56,131.22,128.53(2C),128.49(2C),126.09,126.03,123.28,121.08,119.48,118.70,115.23,108.73,102.37,67.22,32.23,30.67.4-chloro-7-((3'-phenyl)propoxy)quinoline 7l (1 mmol) and o-aminothiophenol (1 mmol) were obtained as a yellow solid (0.28 g, yield: 72.5%) . Mp: 184.9-186.2 ° C. MS (ESI): m/z 386.95 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.40 (d, J = 5.2 Hz, 1H, ArH), 7.62 ( d, J = 7.6 Hz, 1H, ArH), 7.37 - 7.28 (m, 5H, ArH), 7.25 - 7.20 (m, 3H, ArH), 7.16 (t, J = 7.6 Hz, 1H, ArH), 7.05 ( d, J = 8.8 Hz, 1H, ArH), 6.89 (t, J = 7.6 Hz, 1H, ArH), 6.83 (d, J = 5.2 Hz, 1H, ArH), 4.12 (t, J = 6.4 Hz, 2H) , -OCH 2 CH 2 CH 2 Ph), 2.87 (t, J = 7.6 Hz, 2H, -OCH 2 CH 2 CH 2 Ph), 2.25 - 2.15 (m, 2H, -OCH 2 CH 2 CH 2 Ph). 13 C NMR (101 MHz, CDCl 3 ) δ 160.04, 150.93, 150.84, 145.35, 142.07, 141.33, 136.56, 131.22, 128.53 (2C), 128.49 (2C), 126.09, 126.03, 123.28, 121.08, 119.48, 118.70, 115.23, 108.73 , 102.37, 67.22, 32.23, 30.67.
制备实施例6.3：4-(3’-氨基苯硫基)-7–((3’-苯基)丙氧基)喹啉(71)的合成Preparation Example 6.3: Synthesis of 4-(3'-aminophenylthio)-7-((3'-phenyl)propoxy)quinoline (71)
以4-氯-7-((3’–苯基)丙氧基)喹啉7l(1mmol)与间氨基苯硫酚(1mmol)为原料，得黄色固体(0.34g，产率:88.0％)。Mp:110.5-110.8℃.MS(ESI):m/z 386.95[M+H]+.1H NMR(400MHz,CDCl3)δ8.49(d,J＝4.8Hz,1H,ArH),8.09(d,J＝9.2Hz,1H,ArH),7.35(s,1H,ArH),7.30(d,J＝7.2Hz,1H,ArH),7.27–7.17(m,6H,ArH),6.95(d,J＝7.6Hz,1H,ArH),6.87(s,1H,ArH),6.76(d,J＝5.2Hz,2H,ArH),4.12(t,J＝6.2Hz,2H,-OCH2CH2CH2Ph),3.79(s,2H,NH),2.86(t,J＝7.8Hz,2H,-OCH2CH2CH2Ph),2.23–2.15(m,2H,-OCH2CH2CH2Ph).13C NMR(101MHz,CDCl3)δ160.23,149.70,149.41,148.37,147.81,141.35,130.67,130.46,128.53,128.51,128.48,126.02,124.78,124.75,121.15,120.85,119.64,116.40,116.11,108.42,67.23,32.22,30.67,29.73.4-chloro-7-((3'-phenyl)propoxy)quinoline 7l (1 mmol) and m-aminothiophenol (1 mmol) were obtained as a yellow solid (0.34 g, yield: 88.0%) . Mp: 110.5-110.8 ° C. MS (ESI): m/z 386.95 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.49 (d, J = 4.8 Hz, 1H, ArH), 8.09 ( d, J = 9.2 Hz, 1H, ArH), 7.35 (s, 1H, ArH), 7.30 (d, J = 7.2 Hz, 1H, ArH), 7.27 - 7.17 (m, 6H, ArH), 6.95 (d, J = 7.6 Hz, 1H, ArH), 6.87 (s, 1H, ArH), 6.76 (d, J = 5.2 Hz, 2H, ArH), 4.12 (t, J = 6.2 Hz, 2H, -OCH 2 CH 2 CH 2 Ph), 3.79 (s, 2H, NH), 2.86 (t, J = 7.8 Hz, 2H, -OCH 2 CH 2 CH 2 Ph), 2.23 - 2.15 (m, 2H, -OCH 2 CH 2 CH 2 Ph 13 C NMR (101 MHz, CDCl 3 ) δ 160.23, 149.70, 149.41, 148.37, 147.81, 141.35, 130.67, 130.46, 128.53, 128.51, 128.48, 126.02, 124.78, 124.75, 121.15, 120.85, 119.64, 116.40, 116.11, 108.42 , 67.23, 32.22, 30.67, 29.73.
制备实施例6.4：4-(3’-甲氧基苯硫基)-7–((3’-苯基)丙氧基)喹啉(72)的合成Preparation Example 6.4: Synthesis of 4-(3'-methoxyphenylthio)-7-((3'-phenyl)propoxy)quinoline (72)
以4-氯-7-((3’–苯基)丙氧基)喹啉7l(1mmol)与间甲氧基苯硫酚(1mmol)为原料，得白色固体(0.34g，产率:84.7％)。Mp:73.1-75.0℃.MS(ESI):m/z 402.05[M+H]+.1H NMR(400MHz,CDCl3)δ8.50(d,J＝4.8Hz,1H,ArH),8.10(d,J＝9.2Hz,1H,ArH),7.37(t,J＝7.8Hz,2H,ArH),7.29(m,3H,ArH),7.21m,3H,ArH),7.15(d,J＝7.6Hz,1H,ArH),7.10(s,1H,ArH),7.00(d,J＝8.0Hz,1H,ArH),6.72(d,J＝4.8Hz,1H,ArH),4.12(t,J＝6.2Hz,2H,-OCH2CH2CH2Ph),3.81(s,3H,-OCH3),2.89–2.83(m,2H,-OCH2CH2CH2Ph),2.25–2.13(m,2H,-OCH2CH2CH2Ph).13C NMR(101MHz,CDCl3)δ160.49,160.26,149.77,149.56,147.82,141.33,131.04,130.70,128.53(2C),128.49(2C),127.08,126.03,124.73,121.18,119.83,119.76,116.54,115.50,108.53,67.23,55.45,32.23,30.67.4-chloro-7-((3'-phenyl)propoxy)quinoline 7l (1 mmol) and m-methoxythiophenol (1 mmol) were obtained as a white solid (0.34 g, yield: 84.7 %). Mp: 73.1-75.0 ° C. MS (ESI): m/z 402.05 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.50 (d, J = 4.8 Hz, 1H, ArH), 8.10 ( d, J = 9.2 Hz, 1H, ArH), 7.37 (t, J = 7.8 Hz, 2H, ArH), 7.29 (m, 3H, ArH), 7.21m, 3H, ArH), 7.15 (d, J = 7.6 Hz, 1H, ArH), 7.10 (s, 1H, ArH), 7.00 (d, J = 8.0 Hz, 1H, ArH), 6.72 (d, J = 4.8 Hz, 1H, ArH), 4.12 (t, J = 6.2 Hz, 2H, -OCH 2 CH 2 CH 2 Ph), 3.81 (s, 3H, -OCH 3 ), 2.89 - 2.83 (m, 2H, -OCH 2 CH 2 CH 2 Ph), 2.25 - 2.13 (m, 2H, -OCH 2 CH 2 CH 2 Ph). 13 C NMR (101MHz, CDCl 3 ) δ 160.49, 160.26, 149.77, 149.56, 147.82, 141.33, 131.04, 130.70, 128.53 (2C), 128.49 (2C), 127.08, 126.03 , 124.73, 121.18, 119.83, 119.76, 116.54, 115.50, 108.53, 67.23, 55.45, 32.23, 30.67.
制备实施例6.5：4-(4’-氟基苯硫基)-7–((3’-苯基)丙氧基)喹啉(73)的合成Preparation Example 6.5: Synthesis of 4-(4'-fluorophenylthio)-7-((3'-phenyl)propoxy)quinoline (73)
以4-氯-7-((3’–苯基)丙氧基)喹啉7l(1mmol)与对氟苯硫酚(1mmol)为原料，得白色固体(0.35g，产率:89.2％)。Mp:108.3-109.5℃.MS(ESI):m/z 389.95[M+H]+.1H NMR(400MHz,CDCl3)δ8.49(d,J＝4.8 Hz,1H,ArH),8.09(d,J＝9.2Hz,1H,ArH),7.58(dd,J＝8.2,5.4Hz,2H,ArH),7.38(s,1H,ArH),7.34–7.26(m,3H,ArH),7.21(dd,J＝5.6,2.8Hz,5H,ArH),6.58(d,J＝4.8Hz,1H,ArH),4.13(t,J＝6.4Hz,2H,-OCH2CH2CH2Ph),2.86(t,J＝7.6Hz,2H-OCH2CH2CH2Ph),2.26–2.13(m,2H,-OCH2CH2CH2Ph).13C NMR(101MHz,CDCl3)δ164.95,162.45,160.34,149.69,149.49,148.29,141.32,(137.61,137.52),128.54(2C),128.50,126.04,124.90,126.86,124.52,120.87,119.81,117.41,117.19,115.71,108.54,67.26,32.22,30.66.4-chloro-7-((3'-phenyl)propoxy)quinoline 7l (1 mmol) and p-fluorothiophenol (1 mmol) were obtained as a white solid (0.35 g, yield: 89.2%) . Mp: 108.3 - 109.5 ° C. MS (ESI): m/z 399.95 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.49 (d, J = 4.8 Hz, 1H, ArH), 8.09 ( d, J = 9.2 Hz, 1H, ArH), 7.58 (dd, J = 8.2, 5.4 Hz, 2H, ArH), 7.38 (s, 1H, ArH), 7.34 - 7.26 (m, 3H, ArH), 7.21. Dd, J = 5.6, 2.8 Hz, 5H, ArH), 6.58 (d, J = 4.8 Hz, 1H, ArH), 4.13 (t, J = 6.4 Hz, 2H, -OCH 2 CH 2 CH 2 Ph), 2.86 (t, J = 7.6 Hz, 2H-OCH 2 CH 2 CH 2 Ph), 2.26 - 2.13 (m, 2H, -OCH 2 CH 2 CH 2 Ph). 13 C NMR (101 MHz, CDCl 3 ) δ 164.95, 162.45, 160.34, 149.69, 149.49, 148.29, 141.32, (137.61, 137.52), 128.54 (2C), 128.50, 126.04, 124.90, 126.86, 124.52, 120.87, 119.81, 117.41, 117.19, 115.71, 108.54, 67.26, 32.22, 30.66.
制备实施例6.6：4-(3’-羟基苯硫基)-7–((3’-苯基)丙氧基)喹啉(74)的合成Preparation Example 6.6: Synthesis of 4-(3'-hydroxyphenylthio)-7-((3'-phenyl)propoxy)quinoline (74)
以4-氯-7-((3’–苯基)丙氧基)喹啉7l(1mmol)与间羟基苯硫酚(1mmol)为原料，得白色固体(0.23g，产率:59.4％)。Mp:194.8-196.2℃.MS(ESI):m/z 387.95[M+H]+.1H NMR(400MHz,DMSO)δ9.92(s,1H,ArOH),8.57(d,J＝4.4Hz,1H,ArH),8.07(d,J＝9.2Hz,1H,ArH),7.49–7.23(m,7H,ArH),7.19(t,J＝6.8Hz,1H,ArH),7.01(d,J＝7.6Hz,1H,ArH),6.85-6.98(m,2H,ArH),6.77(d,J＝4.4Hz,1H,ArH),4.15(t,J＝6.0Hz,2H,-OCH2CH2CH2Ph),2.80(t,J＝7.6Hz,2H,-OCH2CH2CH2Ph),2.17–2.05(m,2H,-OCH2CH2CH2Ph).13C NMR(101MHz,DMSO)δ160.23,159.01,150.53,149.61,146.89,141.76,131.61,130.22,128.81(4C),126.32,125.26,125.03,121.16,120.76,120.05,117.36,116.98,109.08,67.60,31.95,30.68.4-chloro-7-((3'-phenyl)propoxy)quinoline 7l (1 mmol) and m-hydroxythiophenol (1 mmol) were obtained as a white solid (0.23 g, yield: 59.4%) . Mp: 194.8-196.2 ° C. MS (ESI): m/z 387.95 [M+H] + . 1 H NMR (400 MHz, DMSO) δ 9.92 (s, 1H, ArOH), 8.57 (d, J = 4.4 Hz , 1H, ArH), 8.07 (d, J = 9.2 Hz, 1H, ArH), 7.49 - 7.23 (m, 7H, ArH), 7.19 (t, J = 6.8 Hz, 1H, ArH), 7.01 (d, J) = 7.6 Hz, 1H, ArH), 6.85-6.98 (m, 2H, ArH), 6.77 (d, J = 4.4 Hz, 1H, ArH), 4.15 (t, J = 6.0 Hz, 2H, -OCH 2 CH 2 CH 2 Ph), 2.80 (t, J = 7.6 Hz, 2H, -OCH 2 CH 2 CH 2 Ph), 2.17 - 2.05 (m, 2H, -OCH 2 CH 2 CH 2 Ph). 13 C NMR (101 MHz, DMSO) δ 160.23, 159.01, 150.53, 149.61, 146.89, 141.76, 131.61, 130.22, 128.81 (4C), 126.32, 125.26, 125.03, 121.16, 120.76, 120.05, 117.36, 116.98, 109.08, 67.60, 31.95, 30.68.
制备实施例6.7：4-(3’-羟基苯硫基)-7–((3’,4’,5’-三甲氧基)苄氧基)喹啉(75)的合成Preparation Example 6.7: Synthesis of 4-(3'-hydroxyphenylthio)-7-((3',4',5'-trimethoxy)benzyloxy)quinoline (75)
以4-氯-7-((3’,4’,5’-三甲氧基)苄氧基)喹啉9a(1mmol)与间羟基苯硫酚(1mmol)为原料，得白色固体(0.39g，产率:86.7％)。Mp:173.2-174.1℃.MS(ESI):m/z 449.95[M+H]+.1H NMR(400MHz,CDCl3)δ8.27(d,J＝4.8Hz,1H,ArH),8.04(d,J＝9.6Hz,1H,ArH),7.45(s,1H,ArH),7.36(t,J＝8.0Hz,1H,ArH),7.30(s,1H,ArH),7.11(d,J＝7.6Hz,1H,ArH),7.05(d,J＝8.0Hz,1H,ArH),6.86-6.81(m,2H,ArH),6.70(s,2H,ArH),5.08(s,2H,-OCH2Ph),3.87(s,6H,-OCH3),3.83(s,3H,-OCH3).13C NMR(101MHz,CDCl3)δ160.33,158.90,153.46(2C),150.07,148.13,147.87,137.83,131.55,131.15,129.77,125.30,124.96,121.35,121.06,120.21,118.18,116.09,107.43,104.91(2C),70.61,60.86,56.13(2C).4-chloro-7-((3',4',5'-trimethoxy)benzyloxy)quinoline 9a (1 mmol) and m-hydroxythiophenol (1 mmol) were obtained as a white solid (0.39 g) , yield: 86.7%). Mp: 173.2-174.1 ° C. MS (ESI): m/z 449.95 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.27 (d, J = 4.8 Hz, 1H, ArH), 8.04 ( d, J = 9.6 Hz, 1H, ArH), 7.45 (s, 1H, ArH), 7.36 (t, J = 8.0 Hz, 1H, ArH), 7.30 (s, 1H, ArH), 7.11 (d, J = 7.6 Hz, 1H, ArH), 7.05 (d, J = 8.0 Hz, 1H, ArH), 6.86-6.81 (m, 2H, ArH), 6.70 (s, 2H, ArH), 5.08 (s, 2H, -OCH) 2 Ph), 3.87 (s, 6H, -OCH 3 ), 3.83 (s, 3H, -OCH 3 ). 13 C NMR (101 MHz, CDCl 3 ) δ 160.33, 158.90, 153.46 (2C), 150.07, 148.13, 147.87, 137.83, 131.55, 131.15, 129.77, 125.30, 124.96, 121.35, 121.06, 120.21, 118.18, 116.09, 107.43, 104.91 (2C), 70.61, 60.86, 56.13 (2C).
制备实施例6.8：4-(4’-氟苯硫基)-7–((3’,4’,5’-三甲氧基)苄氧基)喹啉(76)的合成Preparation Example 6.8: Synthesis of 4-(4'-fluorophenylthio)-7-((3',4',5'-trimethoxy)benzyloxy)quinoline (76)
以4-氯-7-((3’,4’,5’-三甲氧基)苄氧基)喹啉9a(1mmol)与对氟苯硫酚(1mmol)为原料，得黄色固体(0.41g，产率:90.9％)。Mp:120.7-121.1℃.MS(ESI):m/z 452.00[M+H]+.1H NMR(400MHz,CDCl3)δ8.50(d,J＝4.8Hz,1H,ArH),8.11(d,J＝9.2Hz,1H,ArH),7.61-7.55(m,2H,ArH),7.49(s,1H,ArH),7.33(dd,J＝9.2,1.2Hz,1H,ArH),7.18(t,J＝8.4Hz,2H,ArH),6.72(s,2H,ArH),6.59(d,J＝4.8Hz,1H,ArH),5.15(s,2H,-OCH2-),3.89(s,6H,-OCH3),3.86(s,3H,-OCH3).13C NMR(101MHz,CDCl3)δ164.94,162.44,159.88,153.49(2C),149.75,149.33,148.44,137.86,(137.62,137.54),131.81,124.69,124.64,121.04,119.76,117.42,117.20,115.81,109.08,104.79(2C),70.50,60.84,56.15(2C).4-Chloro-7-((3',4',5'-trimethoxy)benzyloxy)quinoline 9a (1 mmol) and p-fluorothiophenol (1 mmol) were obtained as a yellow solid (0.41 g) , yield: 90.9%). Mp: 120.7-121.1 ° C. MS (ESI): m/z 452. </RTI> [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.50 (d, J = 4.8 Hz, 1H, ArH), 8.11 ( d, J = 9.2 Hz, 1H, ArH), 7.61 - 7.55 (m, 2H, ArH), 7.49 (s, 1H, ArH), 7.33 (dd, J = 9.2, 1.2 Hz, 1H, ArH), 7.18 ( t, J = 8.4 Hz, 2H, ArH), 6.72 (s, 2H, ArH), 6.59 (d, J = 4.8 Hz, 1H, ArH), 5.15 (s, 2H, -OCH 2 -), 3.89 (s , 6H, -OCH 3 ), 3.86 (s, 3H, -OCH 3 ). 13 C NMR (101MHz, CDCl 3 ) δ 164.94, 162.44, 159.88, 153.49 (2C), 149.75, 149.33, 148.44, 137.86, (137.62, 137.54), 131.81, 124.69, 124.64, 121.04, 119.76, 117.42, 117.20, 115.81, 109.08, 104.79 (2C), 70.50, 60.84, 56.15 (2C).
制备实施例6.9：4-(3’-甲氧基苯硫基)-7–((3’,4’,5’-三甲氧基)苄氧基)喹啉(77)的合成Preparation Example 6.9: Synthesis of 4-(3'-methoxyphenylthio)-7-((3',4',5'-trimethoxy)benzyloxy)quinoline (77)
以4-氯-7-((3’,4’,5’-三甲氧基)苄氧基)喹啉9a(1mmol)与间甲氧基苯硫酚(1mmol)为原料，得黄色固体(0.44g，产率:95.6％)。Mp:106.7-108.2℃.MS(ESI):m/z 463.95[M+H]+.1H NMR(400MHz,CDCl3)δ8.52(d,J＝4.8Hz,1H,ArH),8.13(d,J＝9.2Hz,1H,ArH),7.49(d,J＝1.6Hz,1H,ArH),7.41–7.30(m,2H,ArH),7.15(d,J＝7.6Hz,1H,ArH),7.10(s,1H,ArH),7.01(d,J＝8.0Hz,1H,ArH),6.77–6.70(m,3H,ArH),5.14(s,2H,-OCH2-),3.89(s,6H,-OCH3),3.86(s,3H,-OCH3),3.81(s,3H,-OCH3).13C NMR(101MHz,CDCl3)δ160.51,159.86,153.50,149.77,149.35,148.12,137.86,131.83,130.82,130.74,127.12,124.88,121.36,119.91,119.77,116.64,115.54,109.03,104.79(3C),70.51,60.86,56.17(2C),55.45. 4-Chloro-7-((3',4',5'-trimethoxy)benzyloxy)quinoline 9a (1 mmol) and m-methoxythiophenol (1 mmol) were used as starting material to give a yellow solid ( 0.44 g, yield: 95.6%). Mp: 106.7 - 108.2 ° C. MS (ESI): m/z 463.95 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.52 (d, J = 4.8 Hz, 1H, ArH), 8.13 ( d, J = 9.2 Hz, 1H, ArH), 7.49 (d, J = 1.6 Hz, 1H, ArH), 7.41 - 7.30 (m, 2H, ArH), 7.15 (d, J = 7.6 Hz, 1H, ArH) , 7.10 (s, 1H, ArH), 7.01 (d, J = 8.0 Hz, 1H, ArH), 6.77 - 6.70 (m, 3H, ArH), 5.14 (s, 2H, -OCH 2- ), 3.89 (s , 6H, -OCH 3 ), 3.86 (s, 3H, -OCH 3 ), 3.81 (s, 3H, -OCH 3 ). 13 C NMR (101 MHz, CDCl 3 ) δ 160.51, 159.86, 153.50, 149.77, 149.35, 148.12 , 137.86, 131.83, 130.82, 130.74, 127.12, 124.88, 121.36, 119.91, 119.77, 116.64, 115.54, 109.03, 104.79 (3C), 70.51, 60.86, 56.17 (2C), 55.45.
制备实施例6.10：4-(3’-氨基苯硫基)-7–((3’,4’,5’-三甲氧基)苄氧基)喹啉(78)的合成Preparation Example 6.10: Synthesis of 4-(3'-aminophenylthio)-7-((3',4',5'-trimethoxy)benzyloxy)quinoline (78)
以4-氯-7-((3’,4’,5’-三甲氧基)苄氧基)喹啉9a(1mmol)与间氨基苯硫酚(1mmol)为原料，得黄色固体(0.29g，产率:64.6％)。Mp:60.1-61.8℃.MS(ESI):m/z 448.95[M+H]+.1H NMR(400MHz,CDCl3)δ8.51(d,J＝4.8Hz,1H,ArH),8.12(d,J＝9.2Hz,1H,ArH),7.48(d,J＝1.6Hz,1H,ArH),7.31(dd,J＝9.2,2.0Hz,1H,ArH),7.26-7.20(m,1H,ArH),6.95(d,J＝7.6Hz,1H,ArH),6.88(s,1H,ArH),6.81–6.75(m,2H,ArH),6.72(s,2H,ArH),5.14(s,2H,-OCH2-),3.89(s,6H,-OCH3),3.86(s,3H,-OCH3).13C NMR(101MHz,CDCl3)δ159.79,153.48(2C),149.75,149.26,148.59,147.89,137.82,131.89,130.69,130.24,124.89,124.74,121.33,120.85,119.62,116.50,116.16,108.97,104.80(2C),70.48,60.86,56.17(2C).4-Chloro-7-((3',4',5'-trimethoxy)benzyloxy)quinoline 9a (1 mmol) and m-aminothiophenol (1 mmol) were obtained as a yellow solid (0.29 g) , yield: 64.6%). Mp: 60.1-61.8 ℃ .MS (ESI) :. M / z 448.95 [M + H] + 1 H NMR (400MHz, CDCl 3) δ8.51 (d, J = 4.8Hz, 1H, ArH), 8.12 ( d, J = 9.2 Hz, 1H, ArH), 7.48 (d, J = 1.6 Hz, 1H, ArH), 7.31 (dd, J = 9.2, 2.0 Hz, 1H, ArH), 7.26-7.20 (m, 1H, ArH), 6.95 (d, J = 7.6 Hz, 1H, ArH), 6.88 (s, 1H, ArH), 6.81 - 6.75 (m, 2H, ArH), 6.72 (s, 2H, ArH), 5.14 (s, 2H, -OCH 2- ), 3.89 (s, 6H, -OCH 3 ), 3.86 (s, 3H, -OCH 3 ). 13 C NMR (101 MHz, CDCl 3 ) δ 159.79, 153.48 (2C), 149.75, 149.26, 148.59,147.89,137.82,131.89,130.69,130.24,124.89,124.74,121.33,120.85,119.62,116.50,116.16,108.97,104.80(2C),70.48,60.86,56.17(2C).
制备实施例6.11：4-(3’-甲氧基苯硫基)-7–((3’,4’–二甲氧基)苄氧基)喹啉(79)的合成Preparation Example 6.11: Synthesis of 4-(3'-methoxyphenylthio)-7-((3',4'-dimethoxy)benzyloxy)quinoline (79)
以4-氯-7-((3’,4’-二甲氧基)苄氧基)喹啉9b(1mmol)与间甲氧基苯硫酚(1mmol)为原料，得黄色固体(0.39g，产率:90.2％)。Mp:186.9-187.9℃.MS(ESI):m/z 433.95[M+H]+.1H NMR(400MHz,CDCl3)δ8.38-8.31(m,2H,ArH),8.23(d,J＝9.2Hz,1H,ArH),7.58–7.46(m,2H,ArH),7.23(d,J＝7.6Hz,1H,ArH),7.16(t,J＝10.0Hz,3H,ArH),7.06(s,1H,ArH),6.93(d,J＝8.4Hz,1H,ArH),6.82(d,J＝6.0Hz,1H,ArH),5.27(s,2H,-OCH2Ph),3.95(s,3H,-OCH3),3.90(s,3H,-OCH3),3.87(s,3H,-OCH3).13C NMR(101MHz,CDCl3)δ163.55,162.96,161.16,149.35,149.14,139.33,139.14,131.87,127.78,127.05,126.13,124.99,123.36,121.38,120.87,120.27,117.50,113.31,111.60,111.20,101.11,71.50,56.10,55.93,55.66.4-Chloro-7-((3',4'-dimethoxy)benzyloxy)quinoline 9b (1 mmol) and m-methoxythiophenol (1 mmol) were obtained as a yellow solid (0.39 g) , yield: 90.2%). Mp: 186.9-187.9 ° C. MS (ESI): m/z 433.95 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.38-8.31 (m, 2H, ArH), 8.23 (d, J = 9.2 Hz, 1H, ArH), 7.58 - 7.46 (m, 2H, ArH), 7.23 (d, J = 7.6 Hz, 1H, ArH), 7.16 (t, J = 10.0 Hz, 3H, ArH), 7.06 ( s, 1H, ArH), 6.93 (d, J = 8.4 Hz, 1H, ArH), 6.82 (d, J = 6.0 Hz, 1H, ArH), 5.27 (s, 2H, -OCH 2 Ph), 3.95 (s , 3H, -OCH 3 ), 3.90 (s, 3H, -OCH 3 ), 3.87 (s, 3H, -OCH 3 ). 13 C NMR (101MHz, CDCl 3 ) δ 163.55, 162.96, 161.16, 149.35, 149.14, 139.33 , 139.14, 131.87, 127.78, 127.05, 126.13, 124.99, 123.36, 121.38, 120.87, 120.27, 117.50, 113.31, 111.60, 111.20, 101.11, 71.50, 56.10, 55.93, 55.66.
制备实施例6.12：4-(3’-甲氧基苯硫基)-7–((4’–甲氧基)苄氧基)喹啉(80)的合成Preparation Example 6.12: Synthesis of 4-(3'-methoxyphenylthio)-7-((4'-methoxy)benzyloxy)quinoline (80)
以4-氯-7-((4’-甲氧基)苄氧基)喹啉9c(1mmol)与间甲氧基苯硫酚(1mmol)为原料，得白色固体(0.39g,产率:96.7％)。Mp:127.1-127.7℃.MS(ESI):m/z 403.9[M+H]+.1H NMR(400MHz,CDCl3)δ8.51(d,J＝4.8Hz,1H,ArH),8.11(d,J＝9.2Hz,1H,ArH),7.49(d,J＝1.6Hz,1H,ArH),7.42(d,J＝8.4Hz,2H,ArH),7.37(t,J＝8.0Hz,1H,ArH),7.29(dd,J＝9.2,2.0Hz,1H,ArH),7.15(d,J＝7.6Hz,1H,ArH),7.10(s,1H,ArH),7.00(d,J＝8.4Hz,1H,ArH),6.94(d,J＝8.4Hz,2H,ArH),6.73(d,J＝4.8Hz,1H,ArH),5.14(s,2H,-OCH2Ph),3.82(s,3H,-OCH3),3.81(s,3H,-OCH3).13C NMR(101MHz,CDCl3)δ160.49,160.00,159.63,149.79,149.49,147.86,130.99,130.70,129.50(2C),128.35,127.08,124.80,121.29,119.89,119.84,116.63,115.49,114.10(2C),109.05,70.03,55.43,55.31.4-chloro-7-((4'-methoxy)benzyloxy)quinoline 9c (1 mmol) and m-methoxythiophenol (1 mmol) were obtained as a white solid (0.39 g, yield: 96.7%). Mp: 127.1-127.7 ° C. MS (ESI): m/z 403.9 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.51 (d, J = 4.8 Hz, 1H, ArH), 8.11 ( d, J = 9.2 Hz, 1H, ArH), 7.49 (d, J = 1.6 Hz, 1H, ArH), 7.42 (d, J = 8.4 Hz, 2H, ArH), 7.37 (t, J = 8.0 Hz, 1H) , ArH), 7.29 (dd, J = 9.2, 2.0 Hz, 1H, ArH), 7.15 (d, J = 7.6 Hz, 1H, ArH), 7.10 (s, 1H, ArH), 7.00 (d, J = 8.4) Hz, 1H, ArH), 6.94 (d, J = 8.4 Hz, 2H, ArH), 6.73 (d, J = 4.8 Hz, 1H, ArH), 5.14 (s, 2H, -OCH 2 Ph), 3.82 (s , 3H, -OCH 3 ), 3.81 (s, 3H, -OCH 3 ). 13 C NMR (101MHz, CDCl 3 ) δ 160.49, 160.00, 159.63, 149.79, 149.49, 147.86, 130.99, 130.70, 129.50 (2C), 128.35 , 127.08, 124.80, 121.29, 119.89, 119.84, 116.63, 115.49, 114.10 (2C), 109.05, 70.03, 55.43, 55.31.
制备实施例6.13：4-(3’-氨基苯硫基)-7–((4’–甲氧基)苄氧基)喹啉(81)的合成Preparation Example 6.13: Synthesis of 4-(3'-aminophenylthio)-7-((4'-methoxy)benzyloxy)quinoline (81)
以4-氯-7-((4’-甲氧基)苄氧基)喹啉9c(1mmol)与间氨基苯硫酚(1mmol)为原料，得黄色固体(0.32g,产率:82.3％)。Mp:186.9-188.7℃.MS(ESI):m/z 388.9[M+H]+.1H NMR(400MHz,DMSO)δ8.74(d,J＝6.4Hz,1H,ArH),8.32(d,J＝9.2Hz,1H,ArH),7.67(s,1H,ArH),7.62(d,J＝9.2Hz,1H,ArH),7.49(d,J＝8.4Hz,2H,ArH),7.33(t,J＝7.8Hz,1H,ArH),6.99(d,J＝8.0Hz,2H,ArH),6.95-6.85(m,4H,ArH),5.29(s,2H,-OCH2Ph),3.77(s,3H,-OCH3).13C NMR(101MHz,DMSO)δ162.85,160.66,159.82,149.58,143.39,140.11,131.85,130.54(2C),127.79,126.20,125.94,123.63,122.32,120.97,119.98,117.99,114.65,114.41(2C),102.65,70.66,55.62. 4-Chloro-7-((4'-methoxy)benzyloxy)quinoline 9c (1 mmol) and m-aminothiophenol (1 mmol) were obtained as a yellow solid (0.32 g, yield: 82.3%) ). Mp: 186.9-188.7 ° C. MS (ESI): m/z 388.9 [M+H] + . 1 H NMR (400 MHz, DMSO) δ 8.74 (d, J = 6.4 Hz, 1H, ArH), 8.32 (d) , J = 9.2 Hz, 1H, ArH), 7.67 (s, 1H, ArH), 7.62 (d, J = 9.2 Hz, 1H, ArH), 7.49 (d, J = 8.4 Hz, 2H, ArH), 7.33 ( t, J = 7.8 Hz, 1H, ArH), 6.99 (d, J = 8.0 Hz, 2H, ArH), 6.95-6.85 (m, 4H, ArH), 5.29 (s, 2H, -OCH 2 Ph), 3.77 (s, 3H, -OCH 3 ). 13 C NMR (101MHz, DMSO) δ 162.85, 160.66, 159.82, 149.58, 143.39, 140.11, 131.85, 130.54 (2C), 127.79, 126.20, 125.94, 123.63, 122.32, 120.97, 119.98 , 117.99, 114.65, 114.41 (2C), 102.65, 70.66, 55.62.
Figure PCTCN2017084929-appb-000017
Figure PCTCN2017084929-appb-000017
制备实施例7：化合物82-87的通用合成工艺Preparation Example 7: General Synthesis Process for Compound 82-87
在100mL的圆底烧瓶中加入4-氯-7-取代喹啉1mmol，二甲苯10mL和相应的含取代基的苯酚1.2mmol，4-二甲氨基吡啶0.25mmol(DMAP)，搅拌回流反应2h，TLC跟踪监测至反应完毕。反应液冷却转入500mL烧杯中，加入150mL水，调PH至碱性，DCM萃取3次，合并有机相，水洗3-5次，饱和食盐水洗1次，无水硫酸钠干燥。过滤，减压浓缩至干，柱层析除去反应杂质，用流动相PE：EA＝6：1、PE：EA＝3：1、PE：EA＝2：1洗脱，收集目标产物。In a 100 mL round bottom flask, 1 mmol of 4-chloro-7-substituted quinoline, 10 mL of xylene and 1.2 mmol of the corresponding substituted phenol, 0.25 mmol of 4-dimethylaminopyridine (DMAP) were added, and the mixture was stirred and refluxed for 2 h. The TLC was monitored until the reaction was completed. The reaction solution was cooled and transferred to a 500 mL beaker, and 150 mL of water was added thereto, and the pH was adjusted to be alkaline. The mixture was extracted with DCM three times. The organic phase was combined, washed with water 3-5 times, washed with saturated brine and dried over anhydrous sodium sulfate. Filtration, concentration to dryness under reduced pressure, and removal of the reaction mixture by column chromatography, eluting with mobile phase PE: EA=6:1, PE:EA=3:1, PE:EA=2:1,
制备实施例7.1：4-(4’-硝基苯氧基)-7–正丁氧基喹啉(82)的合成PREPARATIVE EXAMPLE 7.1: Synthesis of 4-(4'-nitrophenoxy)-7-n-butoxyquinoline (82)
以4-氯-7–正丁氧基喹啉7h(1mmol)和对硝基苯酚(1.2mmol)为原料，得白色固体(0.28g,产率:82.8％)。Mp:99.8-101.8℃.MS(ESI):m/z 338.95[M+H]+.1H NMR(400MHz,CDCl3)δ8.72(d,J＝5.2Hz,1H,ArH),8.31(d,J＝9.1Hz,2H,ArH),8.06(d,J＝9.2Hz,1H,ArH),7.46(d,J＝1.9Hz,1H,ArH),7.26(s,1H,ArH),7.23(dd,J＝5.6,2.4Hz,2H,ArH),6.67(d,J＝5.1Hz,1H,ArH),4.15(t,J＝6.8Hz,2H,-OCH2CH2-),1.90–1.82(m,2H,-CH2CH2CH2-),1.55(m,2H,CH3CH2CH2-),1.01(t,J＝7.2Hz,3H,CH3CH2-).13C NMR(101MHz,CDCl3)δ161.14,160.64,159.46,152.21,151.35,144.29,126.16(2C),122.57,120.35,119.71(2C),116.28,107.98,105.54,68.09,31.04,19.27,13.83.4-chloro-7-n-butoxyquinoline 7h (1 mmol) and p-nitrophenol (1.2 mmol) were obtained as a white solid (0.28 g, yield: 82.8%). Mp: 99.8 - 101.8 ° C. MS (ESI): m/z 338.95 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.72 (d, J = 5.2 Hz, 1H, ArH), 8.31 ( d, J = 9.1 Hz, 2H, ArH), 8.06 (d, J = 9.2 Hz, 1H, ArH), 7.46 (d, J = 1.9 Hz, 1H, ArH), 7.26 (s, 1H, ArH), 7.23 (dd, J = 5.6, 2.4 Hz, 2H, ArH), 6.67 (d, J = 5.1 Hz, 1H, ArH), 4.15 (t, J = 6.8 Hz, 2H, -OCH 2 CH 2 -), 1.90 - 1.82 (m, 2H, -CH 2 CH 2 CH 2 -), 1.55 (m, 2H, CH 3 CH 2 CH 2 -), 1.01 (t, J = 7.2Hz, 3H, CH 3 CH 2 -). 13 C NMR (101 MHz, CDCl 3 ) δ 161.14, 160.64, 159.46, 152.21, 151.35, 144.29, 126.16 (2C), 122.57, 120.35, 119.71 (2C), 116.28, 107.98, 105.54, 68.09, 31.04, 19.27, 13.83.
制备实施例7.2：4-(3’-硝基苯氧基)-7–((3’-苯基)丙氧基)喹啉(83)的合成Preparation Example 7.2: Synthesis of 4-(3'-nitrophenoxy)-7-((3'-phenyl)propoxy)quinoline (83)
以4-氯-7-((3’–苯基)丙氧基)喹啉7l(1mmol)与间硝基苯酚(1.2mmol)为原料，得白色固体(0.28g，产率:63.4％)。Mx:61.2-62.4℃.MS(ESI):m/z 400.90[M+H]+.1H NMR(400MHz,CDCl3)δ8.66(d,J＝5.2Hz,1H,ArH),8.19–8.11(m,2H,ArH),8.03(t,J＝2.2Hz,1H,ArH),7.63(t,J＝8.2Hz,1H,ArH),7.54–7.49(m,1H,ArH),7.41(d,J＝2.0Hz,1H,ArH),7.33–7.28(m,2H,ArH),7.26(d,J＝1.7Hz,1H,ArH),7.25(d,J＝1.6Hz,1H,ArH),7.23(s,1H,ArH),7.22–7.15(m,1H,ArH),6.52(d,J＝5.2Hz,1H,ArH),4.14(t,J＝6.4Hz,2H,-OCH2CH2CH2Ph),2.87(t,J＝7.6Hz,2H,-OCH2CH2CH2Ph),2.25–2.17(m,2H,-OCH2CH2CH2Ph).13C NMR(101MHz,CDCl3)δ160.97,160.38,155.57,152.03,151.37,149.49,141.28,130.91,128.51(2C),128.48(2C),126.57,126.04,122.66,120.02(2C),116.07,115.78,108.04,103.97,67.31,32.21,30.63.4-chloro-7-((3'-phenyl)propoxy)quinoline 7l (1 mmol) and m-nitrophenol (1.2 mmol) were obtained as a white solid (0.28 g, yield: 63.4%) . M x : 61.2-62.4 ° C. MS (ESI): m/z 400.90 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.66 (d, J = 5.2 Hz, 1H, ArH), 8.19 – 8.11 (m, 2H, ArH), 8.03 (t, J = 2.2 Hz, 1H, ArH), 7.63 (t, J = 8.2 Hz, 1H, ArH), 7.54 - 7.49 (m, 1H, ArH), 7.41 (d, J = 2.0 Hz, 1H, ArH), 7.33 - 7.28 (m, 2H, ArH), 7.26 (d, J = 1.7 Hz, 1H, ArH), 7.25 (d, J = 1.6 Hz, 1H, ArH) ), 7.23 (s, 1H, ArH), 7.22 - 7.15 (m, 1H, ArH), 6.52 (d, J = 5.2 Hz, 1H, ArH), 4.14 (t, J = 6.4 Hz, 2H, -OCH 2 CH 2 CH 2 Ph), 2.87 (t, J = 7.6 Hz, 2H, -OCH 2 CH 2 CH 2 Ph), 2.25 - 2.17 (m, 2H, -OCH 2 CH 2 CH 2 Ph). 13 C NMR ( 101 MHz, CDCl 3 ) δ 160.97, 160.38, 155.57, 152.03, 151.37, 149.49, 141.28, 130.91, 128.51 (2C), 128.48 (2C), 126.57, 126.04, 122.66, 120.02 (2C), 116.07, 115.78, 108.04, 103.97, 67.31, 32.21, 30.63.
制备实施例7.3：4-(3’-甲氧基苯氧基)-7–((3’,4’,5’-三甲氧基)苄氧基)喹啉(84)的合成Preparation Example 7.3: Synthesis of 4-(3'-methoxyphenoxy)-7-((3',4',5'-trimethoxy)benzyloxy)quinoline (84)
以4-氯-7-((3’,4’,5’-三甲氧基)苄氧基)喹啉9a(1mmol)与间甲氧基苯酚(1.2mmol)为原料，得粉色固体(0.20g，产率:44.7％)。Mp:144.7-146.2℃.MS(ESI):m/z 447.95[M+H]+.1H NMR(400MHz,CDCl3)δ 8.61(d,J＝5.2Hz,1H,ArH),8.26(d,J＝9.2Hz,1H,ArH),7.51(s,1H,ArH),7.38–7.29(m,2H,ArH),6.84(d,J＝8.0Hz,1H,ArH),6.80–6.71(m,4H,ArH),6.52(d,J＝5.2Hz,1H,ArH),5.16(s,2H,-OCH2-),3.90(s,6H,,-OCH3),3.86(s,3H,-OCH3),3.82(s,3H,-OCH3).13C NMR(101MHz,CDCl3)δ161.69,161.22,160.23,155.45,153.49,151.57,137.82,131.92,130.63,123.20,119.31,116.41,112.99,111.26,108.37,106.91,104.76(4C),103.33,70.45,60.86,56.16(2C),55.49.4-chloro-7-((3',4',5'-trimethoxy)benzyloxy)quinoline 9a (1mmol) and m-methoxyphenol (1.2mmol) were used as the starting material to give a pink solid (0.20) g, yield: 44.7%). Mp: 144. 7-146.2 ° C. MS (ESI): m/z 447.95 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.61 (d, J = 5.2 Hz, 1H, ArH), 8.26 (d) , J = 9.2 Hz, 1H, ArH), 7.51 (s, 1H, ArH), 7.38 - 7.29 (m, 2H, ArH), 6.84 (d, J = 8.0 Hz, 1H, ArH), 6.80 - 6.71 (m , 4H, ArH), 6.52 (d, J = 5.2 Hz, 1H, ArH), 5.16 (s, 2H, -OCH 2 ), 3.90 (s, 6H,, -OCH 3 ), 3.86 (s, 3H, -OCH 3 ), 3.82 (s, 3H, -OCH 3 ). 13 C NMR (101 MHz, CDCl 3 ) δ 161.69, 161.22, 160.23, 155.45, 153.49, 151.57, 137.82, 131.92, 130.63, 123.20, 119.31, 116.41, 112.99 , 111.26, 108.37, 106.91, 104.76 (4C), 103.33, 70.45, 60.86, 56.16 (2C), 55.49.
制备实施例7.4：4-(4’-硝基基苯氧基)-7–((3’,4’,5’-三甲氧基)苄氧基)喹啉(85)的合成Preparation Example 7.4: Synthesis of 4-(4'-nitrophenoxy)-7-((3',4',5'-trimethoxy)benzyloxy)quinoline (85)
以4-氯-7-((3’,4’,5’-三甲氧基)苄氧基)喹啉9a(1mmol)与对硝基苯酚(1.2mmol)为原料，得粉色固体(0.26g，产率:56.2％)。Mp:70.8-78.9℃.MS(ESI):m/z 462.95[M+H]+.1H NMR(400MHz,DMSO)δ8.77-8.67(m,1H,ArH),8.35(d,J＝9.0Hz,2H,ArH),8.12-8.00(m,1H,ArH),7.58(s,1H,ArH),7.51–7.37(m,3H,ArH),6.90–6.86(m,2H,ArH),5.23(s,2H,-OCH2-),3.80(s,6H,-OCH3),3.67(s,3H,-OCH3).13C NMR(101MHz,DMSO)δ160.68,160.38,159.18,153.43,152.47,151.97,144.37,137.63,132.51,126.77(2C),123.16,120.60,120.48(2C),120.33,116.25,109.25,106.61,105.80(2C),70.34,60.47,56.36(2C).4-Chloro-7-((3',4',5'-trimethoxy)benzyloxy)quinoline 9a (1mmol) and p-nitrophenol (1.2mmol) were obtained as a pink solid (0.26g) , yield: 56.2%). Mp: 70.8-78.9 ° C. MS (ESI): m/z 462.95 [M+H] + . 1 H NMR (400 MHz, DMSO) δ 8.77-8.67 (m, 1H, ArH), 8.35 (d, J = 9.0 Hz, 2H, ArH), 8.12 - 8.00 (m, 1H, ArH), 7.58 (s, 1H, ArH), 7.51 - 7.37 (m, 3H, ArH), 6.90 - 6.86 (m, 2H, ArH), 5.23 (s, 2H, -OCH 2 -), 3.80 (s, 6H, -OCH 3 ), 3.67 (s, 3H, -OCH 3 ). 13 C NMR (101 MHz, DMSO) δ 160.68, 160.38, 159.18, 153.43, 152.47,151.97,144.37,137.63,132.51,126.77(2C),123.16,120.60,120.48(2C),120.33,116.25,109.25,106.61,105.80(2C),70.34,60.47,56.36(2C).
制备实施例7.5：4-(3’-硝基苯氧基)-7–((3’,4’–二甲氧基)苄氧基)喹啉(86)的合成Preparation Example 7.5: Synthesis of 4-(3'-nitrophenoxy)-7-((3',4'-dimethoxy)benzyloxy)quinoline (86)
以4-氯-7-((3’,4’–二甲氧基)苄氧基)喹啉9b(1mmol)与间硝基苯酚(1.2mmol)为原料，得粉色固体(0.30g，产率:69.4％)。Mp:143.7-144.5℃.MS(ESI):m/z 432.95[M+H]+.1H NMR(400MHz,CDCl3)δ8.69(d,J＝5.2Hz,1H,ArH),8.18(d,J＝9.6Hz,1H,ArH),8.15(d,J＝8.4Hz,1H,ArH),8.04(s,1H,ArH),7.64(t,J＝8.2Hz,1H,ArH),7.58–7.49(m,2H,ArH),7.32(d,J＝8.8Hz,1H,ArH),7.10–7.02(m,2H,ArH),6.90(d,J＝8.0Hz,1H,ArH),6.54(d,J＝5.2Hz,1H,ArH),5.17(s,2H,-OCH2Ph),3.93(s,3H,-OCH3),3.90(s,3H,-OCH3).13C NMR(101MHz,CDCl3)δ160.67,160.43,155.51,151.91,151.42,149.48,149.23,149.13,130.95,128.62,126.62,122.79,120.65,120.14,120.07,116.24,115.80,111.18(2C),108.53,104.06,70.38,55.97,55.94.4-chloro-7-((3',4'-dimethoxy)benzyloxy)quinoline 9b (1mmol) and m-nitrophenol (1.2mmol) were obtained as a pink solid (0.30g, yield Rate: 69.4%). Mp: 143. 7-144.5 ° C. MS (ESI): m/z 422.95 [M+H] + . 1 H NMR (400 MHz, CDCl 3 ) δ 8.69 (d, J = 5.2 Hz, 1H, ArH), 8.18 ( d, J = 9.6 Hz, 1H, ArH), 8.15 (d, J = 8.4 Hz, 1H, ArH), 8.04 (s, 1H, ArH), 7.64 (t, J = 8.2 Hz, 1H, ArH), 7.58 -7.49 (m, 2H, ArH), 7.32 (d, J = 8.8 Hz, 1H, ArH), 7.10 - 7.02 (m, 2H, ArH), 6.90 (d, J = 8.0 Hz, 1H, ArH), 6.54 (d, J = 5.2 Hz, 1H, ArH), 5.17 (s, 2H, -OCH 2 Ph), 3.93 (s, 3H, -OCH 3 ), 3.90 (s, 3H, -OCH 3 ). 13 C NMR (101MHz, CDCl 3 ) δ160.67,160.43,155.51,151.91,151.42,149.48,149.23,149.13,130.95,128.62,126.62,122.79,120.65,120.14,120.07,116.24,115.80,111.18(2C),108.53,104.06,70.38 , 55.97, 55.94.
制备实施例7.6：4-(3’-硝基苯氧基)-7–((4’-三甲氧基)苄氧基)喹啉(87)的合成Preparation Example 7.6: Synthesis of 4-(3'-nitrophenoxy)-7-((4'-trimethoxy)benzyloxy)quinoline (87)
以4-氯-7-((4’–甲氧基)苄氧基)喹啉9c(1mmol)与间硝基苯酚(1.2mmol)为原料，得粉色固体(0.25g，产率:62.5％)。Mp:℃.MS(ESI):m/z 402.90[M+H]+.1H NMR(400MHz,CDCl3)δ8.68(d,J＝5.2Hz,1H,ArH),8.15(t,J＝9.2Hz,2H,ArH),8.03(s,1H,ArH),7.63(t,J＝8.2Hz,1H,ArH),7.57–7.49(m,2H,ArH),7.43(d,J＝8.4Hz,2H,ArH),7.30(d,J＝8.8Hz,1H,ArH),6.95(d,J＝8.0Hz,2H,ArH),6.53(d,J＝5.2Hz,1H,ArH),5.17(s,2H,-OCH2Ph),3.83(s,3H,-OCH3).13C NMR(101MHz,CDCl3)δ160.67,160.37,159.65,155.49,151.94,151.42,149.44,130.93,129.49(2C),128.21,126.61,122.75,120.13,120.03,116.18,115.78,114.10(2C),108.53,104.02,70.07,55.31. 4-Chloro-7-((4'-methoxy)benzyloxy)quinoline 9c (1 mmol) and m-nitrophenol (1.2 mmol) were obtained as a white solid (0.25 g, yield: 62.5%) ). Mp: ℃ .MS (ESI): m / z 402.90 [M + H] + 1 H NMR (400MHz, CDCl 3) δ8.68 (d, J = 5.2Hz, 1H, ArH), 8.15 (t, J. = 9.2 Hz, 2H, ArH), 8.03 (s, 1H, ArH), 7.63 (t, J = 8.2 Hz, 1H, ArH), 7.57 - 7.49 (m, 2H, ArH), 7.43 (d, J = 8.4) Hz, 2H, ArH), 7.30 (d, J = 8.8 Hz, 1H, ArH), 6.95 (d, J = 8.0 Hz, 2H, ArH), 6.53 (d, J = 5.2 Hz, 1H, ArH), 5.17 (s, 2H, -OCH 2 Ph), 3.83 (s, 3H, -OCH 3 ). 13 C NMR (101MHz, CDCl 3 ) δ 160.67, 160.37, 159.65, 155.49, 151.94, 151.42, 149.44, 130.93, 129.49 (2C ), 128.21, 126.61, 122.75, 120.13, 120.03, 116.18, 115.78, 114.10 (2C), 108.53, 104.02, 70.07, 55.31.
Figure PCTCN2017084929-appb-000018
Figure PCTCN2017084929-appb-000018
制备实施例8：化合物88的通用合成工艺Preparation Example 8: General Synthesis Process for Compound 88
在100mL的圆底烧瓶中加入四氢呋喃10mL、3,4,5-三甲氧基苄醇(4mmol,0.79g)、60％的NaH粉末(5mmol,0.2g)，室温下搅拌30min，再加入碘化钾(1.5mmol,0.25g)、7-((3’,4’,5’-三甲氧基)苄氧基)-4氯喹啉9a(1mmol,0.36g)，搅拌回流反应4h，TLC跟踪监测至反应完毕。反应液冷却转入500mL烧杯中，加入150mL水，乙酸乙酯萃取3次，合并有机相，水洗3-5次，饱和食盐水洗1次，无水硫酸钠干燥。过滤，减压浓缩至干，柱层析除去反应杂质，用流动相PE：EA＝6：1、PE：EA＝3：1、PE：EA＝2：1洗脱，收集目标产物，得0.25g白色固体，产率49.9％。To a 100 mL round bottom flask was added 10 mL of tetrahydrofuran, 3,4,5-trimethoxybenzyl alcohol (4 mmol, 0.79 g), 60% NaH powder (5 mmol, 0.2 g), stirred at room temperature for 30 min, and then added potassium iodide ( 1.5mmol, 0.25g), 7-((3',4',5'-trimethoxy)benzyloxy)-4chloroquinoline 9a (1mmol, 0.36g), stirred for 4h, refluxed and monitored by TLC Finished. The reaction solution was cooled and transferred to a 500 mL beaker, and 150 mL of water was added thereto, and the mixture was extracted three times with ethyl acetate. The organic phase was combined, washed with water 3-5 times, washed with brine and dried over anhydrous sodium sulfate. Filtration, concentration under reduced pressure to dryness, and removal of the reaction impurities by column chromatography, eluting with mobile phase PE:EA=6:1, PE:EA=3:1, PE:EA=2:1, g White solid in 49.9% yield.
制备实施例8.1：4,7-二((3’,4’,5’-三甲氧基)苄氧基)喹啉(88)的合成PREPARATIVE EXAMPLE 8.1: Synthesis of 4,7-bis((3',4',5'-trimethoxy)benzyloxy)quinoline (88)
以7–((3’,4’,5’-三甲氧基)苄氧基)喹啉(1mmol)与3,4,5-三甲氧基苯甲醇(4mmol)为原料，得粉色固体(0.25g，产率:49.9％)。Mp:44.2-44.6℃.MS(ESI):m/z 522.05[M+H]+.1H NMR(400MHz,CDCl3)δ8.72(d,J＝5.2Hz,1H,ArH),8.21(d,J＝9.2Hz,1H,ArH),7.50(s,1H,ArH),7.30(d,J＝6.0Hz,1H,ArH),6.75(s,5H,ArH),5.23(s,2H,-OCH2Ph),5.17(s,2H,-OCH2Ph),3.92(s,15H,-OCH3),3.89(s,3H,-OCH3).13C NMR(101MHz,CDCl3)δ161.37,160.00,153.52(2C),153.44(2C),151.78,151.03,138.01,137.76,131.96,131.31,123.29,118.68,116.24,108.36,104.76(4C),100.02,70.57,70.39,60.88,60.83,56.19(2C),56.13(2C).Using 7-((3',4',5'-trimethoxy)benzyloxy)quinoline (1mmol) and 3,4,5-trimethoxybenzyl alcohol (4mmol) as the starting material, a pink solid (0.25) g, yield: 49.9%). Mp: 44.2-44.6 ℃ .MS (ESI) :. M / z 522.05 [M + H] + 1 H NMR (400MHz, CDCl 3) δ8.72 (d, J = 5.2Hz, 1H, ArH), 8.21 ( d, J = 9.2 Hz, 1H, ArH), 7.50 (s, 1H, ArH), 7.30 (d, J = 6.0 Hz, 1H, ArH), 6.75 (s, 5H, ArH), 5.23 (s, 2H, -OCH 2 Ph), 5.17 (s, 2H, -OCH 2 Ph), 3.92 (s, 15H, -OCH 3 ), 3.89 (s, 3H, -OCH 3 ). 13 C NMR (101 MHz, CDCl 3 ) δ 161 .37,160.00,153.52(2C),153.44(2C),151.78,151.03,138.01,137.76,131.96,131.31,123.29,118.68,116.24,108.36,104.76(4C),100.02,70.57,70.39,60.88,60.83,56.19 ( 2C), 56.13 (2C).
测试实施例2Test Example 2
体外抗肿瘤活性试验In vitro antitumor activity test
本测试实施例中，所有测试的化合物在试验前均制备成盐酸盐形式，以临床上常用的抗肿瘤药物－顺铂和伯舒替尼作为阳性对照药物。In the test examples, all the tested compounds were prepared into the hydrochloride form before the test, and the commonly used antitumor drugs, cisplatin and besibutinib, were used as positive control drugs.
分别选用人直肠癌细胞系(HCT116)、人肝癌细胞系(HepG2)、人非小细胞肺癌细胞系(A549)、人卵巢癌细胞系(A2780)、人胃癌细胞系(BGC-823)、等人肿瘤细胞系，采用MTT法进行测试。具体方法如下:按照标准培养方法培养各种细胞系，分别将生长状态良好、处于对数生长期的细胞系以5×104个/ml的浓度接种于96孔板，每孔接种160μl，随后将96孔板置于37℃、含5％CO2的培养箱中培养24小时，弃旧液，换新鲜培养液，加入灭菌处理的喹啉衍生物，继续培养48小时后，然后弃去培养液，每孔加20ul含5mg/ml MTT的RPMI-1640培养液，继续培养4小时，小心除去上清后，每孔加入200μl的DMSO，振荡约10min溶解沉淀，随后用酶标仪检测OD值，波长490nm。用下式求出每一样品浓度下的细胞存活率。 Human rectal cancer cell line (HCT116), human hepatoma cell line (HepG2), human non-small cell lung cancer cell line (A549), human ovarian cancer cell line (A2780), human gastric cancer cell line (BGC-823), etc. Human tumor cell lines were tested using the MTT method. The specific method is as follows: various cell lines are cultured according to standard culture methods, and cell lines in good growth state and in logarithmic growth phase are inoculated into 96-well plates at a concentration of 5×10 4 /ml, and 160 μl is inoculated per well, followed by The 96-well plate was incubated in an incubator containing 5% CO 2 at 37 ° C for 24 hours, the old solution was discarded, the fresh culture solution was replaced, the sterilized quinoline derivative was added, and the culture was continued for 48 hours, and then discarded. The culture medium was added with 20 ul of RPMI-1640 medium containing 5 mg/ml MTT per well, and the culture was continued for 4 hours. After carefully removing the supernatant, 200 μl of DMSO was added to each well, and the precipitate was dissolved by shaking for about 10 minutes, and then the OD was detected by a microplate reader. Value, wavelength 490 nm. The cell viability at each sample concentration was determined by the following formula.
存活率％＝样品组平均OD值/对照组平均OD值×100％Survival rate % = average OD value of the sample group / average OD value of the control group × 100%
以细胞存活率对药物浓度对数作图，按作图法求出每个样品的IC50值，结果见下表3。The cell survival rate was plotted against the logarithm of the drug concentration, and the IC 50 value of each sample was determined by the mapping method. The results are shown in Table 3 below.
表3.化合物9a-9c和52-88体外抗肿瘤活性评价结果(IC50,μM)Table 3. Evaluation results of in vitro antitumor activity of compounds 9a-9c and 52-88 (IC 50 , μM)
Figure PCTCN2017084929-appb-000019
Figure PCTCN2017084929-appb-000019
Figure PCTCN2017084929-appb-000020
Figure PCTCN2017084929-appb-000020

Claims (10)

  1. 一种喹啉衍生物，其是式I化合物：A quinoline derivative which is a compound of formula I:
    Figure PCTCN2017084929-appb-100001
    Figure PCTCN2017084929-appb-100001
    或其可药用盐，其中Or a pharmaceutically acceptable salt thereof, wherein
    R是一个、两个或三个各自独立地选自以下的基团：任选取代的氢、卤素、羟基、氨基、烷基、烷氧基、烷酰基氧基、烷基硫基、烷基氨基、氰基、硝基、羧基、磺酰基、烷基磺酰基、芳基磺酰基、杂芳基磺酰基、酰氨基、烷氧基羰基或烷基酰基，R is one, two or three groups each independently selected from the group consisting of: optionally substituted hydrogen, halogen, hydroxy, amino, alkyl, alkoxy, alkanoyloxy, alkylthio, alkyl Amino, cyano, nitro, carboxy, sulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, acylamino, alkoxycarbonyl or alkyl acyl,
    R1是任选取代的烷基、烯基或炔基，R 1 is an optionally substituted alkyl, alkenyl or alkynyl group,
    当存在时所述任选的取代基各自独立地选自芳基、杂芳基、杂环基、烷基芳基、烷基杂芳基、烷基杂环基、氨基、烷基氨基、酰胺基、烷基酰基氨基、羟基、烷氧基、烷基酰基、烷基酰基氧基、巯基、烷基硫基，所述任选的取代基可进一步被取代；和When present, the optional substituents are each independently selected from the group consisting of aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylheterocyclyl, amino, alkylamino, amide a group, an alkyl acylamino group, a hydroxy group, an alkoxy group, an alkyl acyl group, an alkyl acyloxy group, a decyl group, an alkylthio group, said optional substituent may be further substituted;
    W选自NH、O或S。W is selected from NH, O or S.
  2. 前述任一项权利要求的喹啉衍生物，其中至少一个所述R选自：任选取代的卤素、烷氧基、烷酰基氧基、烷基硫基、烷基氨基、氰基、硝基、羧基、磺酰基、烷基磺酰基、芳基磺酰基、杂芳基磺酰基、酰氨基、烷氧基羰基或烷基酰基，优选地，至少一个所述R选自：任选取代的氰基、硝基、羧基、磺酰基、烷基磺酰基、芳基磺酰基、杂芳基磺酰基、酰氨基、烷氧基羰基或烷基酰基。A quinoline derivative according to any of the preceding claims wherein at least one of said R is selected from the group consisting of: optionally substituted halogen, alkoxy, alkanoyloxy, alkylthio, alkylamino, cyano, nitro a carboxyl group, a sulfonyl group, an alkylsulfonyl group, an arylsulfonyl group, a heteroarylsulfonyl group, an acylamino group, an alkoxycarbonyl group or an alkyl acyl group, preferably at least one of said R is selected from the group consisting of: an optionally substituted cyanogen A nitro group, a carboxy group, a sulfonyl group, an alkylsulfonyl group, an arylsulfonyl group, a heteroarylsulfonyl group, an acylamino group, an alkoxycarbonyl group or an alkylacyl group.
  3. 前述任一项权利要求的喹啉衍生物，其中至少一个所述R是硝基、甲氧基、氟、氯或溴。A quinoline derivative according to any of the preceding claims wherein at least one of said R is nitro, methoxy, fluoro, chloro or bromo.
  4. 前述任一项权利要求的喹啉衍生物，其中所述R1是任选取代的C2-C12烷基、C3-C12烯基或C3-C12炔基，例如是乙基、丙基、丁基、戊基、己基、庚基、辛基、壬基、癸基、烯丙基、烯丁基、炔丙基、或炔丁基。A quinoline derivative according to any of the preceding claims wherein R 1 is optionally substituted C 2 -C 12 alkyl, C 3 -C 12 alkenyl or C 3 -C 12 alkynyl, for example ethyl, propyl, butyl , pentyl, hexyl, heptyl, octyl, decyl, decyl, allyl, enbutyl, propargyl, or alkynyl butyl.
  5. 前述任一项权利要求的喹啉衍生物，其中所述R1是任选取代的芳烷基或杂芳基烷基，优选地是芳基甲基、芳基乙基、芳基丙基，例如是苯甲基、苯乙基、苯基丙基、苯基丁基；所述芳基烷基或杂芳基烷基任选地被一个或更多个卤素如氟、氯或溴、烷基、烷氧基、卤代烷基或卤代烷氧基所取代，例如所述R1可以是氟代苯甲基、氟代苯乙基、氟代苯丙基。A quinoline derivative according to any of the preceding claims wherein said R 1 is an optionally substituted aralkyl or heteroarylalkyl group, preferably an arylmethyl group, an arylethyl group, an arylpropyl group, For example, benzyl, phenethyl, phenylpropyl, phenylbutyl; the arylalkyl or heteroarylalkyl is optionally substituted by one or more halogens such as fluorine, chlorine or bromine, alkane Substituted by a group, an alkoxy group, a halogenated alkyl group or a halogenated alkoxy group, for example, the R 1 may be a fluorobenzyl group, a fluorophenethyl group or a fluorophenyl group.
  6. 前述任一项权利要求的喹啉衍生物，其中所述化合物选自A quinoline derivative according to any of the preceding claims wherein said compound is selected from
    Figure PCTCN2017084929-appb-100002
    Figure PCTCN2017084929-appb-100002
    Figure PCTCN2017084929-appb-100003
    Figure PCTCN2017084929-appb-100003
    Figure PCTCN2017084929-appb-100004
    Figure PCTCN2017084929-appb-100004
    Figure PCTCN2017084929-appb-100005
    Figure PCTCN2017084929-appb-100005
    Figure PCTCN2017084929-appb-100006
    Figure PCTCN2017084929-appb-100006
    Figure PCTCN2017084929-appb-100007
    Figure PCTCN2017084929-appb-100007
    Figure PCTCN2017084929-appb-100008
    Figure PCTCN2017084929-appb-100008
  7. 制备权利要求1-6中任一项所述喹啉衍生物的方法，其包括：A process for the preparation of a quinoline derivative according to any one of claims 1 to 6, which comprises:
    1)使式II化合物在碱存在下与R1X接触，1) contacting a compound of formula II with R 1 X in the presence of a base,
    Figure PCTCN2017084929-appb-100009
    Figure PCTCN2017084929-appb-100009
    获得式III化合物，和Obtaining a compound of formula III, and
    Figure PCTCN2017084929-appb-100010
    Figure PCTCN2017084929-appb-100010
    2)使式III化合物在酸存在下与R取代苯胺接触，获得式I化合物， 2) contacting a compound of formula III with an R-substituted aniline in the presence of an acid to obtain a compound of formula I,
    Figure PCTCN2017084929-appb-100011
    Figure PCTCN2017084929-appb-100011
    其中，X各自独立地是卤素，R、R1和W如权利要求1-6中所定义，Wherein X is each independently halogen, and R, R 1 and W are as defined in claims 1-6,
    所述碱优选地是NaH，和/或所述酸优选地是浓盐酸。The base is preferably NaH, and/or the acid is preferably concentrated hydrochloric acid.
  8. 一种药物组合物，其包含权利要求1-6中任一项所述喹啉衍生物以及可药用载体。A pharmaceutical composition comprising the quinoline derivative of any one of claims 1 to 6 and a pharmaceutically acceptable carrier.
  9. 权利要求1-6任一项所述喹啉衍生物用于制备治疗增生性疾病的药物中的用途。Use of the quinoline derivative according to any one of claims 1 to 6 for the preparation of a medicament for the treatment of a proliferative disease.
  10. 权利要求9的用途，其中所述增生性疾病是恶性肿瘤，优选地所述增生性疾病选自白血病、结直肠癌、肝癌、非小细胞肺癌、卵巢癌、***和胃癌。 The use according to claim 9, wherein the proliferative disease is a malignant tumor, preferably the proliferative disease is selected from the group consisting of leukemia, colorectal cancer, liver cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, and gastric cancer.
PCT/CN2017/084929 2016-05-18 2017-05-18 Quinoline derivative having anti-tumor activity WO2017198196A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610330810.2 2016-05-18
CN201610330810 2016-05-18

Publications (1)

Publication Number Publication Date
WO2017198196A1 true WO2017198196A1 (en) 2017-11-23

Family

ID=60325741

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/084929 WO2017198196A1 (en) 2016-05-18 2017-05-18 Quinoline derivative having anti-tumor activity

Country Status (1)

Country Link
WO (1) WO2017198196A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020109039A1 (en) 2018-11-28 2020-06-04 Basf Se Pesticidal compounds
US20200360365A1 (en) * 2018-01-05 2020-11-19 Instutut National de la Sante et de la Researche Medicale Substituted halo-quinoline derivates for use in the treatment of lymphomas and leukemia
WO2021219513A1 (en) 2020-04-28 2021-11-04 Basf Se Pesticidal compounds
CN115260164A (en) * 2021-05-01 2022-11-01 杭州星鳌生物科技有限公司 Preparation method and structural composition of novel 4 (3H) -quinazolinone analogue and application of analogue in antitumor drugs
CN115466211A (en) * 2022-06-09 2022-12-13 中国人民解放军空军军医大学 N-phenylquinoline-4-amine compound and application thereof
CN116693452A (en) * 2023-05-24 2023-09-05 中山大学 Quinoline derivative and preparation method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1031263C (en) * 1988-01-29 1996-03-13 伊莱利利公司 Quinoline, quinazoline, and cinnoline
CN101248059A (en) * 2005-04-27 2008-08-20 安姆根有限公司 Substituted amide derivatives as protein kinase inhibitors
CN102249997A (en) * 2011-05-25 2011-11-23 沈阳化工大学 Group of 4-substituted phenylaminoquinoline compounds having antitumor activity
US20120122847A1 (en) * 2007-04-05 2012-05-17 Amgen Inc. Aurora kinase modulators and method of use
US20140336182A1 (en) * 2013-05-13 2014-11-13 Amgen Inc. Aurora Kinase Modulators and Method of Use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1031263C (en) * 1988-01-29 1996-03-13 伊莱利利公司 Quinoline, quinazoline, and cinnoline
CN101248059A (en) * 2005-04-27 2008-08-20 安姆根有限公司 Substituted amide derivatives as protein kinase inhibitors
US20120122847A1 (en) * 2007-04-05 2012-05-17 Amgen Inc. Aurora kinase modulators and method of use
CN102249997A (en) * 2011-05-25 2011-11-23 沈阳化工大学 Group of 4-substituted phenylaminoquinoline compounds having antitumor activity
US20140336182A1 (en) * 2013-05-13 2014-11-13 Amgen Inc. Aurora Kinase Modulators and Method of Use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOTIWALA, HASHIM F.: "Microwave-Accelerated Solvent- and Catalyst-Free Synthesis of 4-Aminoaryl/alkyl-7-chloroquinolines and 2-Aminoaryl/alklbenzo- thiazole s", AUST. J. CHEM., 31 December 2007 (2007-12-31) *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200360365A1 (en) * 2018-01-05 2020-11-19 Instutut National de la Sante et de la Researche Medicale Substituted halo-quinoline derivates for use in the treatment of lymphomas and leukemia
WO2020109039A1 (en) 2018-11-28 2020-06-04 Basf Se Pesticidal compounds
WO2021219513A1 (en) 2020-04-28 2021-11-04 Basf Se Pesticidal compounds
CN115260164A (en) * 2021-05-01 2022-11-01 杭州星鳌生物科技有限公司 Preparation method and structural composition of novel 4 (3H) -quinazolinone analogue and application of analogue in antitumor drugs
CN115260164B (en) * 2021-05-01 2024-03-26 杭州星鳌生物科技有限公司 Preparation method, structural composition and application of novel 4 (3H) -quinazolinone analogue in antitumor drugs
CN115466211A (en) * 2022-06-09 2022-12-13 中国人民解放军空军军医大学 N-phenylquinoline-4-amine compound and application thereof
CN115466211B (en) * 2022-06-09 2024-02-23 中国人民解放军空军军医大学 N-phenylquinoline-4-amine compound and application thereof
CN116693452A (en) * 2023-05-24 2023-09-05 中山大学 Quinoline derivative and preparation method and application thereof

Similar Documents

Publication Publication Date Title
WO2017198196A1 (en) Quinoline derivative having anti-tumor activity
JP6621486B2 (en) Pyrido-azaheterocyclic compound and production method and use thereof
TWI674258B (en) Dna alkylating agents
ES2463097T3 (en) Compounds for the prevention and treatment of cardiovascular diseases
JP5905075B2 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
KR20140025484A (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
DK165921B (en) 1 H-IMIDAZOOE4,5 CAAQUINOLIN-5-oxy compounds
WO2008141843A1 (en) Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors
KR102426138B1 (en) FUSED QUINOLINE COMPOUNDS AS PI3K, mTOR INHIBITORS
JP7033588B2 (en) Phthalazine derivatives as inhibitors of PARP1, PARP2, and / or tubulin useful in the treatment of cancer
CA3134791A1 (en) Inhibitors of notch signalling pathway and use thereof in treatment of cancers
JP6386585B2 (en) Furopyridine as an inhibitor of protein kinases
JP2022509076A (en) Aromatic ring-bonded dioxyno-quinazoline or dioxyno-quinoline compounds, compositions and their use
CN105461687B (en) Dihydropyridazinone-containing quinoline compound and application thereof
CN101671301B (en) Heterocyclic substituent acardite derivate and application thereof
CN113924288B (en) Quinolinyl-containing compound, pharmaceutical composition and application thereof
KR101505783B1 (en) Novel pyrrolopyridinyloxyphenylamide derivatives and use thereof
CN107635991B (en) Furoquinolinediones as inhibitors of TDP2
JP7022454B2 (en) Dioxynoquinoline compounds, their preparation methods and uses
JP2004509956A (en) Fluorinated quinolones as antimitotic and antitumor agents
CN115677666A (en) Indole bipyrimidine compound, intermediate thereof, preparation method and application thereof
JP6943886B2 (en) Condensed pyrimidinopiperidin derivative, and its production method and application
RU2803116C2 (en) Quinolinil-containing compound, its pharmaceutical composition and use
JP7282786B2 (en) Heteroaryl compounds, compositions and methods using same as CXCR4 inhibitors
US20230227410A1 (en) Tetrahydroquinoline derivatives and a process of preparation thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17798759

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17798759

Country of ref document: EP

Kind code of ref document: A1